{ "version": "2.2", "instance": { "d78187ds1.htm": { "nsprefix": "ctcx", "nsuri": "http://www.carmellrx.com/20231231", "dts": { "schema": { "local": [ "ctcx-20231231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "calculationLink": { "local": [ "ctcx-20231231_cal.xml" ] }, "definitionLink": { "local": [ "ctcx-20231231_def.xml" ] }, "labelLink": { "local": [ "ctcx-20231231_lab.xml" ] }, "presentationLink": { "local": [ "ctcx-20231231_pre.xml" ] }, "inline": { "local": [ "d78187ds1.htm" ] } }, "keyStandard": 388, "keyCustom": 128, "axisStandard": 42, "axisCustom": 4, "memberStandard": 49, "memberCustom": 68, "hidden": { "total": 14, "http://fasb.org/us-gaap/2023": 9, "http://xbrl.sec.gov/dei/2023": 5 }, "contextCount": 288, "entityCount": 1, "segmentCount": 127, "elementCount": 823, "unitCount": 12, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 842, "http://xbrl.sec.gov/dei/2023": 26 }, "report": { "R1": { "role": "http://www.carmellrx.com/role/CoverPage", "longName": "1001 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.carmellrx.com/role/ConsolidatedBalanceSheets", "longName": "1002 - Statement - Consolidated Balance Sheets", "shortName": "Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "PAsOn12_31_2023", "name": "us-gaap:Cash", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "PAsOn12_31_2023", "name": "us-gaap:Cash", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.carmellrx.com/role/ConsolidatedBalanceSheetsParenthetical", "longName": "1003 - Statement - Consolidated Balance Sheets (Parenthetical)", "shortName": "Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "PAsOn12_31_2023", "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true }, "uniqueAnchor": { "contextRef": "PAsOn12_31_2023_SeriesCOnePreferredStockMemberusgaapStatementClassOfStockAxis", "name": "us-gaap:TemporaryEquityParOrStatedValuePerShare", "unitRef": "Unit_USD_per_Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "us-gaap:TemporaryEquityParOrStatedValuePerShare", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "unique": true } }, "R4": { "role": "http://www.carmellrx.com/role/ConsolidatedStatementsOfOperations", "longName": "1004 - Statement - Consolidated Statements of Operations", "shortName": "Consolidated Statements of Operations", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true } }, "R5": { "role": "http://www.carmellrx.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit", "longName": "1005 - Statement - Consolidated Statements of Stockholders' Equity (Deficit)", "shortName": "Consolidated Statements of Stockholders' Equity (Deficit)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "PAsOn12_31_2021", "name": "us-gaap:StockholdersEquity", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "PAsOn12_31_2021", "name": "us-gaap:StockholdersEquity", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true } }, "R6": { "role": "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows", "longName": "1006 - Statement - Consolidated Statements of Cash Flows", "shortName": "Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:ProfitLoss", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:ProfitLoss", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.carmellrx.com/role/NatureOfTheOrganizationAndBusiness", "longName": "1007 - Disclosure - Nature of the Organization and Business", "shortName": "Nature of the Organization and Business", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPolicies", "longName": "1008 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.carmellrx.com/role/BusinessCombinations", "longName": "1009 - Disclosure - Business Combinations", "shortName": "Business Combinations", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.carmellrx.com/role/GoingConcernAndManagementsLiquidityPlans", "longName": "1010 - Disclosure - Going Concern and Managements Liquidity Plans", "shortName": "Going Concern and Managements Liquidity Plans", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.carmellrx.com/role/PropertyAndEquipment", "longName": "1011 - Disclosure - Property and Equipment", "shortName": "Property and Equipment", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.carmellrx.com/role/GoodwillAndIntangibleAssets", "longName": "1012 - Disclosure - Goodwill and Intangible Assets", "shortName": "Goodwill and Intangible Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.carmellrx.com/role/AccruedExpensesAndOtherLiabilities", "longName": "1013 - Disclosure - Accrued Expenses and Other Liabilities", "shortName": "Accrued Expenses and Other Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "ctcx:DisclosureOfAccruedExpensesAndOtherLiabilitiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "ctcx:DisclosureOfAccruedExpensesAndOtherLiabilitiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.carmellrx.com/role/Debt", "longName": "1014 - Disclosure - Debt", "shortName": "Debt", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.carmellrx.com/role/Leases", "longName": "1015 - Disclosure - Leases", "shortName": "Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.carmellrx.com/role/CommitmentsAndContingencies", "longName": "1016 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.carmellrx.com/role/ProfitSharingPlan", "longName": "1017 - Disclosure - Profit-Sharing Plan", "shortName": "Profit-Sharing Plan", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:DefinedBenefitPlanTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:DefinedBenefitPlanTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficit", "longName": "1018 - Disclosure - Mezzanine Equity And Stockholders' Equity (Deficit)", "shortName": "Mezzanine Equity And Stockholders' Equity (Deficit)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.carmellrx.com/role/OtherRelatedPartyTransactions", "longName": "1019 - Disclosure - Other Related Party Transactions", "shortName": "Other Related Party Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "ctcx:OtherRelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "ctcx:OtherRelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.carmellrx.com/role/IncomeTaxes", "longName": "1020 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.carmellrx.com/role/DiscontinuedOperations", "longName": "1021 - Disclosure - Discontinued Operations", "shortName": "Discontinued Operations", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.carmellrx.com/role/SubsequentEvents", "longName": "1022 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "longName": "1023 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "23", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesTables", "longName": "1024 - Disclosure - Summary of Significant Accounting Policies (Tables)", "shortName": "Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.carmellrx.com/role/BusinessCombinationsTables", "longName": "1025 - Disclosure - Business Combinations (Tables)", "shortName": "Business Combinations (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.carmellrx.com/role/PropertyAndEquipmentTables", "longName": "1026 - Disclosure - Property and Equipment (Tables)", "shortName": "Property and Equipment (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.carmellrx.com/role/GoodwillAndIntangibleAssetsTables", "longName": "1027 - Disclosure - Goodwill and Intangible Assets (Tables)", "shortName": "Goodwill and Intangible Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.carmellrx.com/role/AccruedExpensesAndOtherLiabilitiesTables", "longName": "1028 - Disclosure - Accrued Expenses and Other Liabilities (Tables)", "shortName": "Accrued Expenses and Other Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "ctcx:ScheduleOfAccruedExpensesAndOtherLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ctcx:DisclosureOfAccruedExpensesAndOtherLiabilitiesTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "ctcx:ScheduleOfAccruedExpensesAndOtherLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ctcx:DisclosureOfAccruedExpensesAndOtherLiabilitiesTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.carmellrx.com/role/LeasesTables", "longName": "1029 - Disclosure - Leases (Tables)", "shortName": "Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LeasesOfLesseeDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LeasesOfLesseeDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitTables", "longName": "1030 - Disclosure - Mezzanine Equity And Stockholders' Equity (Deficit) (Tables)", "shortName": "Mezzanine Equity And Stockholders' Equity (Deficit) (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:TemporaryEquityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:TemporaryEquityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.carmellrx.com/role/IncomeTaxesTables", "longName": "1031 - Disclosure - Income Taxes (Tables)", "shortName": "Income Taxes (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.carmellrx.com/role/DiscontinuedOperationsTables", "longName": "1032 - Disclosure - Discontinued Operations (Tables)", "shortName": "Discontinued Operations (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.carmellrx.com/role/NatureOfTheOrganizationAndBusinessAdditionalInformationDetail", "longName": "1033 - Disclosure - Nature of the Organization and Business - Additional Information (Detail)", "shortName": "Nature of the Organization and Business - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "PAsOn12_31_2023", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "Unit_USD_per_Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true }, "uniqueAnchor": { "contextRef": "PAsOn07_09_2023", "name": "us-gaap:TemporaryEquityRedemptionPricePerShare", "unitRef": "Unit_USD_per_Share", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "div", "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "unique": true } }, "R34": { "role": "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "longName": "1034 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)", "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "Unit_Segment", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "div", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "Unit_Segment", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "div", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesConcentrationsAdditionalInformationDetail", "longName": "1035 - Disclosure - Summary of Significant Accounting Policies - Concentrations - Additional Information (Detail)", "shortName": "Summary of Significant Accounting Policies - Concentrations - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023_AmnionAllograftProductMembersrtProductOrServiceAxis_AxolotlBiologixIncMemberusgaapBusinessAcquisitionAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "Unit_pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "div", "us-gaap:ConcentrationRiskCreditRisk", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023_AmnionAllograftProductMembersrtProductOrServiceAxis_AxolotlBiologixIncMemberusgaapBusinessAcquisitionAxis_ProductConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "Unit_pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "div", "us-gaap:ConcentrationRiskCreditRisk", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfGoodwillDetail", "longName": "1036 - Disclosure - Summary of Significant Accounting Policies - Summary of Goodwill (Detail)", "shortName": "Summary of Significant Accounting Policies - Summary of Goodwill (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "PAsOn12_31_2023", "name": "us-gaap:Goodwill", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfGoodwillTextBlock", "us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023_AxobioAcquisitionMemberusgaapBusinessAcquisitionAxis", "name": "us-gaap:GoodwillAcquiredDuringPeriod", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfGoodwillTextBlock", "us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "unique": true } }, "R37": { "role": "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfTheSecuritiesThatWereExcludedFromTheDilutedPerShareDetail", "longName": "1037 - Disclosure - Summary of Significant Accounting Policies - Summary of the Securities that were Excluded from the Diluted Per Share (Detail)", "shortName": "Summary of Significant Accounting Policies - Summary of the Securities that were Excluded from the Diluted Per Share (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Unit_shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Unit_shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfOtherFinancialAssetsAndLiabilitiesRecordedInBalanceSheetAtFairValueDetail", "longName": "1038 - Disclosure - Summary of Significant Accounting Policies - Schedule of Other Financial Assets and Liabilities Recorded in Balance Sheet at Fair Value (Detail)", "shortName": "Summary of Significant Accounting Policies - Schedule of Other Financial Assets and Liabilities Recorded in Balance Sheet at Fair Value (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "PAsOn12_31_2023", "name": "ctcx:ForwardPurchaseAgreement", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true }, "uniqueAnchor": { "contextRef": "PAsOn12_31_2023_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis", "name": "ctcx:SmallBusinessAdministrationLoan", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "unique": true } }, "R39": { "role": "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfChangesInFairValueOfLevel3FinancialAssetsAndLiabilitiesDetail", "longName": "1039 - Disclosure - Summary of Significant Accounting Policies - Schedule of Changes in Fair Value of Level 3 Financial Assets and Liabilities (Detail)", "shortName": "Summary of Significant Accounting Policies - Schedule of Changes in Fair Value of Level 3 Financial Assets and Liabilities (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "PAsOn12_31_2022_ForwardPurchaseAgreementMemberusgaapFairValueByAssetClassAxis", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "PAsOn12_31_2022_ForwardPurchaseAgreementMemberusgaapFairValueByAssetClassAxis", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfFairValueOfEmbeddedDerivativesInTheConvertibleNotesDetail", "longName": "1040 - Disclosure - Summary of Significant Accounting Policies - Summary of Fair Value of Embedded Derivatives in the Convertible Notes (Detail)", "shortName": "Summary of Significant Accounting Policies - Summary of Fair Value of Embedded Derivatives in the Convertible Notes (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "PAsOn12_31_2022_ConvertibleNotesMemberusgaapDebtInstrumentAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis_MonteCarloModelMemberusgaapValuationTechniqueAxis", "name": "us-gaap:EmbeddedDerivativeLiabilityMeasurementInput", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "ix:continuation", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "PAsOn12_31_2022_ConvertibleNotesMemberusgaapDebtInstrumentAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis_MonteCarloModelMemberusgaapValuationTechniqueAxis", "name": "us-gaap:EmbeddedDerivativeLiabilityMeasurementInput", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "ix:continuation", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.carmellrx.com/role/BusinessCombinationsAdditionalInformationDetail", "longName": "1041 - Disclosure - Business Combinations - Additional Information (Detail)", "shortName": "Business Combinations - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "PAsOn08_09_2023_CashEarnoutMemberusgaapContingentConsiderationByTypeAxis_MaximumMembersrtRangeAxis", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "div", "ctcx:EarnoutLiabilityPolicyTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true }, "uniqueAnchor": { "contextRef": "PAsOn08_09_2023_AxobioMemberusgaapBusinessAcquisitionAxis", "name": "ctcx:BusinessCombinationDeferredClosingCashConsideration", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "div", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "unique": true } }, "R42": { "role": "http://www.carmellrx.com/role/BusinessCombinationsSummaryOfFairValueOfPurchaseConsiderationTransferredDetail", "longName": "1042 - Disclosure - Business Combinations - Summary of Fair Value of Purchase Consideration Transferred (Detail)", "shortName": "Business Combinations - Summary of Fair Value of Purchase Consideration Transferred (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "P08_09_2023To08_09_2023_AxobioMemberusgaapBusinessAcquisitionAxis", "name": "ctcx:BusinessCombinationContingentEarnOut", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P08_09_2023To08_09_2023_AxobioMemberusgaapBusinessAcquisitionAxis", "name": "ctcx:BusinessCombinationContingentEarnOut", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.carmellrx.com/role/BusinessCombinationsSummaryOfFairValueOfPurchaseConsiderationTransferredParentheticalDetail", "longName": "1043 - Disclosure - Business Combinations - Summary of Fair Value of Purchase Consideration Transferred (Parenthetical) (Detail)", "shortName": "Business Combinations - Summary of Fair Value of Purchase Consideration Transferred (Parenthetical) (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "P08_09_2023To08_09_2023_AxobioMemberusgaapBusinessAcquisitionAxis_SeriesAConvertibleVotingPreferredStockMemberusgaapStatementClassOfStockAxis", "name": "us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued", "unitRef": "Unit_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P08_09_2023To08_09_2023_AxobioMemberusgaapBusinessAcquisitionAxis_SeriesAConvertibleVotingPreferredStockMemberusgaapStatementClassOfStockAxis", "name": "us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued", "unitRef": "Unit_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.carmellrx.com/role/BusinessCombinationsSummaryOfAllocationOfPurchasePriceDetail", "longName": "1044 - Disclosure - Business Combinations - Summary of Allocation of Purchase Price (Detail)", "shortName": "Business Combinations - Summary of Allocation of Purchase Price (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "PAsOn12_31_2023", "name": "us-gaap:Goodwill", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfGoodwillTextBlock", "us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true }, "uniqueAnchor": { "contextRef": "PAsOn08_09_2023_AxobioMemberusgaapBusinessAcquisitionAxis", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "unique": true } }, "R45": { "role": "http://www.carmellrx.com/role/BusinessCombinationsSummaryOfBusinessCombinationsUnauditedProFromaStatementsOfOperationsDetail", "longName": "1045 - Disclosure - Business Combinations - Summary of Business Combinations Unaudited Pro Froma Statements of Operations (Detail)", "shortName": "Business Combinations - Summary of Business Combinations Unaudited Pro Froma Statements of Operations (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:NetIncomeLoss", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023_AxobioMemberusgaapBusinessAcquisitionAxis", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "unique": true } }, "R46": { "role": "http://www.carmellrx.com/role/BusinessCombinationsSummaryOfBusinessCombinationsUnauditedProFromaStatementsOfOperationsParentheticalDetail", "longName": "1046 - Disclosure - Business Combinations - Summary of Business Combinations Unaudited Pro Froma Statements of Operations (Parenthetical) (Detail)", "shortName": "Business Combinations - Summary of Business Combinations Unaudited Pro Froma Statements of Operations (Parenthetical) (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "P01_01_2023To08_09_2023_AxobioMemberusgaapBusinessAcquisitionAxis", "name": "ctcx:AdditionalAmortization", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "div", "div", "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To08_09_2023_AxobioMemberusgaapBusinessAcquisitionAxis", "name": "ctcx:AdditionalAmortization", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "div", "div", "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.carmellrx.com/role/GoingConcernAndManagementsLiquidityPlansAdditionalInformationDetail", "longName": "1047 - Disclosure - Going Concern and Managements Liquidity Plans - Additional Information (Detail)", "shortName": "Going Concern and Managements Liquidity Plans - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "PAsOn12_31_2023", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "div", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "PAsOn12_31_2023", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "div", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.carmellrx.com/role/PropertyAndEquipmentScheduleOfPropertyPlantAndEquipmentIncludeInContinuingOperationsDetail", "longName": "1048 - Disclosure - Property and Equipment - Schedule of Property Plant and Equipment Include In Continuing Operations (Detail)", "shortName": "Property and Equipment - Schedule of Property Plant and Equipment Include In Continuing Operations (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "PAsOn12_31_2023", "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true }, "uniqueAnchor": { "contextRef": "PAsOn12_31_2023_SegmentContinuingOperationsMemberusgaapStatementOperatingActivitiesSegmentAxis", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "unique": true } }, "R49": { "role": "http://www.carmellrx.com/role/PropertyAndEquipmentAdditionalInformationDetail", "longName": "1049 - Disclosure - Property and Equipment - Additional Information (Detail)", "shortName": "Property and Equipment - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023_SegmentContinuingOperationsMemberusgaapStatementOperatingActivitiesSegmentAxis", "name": "us-gaap:Depreciation", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023_SegmentContinuingOperationsMemberusgaapStatementOperatingActivitiesSegmentAxis", "name": "us-gaap:Depreciation", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.carmellrx.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetail", "longName": "1050 - Disclosure - Goodwill and Intangible Assets - Additional Information (Detail)", "shortName": "Goodwill and Intangible Assets - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "PAsOn12_31_2023", "name": "us-gaap:FiniteLivedPatentsGross", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "us-gaap:FiniteLivedPatentsGross", "div", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "PAsOn12_31_2023", "name": "us-gaap:FiniteLivedPatentsGross", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "us-gaap:FiniteLivedPatentsGross", "div", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.carmellrx.com/role/GoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetail", "longName": "1051 - Disclosure - Goodwill and Intangible Assets - Summary of Intangible Assets (Detail)", "shortName": "Goodwill and Intangible Assets - Summary of Intangible Assets (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "PAsOn12_31_2023", "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true }, "uniqueAnchor": { "contextRef": "PAsOn12_31_2023_SegmentDiscontinuedOperationsMemberusgaapStatementOperatingActivitiesSegmentAxis", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "unique": true } }, "R52": { "role": "http://www.carmellrx.com/role/GoodwillAndIntangibleAssetsSummaryOfAmortizationExpenseRelatedToIntangibleAssetsDetail", "longName": "1052 - Disclosure - Goodwill and Intangible Assets - Summary of Amortization Expense Related to Intangible Assets (Detail)", "shortName": "Goodwill and Intangible Assets - Summary of Amortization Expense Related to Intangible Assets (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "PAsOn12_31_2023", "name": "us-gaap:FiniteLivedIntangibleAssetsNet", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true }, "uniqueAnchor": { "contextRef": "PAsOn12_31_2023_SegmentContinuingOperationsMemberusgaapStatementOperatingActivitiesSegmentAxis", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "unique": true } }, "R53": { "role": "http://www.carmellrx.com/role/AccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetail", "longName": "1053 - Disclosure - Accrued Expenses and Other Liabilities - Schedule Of Accrued Expenses and Other Liabilities (Detail)", "shortName": "Accrued Expenses and Other Liabilities - Schedule Of Accrued Expenses and Other Liabilities (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "PAsOn12_31_2023", "name": "ctcx:AccruedSeverance", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "div", "ctcx:RestructuringChargesPolicyPolicyTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true }, "uniqueAnchor": { "contextRef": "PAsOn12_31_2023_SegmentContinuingOperationsMemberusgaapStatementOperatingActivitiesSegmentAxis", "name": "us-gaap:CompensatedAbsencesLiability", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "ctcx:ScheduleOfAccruedExpensesAndOtherLiabilitiesTableTextBlock", "ctcx:DisclosureOfAccruedExpensesAndOtherLiabilitiesTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "unique": true } }, "R54": { "role": "http://www.carmellrx.com/role/DebtAdditionalInformationDetail", "longName": "1054 - Disclosure - Debt - Additional information (Detail)", "shortName": "Debt - Additional information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:AmortizationOfDebtDiscountPremium", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true }, "uniqueAnchor": { "contextRef": "P09_23_2022To09_23_2022", "name": "us-gaap:DebtConversionConvertedInstrumentIssuanceDateDayMonthAndYear", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "unique": true } }, "R55": { "role": "http://www.carmellrx.com/role/LeasesAdditionalInformationDetail", "longName": "1055 - Disclosure - Leases - Additional Information (Detail)", "shortName": "Leases - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "PAsOn12_31_2023", "name": "ctcx:NumberOfOfficeLeases", "unitRef": "Unit_Lease", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "div", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "PAsOn12_31_2023", "name": "ctcx:NumberOfOfficeLeases", "unitRef": "Unit_Lease", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "div", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true } }, "R56": { "role": "http://www.carmellrx.com/role/LeasesSummaryOfNetLeaseCostAndOtherSupplementalLeaseInformationDetail", "longName": "1056 - Disclosure - Leases - Summary of Net Lease Cost and Other Supplemental Lease Information (Detail)", "shortName": "Leases - Summary of Net Lease Cost and Other Supplemental Lease Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:OperatingLeaseCost", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:OperatingLeaseCost", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.carmellrx.com/role/LeasesScheduleOfEstimatedFutureMinimumLeasePaymentsExcludingNonLeaseComponentsDetail", "longName": "1057 - Disclosure - Leases - Schedule of Estimated Future Minimum Lease Payments, Excluding Non-Lease Components (Detail)", "shortName": "Leases - Schedule of Estimated Future Minimum Lease Payments, Excluding Non-Lease Components (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "PAsOn12_31_2023", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "PAsOn12_31_2023", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.carmellrx.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "longName": "1058 - Disclosure - Commitments and Contingencies - Additional Information (Detail)", "shortName": "Commitments and Contingencies - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "PAsOn12_31_2023", "name": "us-gaap:CommonStockSharesIssued", "unitRef": "Unit_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true }, "uniqueAnchor": { "contextRef": "P01_30_2008To01_30_2008_AmendedLicenseAgreementMemberCTCXAgreementNameAxis_CarnegieMellonUniversityMembersrtCounterpartyNameAxis", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "Unit_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "unique": true } }, "R59": { "role": "http://www.carmellrx.com/role/ProfitSharingPlanAdditionalInformationDetail", "longName": "1059 - Disclosure - Profit-Sharing Plan - Additional Information (Detail)", "shortName": "Profit-Sharing Plan - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:DefinedBenefitPlanTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:DefinedBenefitPlanTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitAdditionalInformationDetail", "longName": "1060 - Disclosure - Mezzanine Equity And Stockholders' Equity (Deficit) - Additional Information (Detail)", "shortName": "Mezzanine Equity And Stockholders' Equity (Deficit) - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "PAsOn12_31_2023", "name": "us-gaap:CommonStockSharesIssued", "unitRef": "Unit_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "ctcx:PercentageOfOutstandingCommonStock", "unitRef": "Unit_pure", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "unique": true } }, "R61": { "role": "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitRedeemableConvertiblePreferredStockDetail", "longName": "1061 - Disclosure - Mezzanine Equity And Stockholders' Equity (Deficit) - Redeemable Convertible Preferred Stock (Detail)", "shortName": "Mezzanine Equity And Stockholders' Equity (Deficit) - Redeemable Convertible Preferred Stock (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "PAsOn12_31_2022_SeriesAConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis", "name": "us-gaap:TemporaryEquitySharesAuthorized", "unitRef": "Unit_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:TemporaryEquityTableTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "PAsOn12_31_2022_SeriesAConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis", "name": "us-gaap:TemporaryEquitySharesAuthorized", "unitRef": "Unit_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:TemporaryEquityTableTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true } }, "R62": { "role": "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitSummaryOfInformationRelatedToCommonStockWarrantsDetail", "longName": "1062 - Disclosure - Mezzanine Equity And Stockholders' Equity (Deficit) - Summary Of Information Related To Common Stock Warrants (Detail)", "shortName": "Mezzanine Equity And Stockholders' Equity (Deficit) - Summary Of Information Related To Common Stock Warrants (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "PAsOn12_31_2022_CommonStockWarrantsMemberusgaapStatementEquityComponentsAxis", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "Unit_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023_CommonStockWarrantsMemberusgaapStatementEquityComponentsAxis", "name": "ctcx:ClassOfWarrantsOrRightsGrantedDuringThePeriodUnits", "unitRef": "Unit_shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "unique": true } }, "R63": { "role": "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitSummaryOfOptionActivityDetail", "longName": "1063 - Disclosure - Mezzanine Equity And Stockholders' Equity (Deficit) - Summary of Option Activity (Detail)", "shortName": "Mezzanine Equity And Stockholders' Equity (Deficit) - Summary of Option Activity (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "PAsOn12_31_2022", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Unit_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "Unit_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "unique": true } }, "R64": { "role": "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelDetail", "longName": "1064 - Disclosure - Mezzanine Equity And Stockholders' Equity (Deficit) - Schedule of Assumptions used in Black Scholes Option Pricing Model (Detail)", "shortName": "Mezzanine Equity And Stockholders' Equity (Deficit) - Schedule of Assumptions used in Black Scholes Option Pricing Model (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "unitRef": "Unit_pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "div", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "unitRef": "Unit_pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "div", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true } }, "R65": { "role": "http://www.carmellrx.com/role/OtherRelatedPartyTransactionsAdditionalInformationDetail", "longName": "1065 - Disclosure - Other Related Party Transactions - Additional Information (Detail)", "shortName": "Other Related Party Transactions - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "PAsOn12_31_2023", "name": "ctcx:PayableToRelatedParty", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "div", "ctcx:OtherRelatedPartyTransactionsDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "PAsOn12_31_2023", "name": "ctcx:PayableToRelatedParty", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "div", "ctcx:OtherRelatedPartyTransactionsDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true } }, "R66": { "role": "http://www.carmellrx.com/role/IncomeTaxesComponentsOfIncomeTaxRateDetail", "longName": "1066 - Disclosure - Income Taxes - Components of Income Tax Rate (Detail)", "shortName": "Income Taxes - Components of Income Tax Rate (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "Unit_pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "Unit_pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true } }, "R67": { "role": "http://www.carmellrx.com/role/IncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetail", "longName": "1067 - Disclosure - Income Taxes - Significant Components of Deferred Tax Assets (Detail)", "shortName": "Income Taxes - Significant Components of Deferred Tax Assets (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "PAsOn12_31_2023", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "PAsOn12_31_2023", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true } }, "R68": { "role": "http://www.carmellrx.com/role/IncomeTaxesAdditionalInformationDetail", "longName": "1068 - Disclosure - Income Taxes - Additional Information (Detail)", "shortName": "Income Taxes - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "PAsOn12_31_2023", "name": "us-gaap:OperatingLossCarryforwards", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "div", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "PAsOn12_31_2023", "name": "us-gaap:OperatingLossCarryforwards", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "div", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true } }, "R69": { "role": "http://www.carmellrx.com/role/DiscontinuedOperationsSummaryOfAssetsAndLiabilitiesClassifiedAsAvailableForSaleDetail", "longName": "1069 - Disclosure - Discontinued Operations - Summary of Assets and Liabilities Classified as Available For Sale (Detail)", "shortName": "Discontinued Operations - Summary of Assets and Liabilities Classified as Available For Sale (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "PAsOn12_31_2023", "name": "us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true }, "uniqueAnchor": { "contextRef": "PAsOn12_31_2023_AxobioMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_DiscontinuedOperationsDisposedOfBySaleMemberusgaapDisposalGroupClassificationAxis", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "unique": true } }, "R70": { "role": "http://www.carmellrx.com/role/DiscontinuedOperationsSummaryOfDiscontinuedOperationsInConsolidatedStatementsOfIncomeDetail", "longName": "1070 - Disclosure - Discontinued Operations - Summary of Discontinued Operations in Consolidated Statements of Income (Detail)", "shortName": "Discontinued Operations - Summary of Discontinued Operations in Consolidated Statements of Income (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "P01_01_2023To12_31_2023_AxobioMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2023To12_31_2023_AxobioMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78187ds1.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountingStandardsUpdate201613Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingStandardsUpdate201613Member", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Accounting Standards Update 2016-13 [Member]", "terseLabel": "ASU 2016-13 [Member]", "documentation": "Accounting Standards Update 2016-13 Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments." } } }, "auth_ref": [ "r391" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 15.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts Payable, Current", "terseLabel": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r34", "r937" ] }, "us-gaap_AccountsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableMember", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesConcentrationsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable [Member]", "terseLabel": "Accounts Receivable [Member]", "documentation": "Due from customers or clients for goods or services that have been delivered or sold." } } }, "auth_ref": [ "r900" ] }, "ctcx_AccrualToCashAndOther": { "xbrltype": "monetaryItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "AccrualToCashAndOther", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/IncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetail" ], "lang": { "en-us": { "role": { "label": "Accrual to Cash and Other", "terseLabel": "Accrual to cash and other", "documentation": "Accrual to cash and other." } } }, "auth_ref": [] }, "ctcx_AccruedExpensesAndOtherLiabilitiesExcludingInterestPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "AccruedExpensesAndOtherLiabilitiesExcludingInterestPayableCurrent", "crdr": "credit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 17.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accrued Expenses And Other Liabilities Excluding Interest Payable Current", "terseLabel": "Accrued expenses and other liabilities", "documentation": "Accrued expenses and other liabilities excluding interest payable current." } } }, "auth_ref": [] }, "ctcx_AccruedExpensesAndOtherLiabilitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "AccruedExpensesAndOtherLiabilitiesLineItems", "presentation": [ "http://www.carmellrx.com/role/AccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetail" ], "lang": { "en-us": { "role": { "label": "Accrued Expenses And Other Liabilities [Line items]", "documentation": "Accrued expenses and other liabilities." } } }, "auth_ref": [] }, "ctcx_AccruedExpensesAndOtherLiabilitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "AccruedExpensesAndOtherLiabilitiesTable", "presentation": [ "http://www.carmellrx.com/role/AccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetail" ], "lang": { "en-us": { "role": { "label": "Accrued Expenses And Other Liabilities [Table]", "documentation": "Accrued expenses and other liabilities ." } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesAndOtherLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesAndOtherLiabilities", "crdr": "credit", "calculation": { "http://www.carmellrx.com/role/AccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetail": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.carmellrx.com/role/AccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetail" ], "lang": { "en-us": { "role": { "label": "Accrued Liabilities and Other Liabilities", "totalLabel": "Accrued expenses and other liabilities", "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other." } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesAndOtherLiabilitiesAbstract", "lang": { "en-us": { "role": { "label": "Accrued Liabilities and Other Liabilities [Abstract]" } } }, "auth_ref": [] }, "ctcx_AccruedSeriesAPreferredStockDividends": { "xbrltype": "monetaryItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "AccruedSeriesAPreferredStockDividends", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Accrued Series A Preferred Stock Dividends", "terseLabel": "Accrued Series A preferred stock dividends", "documentation": "Accrued Series A preferred stock dividends" } } }, "auth_ref": [] }, "ctcx_AccruedSeriesC1PreferredStockDividends": { "xbrltype": "monetaryItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "AccruedSeriesC1PreferredStockDividends", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Accrued Series C1 Preferred Stock Dividends", "terseLabel": "Accrued Series C-1 preferred stock dividends", "documentation": "Accrued Series\u00a0C1\u00a0preferred stock dividends." } } }, "auth_ref": [] }, "ctcx_AccruedSeriesC2PreferredStockDividends": { "xbrltype": "monetaryItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "AccruedSeriesC2PreferredStockDividends", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Accrued Series C2 Preferred Stock Dividends", "terseLabel": "Accrued Series C-2 preferred stock dividends", "documentation": "Accrued Series\u00a0C2\u00a0preferred stock dividends." } } }, "auth_ref": [] }, "ctcx_AccruedSeverance": { "xbrltype": "monetaryItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "AccruedSeverance", "crdr": "credit", "calculation": { "http://www.carmellrx.com/role/AccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetail": { "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.carmellrx.com/role/AccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetail", "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Accrued Severance", "verboseLabel": "Severance unpaid", "terseLabel": "Accrued severance", "documentation": "Accrued Severance" } } }, "auth_ref": [] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.carmellrx.com/role/PropertyAndEquipmentScheduleOfPropertyPlantAndEquipmentIncludeInContinuingOperationsDetail": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.carmellrx.com/role/PropertyAndEquipmentScheduleOfPropertyPlantAndEquipmentIncludeInContinuingOperationsDetail" ], "lang": { "en-us": { "role": { "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "terseLabel": "Accumulated depreciation on property plant and equipment", "negatedLabel": "Less: accumulated depreciation", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r72", "r256", "r757" ] }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "presentation": [ "http://www.carmellrx.com/role/BusinessCombinationsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life", "terseLabel": "Expected useful life", "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r180" ] }, "ctcx_AdditionalAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "AdditionalAmortization", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/BusinessCombinationsSummaryOfBusinessCombinationsUnauditedProFromaStatementsOfOperationsParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Additional Amortization", "terseLabel": "Additional amortization", "documentation": "Additional amortization." } } }, "auth_ref": [] }, "ctcx_AdditionalCostOfGoodsSold": { "xbrltype": "monetaryItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "AdditionalCostOfGoodsSold", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/BusinessCombinationsSummaryOfBusinessCombinationsUnauditedProFromaStatementsOfOperationsParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Additional Cost of Goods Sold", "terseLabel": "Additional cost of goods sold", "documentation": "Additional cost of goods sold." } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 26.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Additional Paid in Capital", "verboseLabel": "Additional\u00a0paid-in\u00a0capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r160", "r937", "r1080" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r557", "r558", "r559", "r797", "r987", "r988", "r989", "r1056", "r1082" ] }, "ctcx_AdditionalPaymentOfPrincipalAndInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "AdditionalPaymentOfPrincipalAndInterest", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Additional Payment Of Principal And Interest", "terseLabel": "Additional payment of principal and interest", "documentation": "Additional payment of principal and interest." } } }, "auth_ref": [] }, "dei_AddressTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AddressTypeDomain", "presentation": [ "http://www.carmellrx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Address Type [Domain]", "documentation": "An entity may have several addresses for different purposes and this domain represents all such types." } } }, "auth_ref": [] }, "ctcx_AdjustedExercisePriceOfWarrantsAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "AdjustedExercisePriceOfWarrantsAxis", "presentation": [ "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Adjusted Exercise Price Of Warrants [Axis]", "documentation": "Adjusted exercise price of warrants." } } }, "auth_ref": [] }, "ctcx_AdjustedExercisePriceOfWarrantsDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "AdjustedExercisePriceOfWarrantsDomain", "presentation": [ "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Adjusted Exercise Price Of Warrants [Domain]", "documentation": "Adjusted exercise price of warrants." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Accounting Standards Update [Axis]", "documentation": "Information by amendment to accounting standards." } } }, "auth_ref": [ "r243", "r244", "r245", "r246", "r247", "r298", "r299", "r300", "r301", "r313", "r355", "r356", "r393", "r394", "r395", "r396", "r398", "r399", "r400", "r401", "r402", "r403", "r435", "r557", "r558", "r559", "r581", "r582", "r583", "r584", "r597", "r598", "r599", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r645", "r646", "r651", "r652", "r653", "r654", "r662", "r663", "r666", "r667", "r668", "r669", "r681", "r682", "r683", "r684", "r685", "r728", "r729", "r730", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785" ] }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "Changes in operating assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation expense", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r97", "r98", "r527" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit", "http://www.carmellrx.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Adjustments to Additional Paid in Capital, Warrant Issued", "terseLabel": "Warrants issued in connection with notes/preferred stock", "verboseLabel": "Adjustment to additional paid in capital warrants issued", "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants." } } }, "auth_ref": [ "r18", "r76", "r197" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "auth_ref": [] }, "ctcx_AggregateIntrinsicValueOfWarrantsOutstandingAndExercisable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "AggregateIntrinsicValueOfWarrantsOutstandingAndExercisable", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitSummaryOfInformationRelatedToCommonStockWarrantsDetail" ], "lang": { "en-us": { "role": { "label": "Aggregate Intrinsic Value of Warrants Outstanding and Exercisable", "terseLabel": "Aggregate intrinsic value of warrants outstanding and exercisable", "documentation": "Aggregate intrinsic value of warrants outstanding and exercisable." } } }, "auth_ref": [] }, "ctcx_AgreementAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "AgreementAxis", "presentation": [ "http://www.carmellrx.com/role/BusinessCombinationsAdditionalInformationDetail", "http://www.carmellrx.com/role/NatureOfTheOrganizationAndBusinessAdditionalInformationDetail", "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfOtherFinancialAssetsAndLiabilitiesRecordedInBalanceSheetAtFairValueDetail" ], "lang": { "en-us": { "role": { "label": "Agreement [Axis]", "documentation": "Agreement." } } }, "auth_ref": [] }, "ctcx_AgreementDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "AgreementDomain", "presentation": [ "http://www.carmellrx.com/role/BusinessCombinationsAdditionalInformationDetail", "http://www.carmellrx.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.carmellrx.com/role/NatureOfTheOrganizationAndBusinessAdditionalInformationDetail", "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfOtherFinancialAssetsAndLiabilitiesRecordedInBalanceSheetAtFairValueDetail" ], "lang": { "en-us": { "role": { "label": "Agreement [Domain]", "documentation": "Agreement." } } }, "auth_ref": [] }, "ctcx_AgreementNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "AgreementNameAxis", "presentation": [ "http://www.carmellrx.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Agreement Name [Axis]", "documentation": "Agreement Name Axis" } } }, "auth_ref": [] }, "ctcx_AllegedCashForRepurchaseOfConvertibleNoteWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "AllegedCashForRepurchaseOfConvertibleNoteWarrants", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.carmellrx.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Alleged Cash For Repurchase Of Convertible Note Warrants", "terseLabel": "Alleged cash amount for repurchase of convertible note warrants", "documentation": "Alleged cash for repurchase of convertible note warrants." } } }, "auth_ref": [] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Share based compensation", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r555", "r561" ] }, "ctcx_AmendedLicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "AmendedLicenseAgreementMember", "presentation": [ "http://www.carmellrx.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Amended License Agreement [Member]", "terseLabel": "Amended License Agreement [Member]", "documentation": "Amended license agreement." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.carmellrx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "ctcx_AmnionAllograftProductMember": { "xbrltype": "domainItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "AmnionAllograftProductMember", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesConcentrationsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Amnion Allograft Product [Member]", "documentation": "Amnion allograft product." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfDebtDiscountPremium": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfDebtDiscountPremium", "crdr": "debit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 }, "http://www.carmellrx.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 17.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows", "http://www.carmellrx.com/role/ConsolidatedStatementsOfOperations", "http://www.carmellrx.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Amortization of Debt Discount (Premium)", "negatedLabel": "Amortization of debt discount", "terseLabel": "Amortization of debt discount", "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense." } } }, "auth_ref": [ "r11", "r120", "r170", "r480" ] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Amortization of Intangible Assets", "terseLabel": "Amortization expense", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r11", "r67", "r70" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfTheSecuritiesThatWereExcludedFromTheDilutedPerShareDetail" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r324" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfTheSecuritiesThatWereExcludedFromTheDilutedPerShareDetail" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r56" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfTheSecuritiesThatWereExcludedFromTheDilutedPerShareDetail" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfTheSecuritiesThatWereExcludedFromTheDilutedPerShareDetail" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r56" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets", "totalLabel": "Total assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r209", "r259", "r287", "r329", "r343", "r347", "r390", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r604", "r608", "r649", "r748", "r840", "r937", "r950", "r1017", "r1018", "r1063" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "verboseLabel": "Assets" } } }, "auth_ref": [] }, "ctcx_AssetsAcquiredInAcquisitionNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "AssetsAcquiredInAcquisitionNet", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Assets Acquired in Acquisition Net", "terseLabel": "Net assets acquired in AxoBio Acquisition", "documentation": "Assets acquired in acquisition net." } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets, Current", "totalLabel": "Total current assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r251", "r266", "r287", "r390", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r604", "r608", "r649", "r937", "r1017", "r1018", "r1063" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "auth_ref": [] }, "us-gaap_AssetsHeldInTrust": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsHeldInTrust", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/NatureOfTheOrganizationAndBusinessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Asset, Held-in-Trust", "terseLabel": "Asset, held-in-trust", "documentation": "The total amount of cash and securities held by third party trustees pursuant to terms of debt instruments or other agreements as of the date of each statement of financial position presented, which can be used by the trustee only to pay the noncurrent portion of specified obligations." } } }, "auth_ref": [ "r981" ] }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "crdr": "debit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedBalanceSheets", "http://www.carmellrx.com/role/DiscontinuedOperationsSummaryOfAssetsAndLiabilitiesClassifiedAsAvailableForSaleDetail" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Assets, Current", "terseLabel": "Assets available for sale", "totalLabel": "Total assets available for sale", "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r5", "r134", "r149", "r184", "r186", "r249", "r250" ] }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract", "presentation": [ "http://www.carmellrx.com/role/DiscontinuedOperationsSummaryOfAssetsAndLiabilitiesClassifiedAsAvailableForSaleDetail" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Assets, Current [Abstract]", "terseLabel": "Assets available for sale" } } }, "auth_ref": [] }, "ctcx_AxbioAcquisitionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "AxbioAcquisitionMember", "presentation": [ "http://www.carmellrx.com/role/GoingConcernAndManagementsLiquidityPlansAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "AxBio Acquisition [Member]", "terseLabel": "AxBio Acquisition [Member]", "documentation": "AxBio Acquisition." } } }, "auth_ref": [] }, "ctcx_AxbioMember": { "xbrltype": "domainItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "AxbioMember", "presentation": [ "http://www.carmellrx.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "AxBio [Member]", "documentation": "AxBio." } } }, "auth_ref": [] }, "ctcx_AxobioAcquisitionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "AxobioAcquisitionMember", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfGoodwillDetail" ], "lang": { "en-us": { "role": { "label": "AxoBio Acquisition [Member]", "terseLabel": "AxoBio Acquisition [Member]", "documentation": "Axo bio acquisition." } } }, "auth_ref": [] }, "ctcx_AxobioMember": { "xbrltype": "domainItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "AxobioMember", "presentation": [ "http://www.carmellrx.com/role/BusinessCombinationsAdditionalInformationDetail", "http://www.carmellrx.com/role/BusinessCombinationsSummaryOfAllocationOfPurchasePriceDetail", "http://www.carmellrx.com/role/BusinessCombinationsSummaryOfBusinessCombinationsUnauditedProFromaStatementsOfOperationsDetail", "http://www.carmellrx.com/role/BusinessCombinationsSummaryOfBusinessCombinationsUnauditedProFromaStatementsOfOperationsParentheticalDetail", "http://www.carmellrx.com/role/BusinessCombinationsSummaryOfFairValueOfPurchaseConsiderationTransferredDetail", "http://www.carmellrx.com/role/BusinessCombinationsSummaryOfFairValueOfPurchaseConsiderationTransferredParentheticalDetail", "http://www.carmellrx.com/role/DiscontinuedOperationsSummaryOfAssetsAndLiabilitiesClassifiedAsAvailableForSaleDetail", "http://www.carmellrx.com/role/DiscontinuedOperationsSummaryOfDiscontinuedOperationsInConsolidatedStatementsOfIncomeDetail", "http://www.carmellrx.com/role/NatureOfTheOrganizationAndBusinessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "AxoBio [Member]", "terseLabel": "AxoBio [Member]", "documentation": "AxoBio." } } }, "auth_ref": [] }, "ctcx_AxobioMembershipInterestPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "AxobioMembershipInterestPurchaseAgreementMember", "presentation": [ "http://www.carmellrx.com/role/NatureOfTheOrganizationAndBusinessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Axobio Membership Interest Purchase Agreement [Member]", "documentation": "Axobio membership interest purchase agreement." } } }, "auth_ref": [] }, "ctcx_AxobioMergerAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "AxobioMergerAgreementMember", "presentation": [ "http://www.carmellrx.com/role/NatureOfTheOrganizationAndBusinessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "AxoBio Merger Agreement [Member]", "documentation": "AxoBio merger agreement." } } }, "auth_ref": [] }, "ctcx_AxolotlAcquisitionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "AxolotlAcquisitionMember", "presentation": [ "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Axolotl Acquisition [Member]", "terseLabel": "Axolotl Acquisition [Member]", "documentation": "Axolotl Acquisition." } } }, "auth_ref": [] }, "ctcx_AxolotlBiologixDispositionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "AxolotlBiologixDispositionMember", "presentation": [ "http://www.carmellrx.com/role/NatureOfTheOrganizationAndBusinessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Axolotl Biologix Disposition [Member]", "documentation": "Axolotl Biologix Disposition." } } }, "auth_ref": [] }, "ctcx_AxolotlBiologixIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "AxolotlBiologixIncMember", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesConcentrationsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Axolotl Biologix Inc [Member]", "verboseLabel": "Axolotl Biologix Acquisition [Member]", "documentation": "Axolotl Biologix, Inc." } } }, "auth_ref": [] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Basis of Accounting, Policy [Policy Text Block]", "verboseLabel": "Basis of Presentation", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "ctcx_BreachOfObligationsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "BreachOfObligationsMember", "presentation": [ "http://www.carmellrx.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Breach of Obligations [Member]", "documentation": "Breach of obligations." } } }, "auth_ref": [] }, "ctcx_BurnsVenturesLlcMember": { "xbrltype": "domainItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "BurnsVenturesLlcMember", "presentation": [ "http://www.carmellrx.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Burns Ventures LLC [Member]", "documentation": "Burns Ventures LLC." } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://www.carmellrx.com/role/BusinessCombinationsAdditionalInformationDetail", "http://www.carmellrx.com/role/BusinessCombinationsSummaryOfAllocationOfPurchasePriceDetail", "http://www.carmellrx.com/role/BusinessCombinationsSummaryOfBusinessCombinationsUnauditedProFromaStatementsOfOperationsDetail", "http://www.carmellrx.com/role/BusinessCombinationsSummaryOfBusinessCombinationsUnauditedProFromaStatementsOfOperationsParentheticalDetail", "http://www.carmellrx.com/role/BusinessCombinationsSummaryOfFairValueOfPurchaseConsiderationTransferredDetail", "http://www.carmellrx.com/role/BusinessCombinationsSummaryOfFairValueOfPurchaseConsiderationTransferredParentheticalDetail", "http://www.carmellrx.com/role/DebtAdditionalInformationDetail", "http://www.carmellrx.com/role/DiscontinuedOperationsSummaryOfAssetsAndLiabilitiesClassifiedAsAvailableForSaleDetail", "http://www.carmellrx.com/role/GoingConcernAndManagementsLiquidityPlansAdditionalInformationDetail", "http://www.carmellrx.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetail", "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitAdditionalInformationDetail", "http://www.carmellrx.com/role/NatureOfTheOrganizationAndBusinessAdditionalInformationDetail", "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesConcentrationsAdditionalInformationDetail", "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfGoodwillDetail" ], "lang": { "en-us": { "role": { "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r595", "r930", "r931" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://www.carmellrx.com/role/BusinessCombinationsAdditionalInformationDetail", "http://www.carmellrx.com/role/BusinessCombinationsSummaryOfAllocationOfPurchasePriceDetail", "http://www.carmellrx.com/role/BusinessCombinationsSummaryOfBusinessCombinationsUnauditedProFromaStatementsOfOperationsDetail", "http://www.carmellrx.com/role/BusinessCombinationsSummaryOfBusinessCombinationsUnauditedProFromaStatementsOfOperationsParentheticalDetail", "http://www.carmellrx.com/role/BusinessCombinationsSummaryOfFairValueOfPurchaseConsiderationTransferredDetail", "http://www.carmellrx.com/role/BusinessCombinationsSummaryOfFairValueOfPurchaseConsiderationTransferredParentheticalDetail", "http://www.carmellrx.com/role/DebtAdditionalInformationDetail", "http://www.carmellrx.com/role/DiscontinuedOperationsSummaryOfAssetsAndLiabilitiesClassifiedAsAvailableForSaleDetail", "http://www.carmellrx.com/role/GoingConcernAndManagementsLiquidityPlansAdditionalInformationDetail", "http://www.carmellrx.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetail", "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitAdditionalInformationDetail", "http://www.carmellrx.com/role/NatureOfTheOrganizationAndBusinessAdditionalInformationDetail", "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesConcentrationsAdditionalInformationDetail", "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfGoodwillDetail" ], "lang": { "en-us": { "role": { "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r103", "r105", "r595", "r930", "r931" ] }, "us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionCostOfAcquiredEntityTransactionCosts", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/BusinessCombinationsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Business Acquisition, Transaction Costs", "terseLabel": "Transaction costs related to acquisition", "documentation": "Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition." } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued", "presentation": [ "http://www.carmellrx.com/role/BusinessCombinationsSummaryOfFairValueOfPurchaseConsiderationTransferredParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares", "terseLabel": "Number of shares issued at acquisition", "documentation": "Number of shares of equity interests issued or issuable to acquire entity." } } }, "auth_ref": [ "r205" ] }, "us-gaap_BusinessAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionLineItems", "presentation": [ "http://www.carmellrx.com/role/BusinessCombinationsAdditionalInformationDetail", "http://www.carmellrx.com/role/BusinessCombinationsSummaryOfAllocationOfPurchasePriceDetail", "http://www.carmellrx.com/role/BusinessCombinationsSummaryOfBusinessCombinationsUnauditedProFromaStatementsOfOperationsDetail", "http://www.carmellrx.com/role/BusinessCombinationsSummaryOfBusinessCombinationsUnauditedProFromaStatementsOfOperationsParentheticalDetail", "http://www.carmellrx.com/role/BusinessCombinationsSummaryOfFairValueOfPurchaseConsiderationTransferredDetail", "http://www.carmellrx.com/role/BusinessCombinationsSummaryOfFairValueOfPurchaseConsiderationTransferredParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Business Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r595" ] }, "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionProFormaInformationTextBlock", "presentation": [ "http://www.carmellrx.com/role/BusinessCombinationsTables" ], "lang": { "en-us": { "role": { "label": "Business Acquisition, Pro Forma Information [Table Text Block]", "terseLabel": "Summary of Business Combinations Unaudited Pro Froma Statements of Operations", "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate." } } }, "auth_ref": [ "r958", "r959" ] }, "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionsProFormaNetIncomeLoss", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/BusinessCombinationsSummaryOfBusinessCombinationsUnauditedProFromaStatementsOfOperationsDetail" ], "lang": { "en-us": { "role": { "label": "Business Acquisition, Pro Forma Net Income (Loss)", "terseLabel": "Add: AxoBio net income (loss) not reflected in the consolidated statements of operations", "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period." } } }, "auth_ref": [ "r593", "r594" ] }, "us-gaap_BusinessAcquisitionsProFormaRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionsProFormaRevenue", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/BusinessCombinationsSummaryOfBusinessCombinationsUnauditedProFromaStatementsOfOperationsDetail" ], "lang": { "en-us": { "role": { "label": "Business Acquisition, Pro Forma Revenue", "terseLabel": "Add: AxoBio revenue not reflected in the consolidated statements of operations", "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period." } } }, "auth_ref": [ "r593", "r594" ] }, "ctcx_BusinessCombinationAdjustedInventory": { "xbrltype": "monetaryItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "BusinessCombinationAdjustedInventory", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/BusinessCombinationsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Business Combination Adjusted Inventory", "terseLabel": "Business combination adjusted inventory", "documentation": "Business combination adjusted inventory." } } }, "auth_ref": [] }, "ctcx_BusinessCombinationAdjustedLoanPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "BusinessCombinationAdjustedLoanPayable", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/BusinessCombinationsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Business Combination Adjusted Loan Payable", "terseLabel": "Business combination adjusted loan payable", "documentation": "Business combination adjusted loan payable." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationConsiderationTransferred1", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/BusinessCombinationsSummaryOfFairValueOfPurchaseConsiderationTransferredDetail" ], "lang": { "en-us": { "role": { "label": "Business Combination, Consideration Transferred", "totalLabel": "Total estimated value of consideration transferred", "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer." } } }, "auth_ref": [ "r1", "r2", "r16" ] }, "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/BusinessCombinationsSummaryOfFairValueOfPurchaseConsiderationTransferredDetail" ], "lang": { "en-us": { "role": { "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable", "terseLabel": "Shares issued", "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination." } } }, "auth_ref": [ "r1", "r2" ] }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "terseLabel": "Change in the fair value of the earnout liability", "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement." } } }, "auth_ref": [ "r602", "r980" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationLiability", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/BusinessCombinationsAdditionalInformationDetail", "http://www.carmellrx.com/role/NatureOfTheOrganizationAndBusinessAdditionalInformationDetail", "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Performance-based earn-outs liability", "terseLabel": "Business combination, contingent consideration, liability", "verboseLabel": "Contingent liabilities (see Note 9)", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination." } } }, "auth_ref": [ "r3", "r110", "r601" ] }, "ctcx_BusinessCombinationContingentEarnOut": { "xbrltype": "monetaryItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "BusinessCombinationContingentEarnOut", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/BusinessCombinationsSummaryOfFairValueOfPurchaseConsiderationTransferredDetail" ], "lang": { "en-us": { "role": { "label": "Business Combination, Contingent Earn-Out", "terseLabel": "Earnout", "documentation": "Business combination, contingent earn-out." } } }, "auth_ref": [] }, "ctcx_BusinessCombinationDeferredClosingCashConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "BusinessCombinationDeferredClosingCashConsideration", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/BusinessCombinationsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Business Combination Deferred Closing Cash Consideration", "terseLabel": "Deferred cash consideration", "documentation": "Business combination deferred closing cash consideration." } } }, "auth_ref": [] }, "ctcx_BusinessCombinationDeferredConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "BusinessCombinationDeferredConsideration", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/BusinessCombinationsSummaryOfFairValueOfPurchaseConsiderationTransferredDetail" ], "lang": { "en-us": { "role": { "label": "Business Combination, Deferred Consideration", "terseLabel": "Deferred Consideration", "documentation": "Business combination, deferred consideration." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationDisclosureTextBlock", "presentation": [ "http://www.carmellrx.com/role/BusinessCombinations" ], "lang": { "en-us": { "role": { "label": "Business Combination Disclosure [Text Block]", "terseLabel": "Business Combinations", "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)." } } }, "auth_ref": [ "r202", "r596" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/BusinessCombinationsSummaryOfAllocationOfPurchasePriceDetail" ], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets", "totalLabel": "Total assets", "documentation": "Amount of assets acquired at the acquisition date." } } }, "auth_ref": [ "r107" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/BusinessCombinationsSummaryOfAllocationOfPurchasePriceDetail" ], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "terseLabel": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r107" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/BusinessCombinationsSummaryOfAllocationOfPurchasePriceDetail" ], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets", "terseLabel": "Prepaid expenses", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": [ "r107" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/BusinessCombinationsSummaryOfAllocationOfPurchasePriceDetail" ], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables", "terseLabel": "Accounts receivable", "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": [ "r107" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/BusinessCombinationsSummaryOfAllocationOfPurchasePriceDetail" ], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable", "terseLabel": "Accounts payable", "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date." } } }, "auth_ref": [ "r107" ] }, "ctcx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedInterest", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/BusinessCombinationsSummaryOfAllocationOfPurchasePriceDetail" ], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Interest", "terseLabel": "Accrued interest", "documentation": "Business combination, recognized identifiable assets acquired and liabilities assumed, current liabilities, accrued interest." } } }, "auth_ref": [] }, "ctcx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOtherAccruedExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOtherAccruedExpenses", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/BusinessCombinationsSummaryOfAllocationOfPurchasePriceDetail" ], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other Accrued Expenses", "terseLabel": "Other accrued expenses", "documentation": "Business combination, recognized identifiable assets acquired and liabilities assumed, current liabilities, other accrued expenses." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/BusinessCombinationsSummaryOfAllocationOfPurchasePriceDetail" ], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities", "terseLabel": "Deferred tax liabilities", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date." } } }, "auth_ref": [ "r107" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/BusinessCombinationsSummaryOfAllocationOfPurchasePriceDetail" ], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill", "terseLabel": "Intangible assets", "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date." } } }, "auth_ref": [ "r107" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/BusinessCombinationsSummaryOfAllocationOfPurchasePriceDetail" ], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory", "terseLabel": "Inventories", "documentation": "The amount of inventory recognized as of the acquisition date." } } }, "auth_ref": [ "r106", "r107" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/BusinessCombinationsSummaryOfAllocationOfPurchasePriceDetail" ], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net", "totalLabel": "Net assets to be acquired", "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed." } } }, "auth_ref": [ "r106", "r107" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/BusinessCombinationsSummaryOfAllocationOfPurchasePriceDetail" ], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-Term Debt", "terseLabel": "Loan payable", "documentation": "Amount of long-term debt due after one year or the normal operating cycle, if longer, assumed at the acquisition date." } } }, "auth_ref": [ "r107" ] }, "ctcx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesRelatedPartyLoans": { "xbrltype": "monetaryItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesRelatedPartyLoans", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/BusinessCombinationsSummaryOfAllocationOfPurchasePriceDetail" ], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Related Party Loans", "terseLabel": "Related party loans", "documentation": "Business combination, recognized identifiable assets acquired and liabilities assumed, noncurrent liabilities, related party loans." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/BusinessCombinationsSummaryOfAllocationOfPurchasePriceDetail" ], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment", "terseLabel": "Property and equipment", "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date." } } }, "auth_ref": [ "r106", "r107" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/BusinessCombinationsSummaryOfAllocationOfPurchasePriceDetail" ], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net", "totalLabel": "Total estimated value of consideration transferred", "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed." } } }, "auth_ref": [ "r107" ] }, "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Expensed", "terseLabel": "Business combination trasaction cost", "documentation": "For transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination, such as related to pre-existing relationships with the acquiree, this element represents the disclosure of the amount of acquisition related costs which have been expensed." } } }, "auth_ref": [ "r104" ] }, "us-gaap_BusinessCombinationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationsAbstract", "lang": { "en-us": { "role": { "label": "Business Combinations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationsPolicy", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Business Combinations Policy [Policy Text Block]", "terseLabel": "Business combinations", "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy." } } }, "auth_ref": [ "r102" ] }, "dei_BusinessContactMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "BusinessContactMember", "presentation": [ "http://www.carmellrx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Business Contact [Member]", "documentation": "Business contact for the entity" } } }, "auth_ref": [ "r952", "r953" ] }, "ctcx_CancellationOfNotesPayableAggregatePrincipalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "CancellationOfNotesPayableAggregatePrincipalAmount", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/NatureOfTheOrganizationAndBusinessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Cancellation of Notes Payable Aggregate Principal Amount", "terseLabel": "Cancellation of notes payable aggregate principal amount", "documentation": "Cancellation of notes payable aggregate principal amount." } } }, "auth_ref": [] }, "ctcx_CapitalizationOfStartUpCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "CapitalizationOfStartUpCosts", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/IncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetail" ], "lang": { "en-us": { "role": { "label": "Capitalization of Start-Up Costs", "terseLabel": "Capitalization of start-up costs", "documentation": "Capitalization of start-up costs." } } }, "auth_ref": [] }, "ctcx_CapitalizedOfferingCostsWriteoff": { "xbrltype": "monetaryItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "CapitalizedOfferingCostsWriteoff", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Capitalized Offering Costs, Writeoff", "terseLabel": "Capitalized offering costs wrote off", "documentation": "Capitalized offering costs, writeoff." } } }, "auth_ref": [] }, "ctcx_CarnegieMellonUniversityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "CarnegieMellonUniversityMember", "presentation": [ "http://www.carmellrx.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Carnegie Mellon University [Member]", "documentation": "Carnegie mellon university." } } }, "auth_ref": [] }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CarryingReportedAmountFairValueDisclosureMember", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfOtherFinancialAssetsAndLiabilitiesRecordedInBalanceSheetAtFairValueDetail" ], "lang": { "en-us": { "role": { "label": "Reported Value Measurement [Member]", "terseLabel": "Carrying Value [Member]", "documentation": "Measured as reported on the statement of financial position (balance sheet)." } } }, "auth_ref": [ "r116", "r117" ] }, "us-gaap_Cash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Cash", "crdr": "debit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Cash", "terseLabel": "Cash", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r223", "r750", "r808", "r835", "r937", "r950", "r971" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/GoingConcernAndManagementsLiquidityPlansAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r51", "r254", "r906" ] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r52" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash - end of the period", "periodStartLabel": "Cash - beginning of the period", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r51", "r173", "r283" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel": "Net increase in cash", "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r4", "r173" ] }, "ctcx_CashEarnoutMember": { "xbrltype": "domainItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "CashEarnoutMember", "presentation": [ "http://www.carmellrx.com/role/BusinessCombinationsAdditionalInformationDetail", "http://www.carmellrx.com/role/NatureOfTheOrganizationAndBusinessAdditionalInformationDetail", "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Cash Earnout [Member]", "terseLabel": "Cash Earnout [Member]", "documentation": "Cash Earnout." } } }, "auth_ref": [] }, "us-gaap_CashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Cash Equivalents, at Carrying Value", "terseLabel": "Cash equivalents", "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r971", "r1074" ] }, "ctcx_CashInExcessOfFederallyInsuredLimitsFromContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "CashInExcessOfFederallyInsuredLimitsFromContinuingOperations", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Cash In Excess Of Federally Insured Limits From Continuing Operations", "terseLabel": "Cash in excess of federally insured limits from continuing operations", "documentation": "Cash in excess of federally insured limits from continuing operations." } } }, "auth_ref": [] }, "ctcx_CashInExcessOfFederallyInsuredLimitsFromDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "CashInExcessOfFederallyInsuredLimitsFromDiscontinuedOperations", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Cash In Excess Of Federally Insured Limits From Discontinued Operations", "terseLabel": "Cash in excess of federally insured limits from discontinued operations", "documentation": "Cash in excess of federally insured limits from discontinued operations." } } }, "auth_ref": [] }, "ctcx_CashTransferredInConnectionWithForwardPurchaseAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "CashTransferredInConnectionWithForwardPurchaseAgreement", "crdr": "credit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 28.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash Transferred In Connection With Forward Purchase Agreement", "negatedLabel": "Cash transferred in connection with Forward Purchase Agreement", "documentation": "Cash Transferred In Connection With Forward Purchase Agreement" } } }, "auth_ref": [] }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": { "xbrltype": "booleanItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]", "terseLabel": "Change in Accounting Principle, Accounting Standards Update, Adopted", "documentation": "Indicates (true false) whether accounting standards update was adopted." } } }, "auth_ref": [ "r236", "r237", "r238", "r243", "r244", "r297", "r355", "r356", "r392", "r393", "r394", "r400", "r401", "r435", "r581", "r597", "r598", "r611", "r612", "r613", "r625", "r626", "r636", "r645", "r646", "r650", "r651", "r652", "r662", "r666", "r667", "r668", "r681", "r728", "r729", "r774", "r775" ] }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Change in Accounting Principle, Accounting Standards Update, Adoption Date", "terseLabel": "Change in Accounting Principle, Accounting Standards Update, Adoption Date", "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format." } } }, "auth_ref": [ "r236", "r237", "r238", "r243", "r244", "r355", "r356", "r392", "r393", "r394", "r400", "r401", "r402", "r435", "r581", "r597", "r598", "r599", "r611", "r612", "r613", "r614", "r625", "r626", "r627", "r630", "r636", "r645", "r646", "r650", "r651", "r652", "r662", "r666", "r667", "r668", "r681", "r728", "r729", "r774", "r775", "r960" ] }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": { "xbrltype": "booleanItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]", "terseLabel": "Change in Accounting Principle, Accounting Standards Update, Immaterial Effect", "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial." } } }, "auth_ref": [ "r235", "r298", "r312", "r397", "r585" ] }, "ctcx_ChangeInFairValueOfEarnoutLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "ChangeInFairValueOfEarnoutLiabilities", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/IncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetail" ], "lang": { "en-us": { "role": { "label": "Change In Fair Value Of Earnout Liabilities", "terseLabel": "Change in fair value of earnout liability", "documentation": "Change in fair value of earnout liabilities." } } }, "auth_ref": [] }, "ctcx_ChangeInFairValueOfForwardPurchaseAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "ChangeInFairValueOfForwardPurchaseAgreement", "crdr": "debit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Change in Fair Value of Forward Purchase Agreement", "terseLabel": "Change in fair value of forward purchase agreement", "documentation": "Change in fair value of forward purchase agreement." } } }, "auth_ref": [] }, "ctcx_ChangeInFairValueOfForwardPurchasesAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "ChangeInFairValueOfForwardPurchasesAgreement", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/IncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetail" ], "lang": { "en-us": { "role": { "label": "Change in Fair Value of Forward Purchases Agreement", "terseLabel": "Change in fair value of forward purchase agreement", "documentation": "Change in fair value of forward purchases agreement." } } }, "auth_ref": [] }, "ctcx_ChangeInParValueOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "ChangeInParValueOfCommonStock", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Change in Par Value of Common Stock", "terseLabel": "Change in par value of common stock", "documentation": "Change in par value of common stock." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.carmellrx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://www.carmellrx.com/role/BusinessCombinationsAdditionalInformationDetail", "http://www.carmellrx.com/role/BusinessCombinationsSummaryOfFairValueOfPurchaseConsiderationTransferredDetail", "http://www.carmellrx.com/role/BusinessCombinationsSummaryOfFairValueOfPurchaseConsiderationTransferredParentheticalDetail", "http://www.carmellrx.com/role/ConsolidatedBalanceSheets", "http://www.carmellrx.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.carmellrx.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit", "http://www.carmellrx.com/role/CoverPage", "http://www.carmellrx.com/role/DebtAdditionalInformationDetail", "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitAdditionalInformationDetail", "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitRedeemableConvertiblePreferredStockDetail", "http://www.carmellrx.com/role/NatureOfTheOrganizationAndBusinessAdditionalInformationDetail", "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfTheSecuritiesThatWereExcludedFromTheDilutedPerShareDetail" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r242", "r260", "r261", "r262", "r287", "r317", "r318", "r321", "r323", "r327", "r328", "r390", "r449", "r451", "r452", "r453", "r456", "r457", "r486", "r487", "r490", "r493", "r501", "r649", "r790", "r791", "r792", "r793", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r809", "r827", "r849", "r871", "r894", "r895", "r896", "r897", "r898", "r955", "r982", "r990" ] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockLineItems", "presentation": [ "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r260", "r261", "r262", "r327", "r486", "r487", "r488", "r490", "r493", "r499", "r501", "r790", "r791", "r792", "r793", "r924", "r955", "r982" ] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightAxis", "presentation": [ "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitAdditionalInformationDetail", "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitSummaryOfInformationRelatedToCommonStockWarrantsDetail", "http://www.carmellrx.com/role/NatureOfTheOrganizationAndBusinessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": [ "r93" ] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightDomain", "presentation": [ "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitAdditionalInformationDetail", "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitSummaryOfInformationRelatedToCommonStockWarrantsDetail", "http://www.carmellrx.com/role/NatureOfTheOrganizationAndBusinessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://www.carmellrx.com/role/DebtAdditionalInformationDetail", "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitAdditionalInformationDetail", "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitSummaryOfInformationRelatedToCommonStockWarrantsDetail", "http://www.carmellrx.com/role/NatureOfTheOrganizationAndBusinessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "verboseLabel": "Exercise price of warrant", "terseLabel": "Class of warrant or right, exercise price of warrants or rights", "periodEndLabel": "Weighted average exercise price, outstanding and exercisable, ending balance", "periodStartLabel": "Weighted average exercise price, outstanding and exercisable, beginning balance", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r502" ] }, "us-gaap_ClassOfWarrantOrRightLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightLineItems", "presentation": [ "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitSummaryOfInformationRelatedToCommonStockWarrantsDetail" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": [ "http://www.carmellrx.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "verboseLabel": "Class of warrants or rights number of securities covered by warrants or rights", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": [ "r502" ] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": [ "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitSummaryOfInformationRelatedToCommonStockWarrantsDetail" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Outstanding", "periodEndLabel": "Number of warrants outstanding and exercisable, ending balance", "periodStartLabel": "Number of warrants outstanding and exercisable, beginning balance", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightTable", "presentation": [ "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitSummaryOfInformationRelatedToCommonStockWarrantsDetail" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Table]", "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": [ "r93" ] }, "ctcx_ClassOfWarrantsOrRightsGrantedDuringThePeriodExercisePriceOfWarrantsOrRights": { "xbrltype": "perShareItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "ClassOfWarrantsOrRightsGrantedDuringThePeriodExercisePriceOfWarrantsOrRights", "presentation": [ "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitSummaryOfInformationRelatedToCommonStockWarrantsDetail" ], "lang": { "en-us": { "role": { "label": "Class Of Warrants Or Rights Granted During The Period Exercise Price Of Warrants Or Rights", "terseLabel": "Weighted average exercise price, warrants issued", "documentation": "Class of warrants or rights granted during the period exercise price of warrants or rights." } } }, "auth_ref": [] }, "ctcx_ClassOfWarrantsOrRightsGrantedDuringThePeriodUnits": { "xbrltype": "sharesItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "ClassOfWarrantsOrRightsGrantedDuringThePeriodUnits", "presentation": [ "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitSummaryOfInformationRelatedToCommonStockWarrantsDetail" ], "lang": { "en-us": { "role": { "label": "Class Of Warrants Or Rights Granted During The Period Units", "terseLabel": "Number of warrants issued", "documentation": "Class of warrants or rights granted during the period units." } } }, "auth_ref": [] }, "ctcx_ClassOfWarrantsOrRightsIssuedDuringThePeriod": { "xbrltype": "sharesItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "ClassOfWarrantsOrRightsIssuedDuringThePeriod", "presentation": [ "http://www.carmellrx.com/role/NatureOfTheOrganizationAndBusinessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Class Of Warrants Or Rights Issued During The Period", "terseLabel": "Class of warrants or rights issued during the period", "documentation": "Class of warrants or rights issued during the period." } } }, "auth_ref": [] }, "ctcx_ClassOfWarrantsOrRightsOutstandingWeightedAverageRemainingContractualLife": { "xbrltype": "durationItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "ClassOfWarrantsOrRightsOutstandingWeightedAverageRemainingContractualLife", "presentation": [ "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitSummaryOfInformationRelatedToCommonStockWarrantsDetail" ], "lang": { "en-us": { "role": { "label": "Class Of Warrants Or Rights Outstanding Weighted Average Remaining Contractual Life", "verboseLabel": "Weighted average remaining contractual life in years, outstanding and exercisable", "documentation": "Class of warrants or rights outstanding weighted average remaining contractual life." } } }, "auth_ref": [] }, "ctcx_ClosingDateOfMergerAgreement": { "xbrltype": "dateItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "ClosingDateOfMergerAgreement", "presentation": [ "http://www.carmellrx.com/role/NatureOfTheOrganizationAndBusinessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Closing Date of Merger Agreement", "terseLabel": "Closing date of merger agreement", "documentation": "Closing date of merger agreement." } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies", "verboseLabel": "Commitments and contingencies (see Note 10)", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r41", "r128", "r749", "r826" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.carmellrx.com/role/CommitmentsAndContingencies" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Text Block]", "verboseLabel": "Commitments and Contingencies", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r188", "r441", "r442", "r901", "r1011" ] }, "us-gaap_CommonClassAMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonClassAMember", "presentation": [ "http://www.carmellrx.com/role/NatureOfTheOrganizationAndBusinessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Common Class A [Member]", "documentation": "Classification of common stock representing ownership interest in a corporation." } } }, "auth_ref": [ "r1082" ] }, "us-gaap_CommonClassBMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonClassBMember", "presentation": [ "http://www.carmellrx.com/role/NatureOfTheOrganizationAndBusinessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Common Class B [Member]", "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation." } } }, "auth_ref": [ "r1082" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.carmellrx.com/role/BusinessCombinationsAdditionalInformationDetail", "http://www.carmellrx.com/role/BusinessCombinationsSummaryOfFairValueOfPurchaseConsiderationTransferredDetail", "http://www.carmellrx.com/role/BusinessCombinationsSummaryOfFairValueOfPurchaseConsiderationTransferredParentheticalDetail", "http://www.carmellrx.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit", "http://www.carmellrx.com/role/DebtAdditionalInformationDetail", "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitAdditionalInformationDetail", "http://www.carmellrx.com/role/NatureOfTheOrganizationAndBusinessAdditionalInformationDetail", "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r940", "r941", "r942", "r944", "r945", "r946", "r947", "r987", "r988", "r1056", "r1078", "r1082" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.carmellrx.com/role/NatureOfTheOrganizationAndBusinessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Common Stock, Par or Stated Value Per Share", "verboseLabel": "Common stock par or stated value per share", "terseLabel": "Common stock, par or stated value per share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r159" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares Authorized", "verboseLabel": "Common stock shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r159", "r827" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.carmellrx.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.carmellrx.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.carmellrx.com/role/DebtAdditionalInformationDetail", "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitAdditionalInformationDetail", "http://www.carmellrx.com/role/NatureOfTheOrganizationAndBusinessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Issued", "verboseLabel": "Common stock shares issued", "terseLabel": "Common stock, shares, issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r159" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitAdditionalInformationDetail", "http://www.carmellrx.com/role/NatureOfTheOrganizationAndBusinessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Outstanding", "verboseLabel": "Common stock shares outstanding", "terseLabel": "Common stock, shares, outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r18", "r159", "r827", "r846", "r1082", "r1083" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 25.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.0001 and $.001 par value, 250,000,000 and 240,000,000 shares authorized, and 23,090,585 and 896,580 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r159", "r752", "r937" ] }, "ctcx_CommonStockWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "CommonStockWarrantsMember", "presentation": [ "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitAdditionalInformationDetail", "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitSummaryOfInformationRelatedToCommonStockWarrantsDetail" ], "lang": { "en-us": { "role": { "label": "Common Stock Warrants [Member]", "terseLabel": "Common Stock Warrants [Member]", "documentation": "Common Stock Warrants Member" } } }, "auth_ref": [] }, "us-gaap_CompensatedAbsencesLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CompensatedAbsencesLiability", "crdr": "credit", "calculation": { "http://www.carmellrx.com/role/AccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetail": { "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.carmellrx.com/role/AccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetail" ], "lang": { "en-us": { "role": { "label": "Compensated Absences Liability", "terseLabel": "Accrued compensation", "documentation": "Amount of liability accrued for the employer's obligation related to an employee's right to receive compensation for future absences that have been earned by employee." } } }, "auth_ref": [ "r92" ] }, "us-gaap_CompensationRelatedCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CompensationRelatedCostsPolicyTextBlock", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Compensation Related Costs, Policy [Policy Text Block]", "terseLabel": "Stock-Based Compensation", "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense." } } }, "auth_ref": [ "r95" ] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesConcentrationsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r58", "r61", "r118", "r119", "r351", "r900" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesConcentrationsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r58", "r61", "r118", "r119", "r351", "r786", "r900" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesConcentrationsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r58", "r61", "r118", "r119", "r351", "r900", "r957" ] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskCreditRisk", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentrations", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": [ "r131", "r227" ] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesConcentrationsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Concentration Risk, Percentage", "terseLabel": "Concentrations of risk percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r58", "r61", "r118", "r119", "r351" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesConcentrationsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r58", "r61", "r118", "r119", "r351", "r900" ] }, "dei_ContactPersonnelName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "ContactPersonnelName", "presentation": [ "http://www.carmellrx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Contact Personnel Name", "documentation": "Name of contact personnel" } } }, "auth_ref": [] }, "us-gaap_ContingentConsiderationByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContingentConsiderationByTypeAxis", "presentation": [ "http://www.carmellrx.com/role/BusinessCombinationsAdditionalInformationDetail", "http://www.carmellrx.com/role/NatureOfTheOrganizationAndBusinessAdditionalInformationDetail", "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfOtherFinancialAssetsAndLiabilitiesRecordedInBalanceSheetAtFairValueDetail" ], "lang": { "en-us": { "role": { "label": "Contingent Consideration by Type [Axis]", "documentation": "Information by type of contingent consideration." } } }, "auth_ref": [] }, "us-gaap_ContingentConsiderationTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContingentConsiderationTypeDomain", "presentation": [ "http://www.carmellrx.com/role/BusinessCombinationsAdditionalInformationDetail", "http://www.carmellrx.com/role/NatureOfTheOrganizationAndBusinessAdditionalInformationDetail", "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfOtherFinancialAssetsAndLiabilitiesRecordedInBalanceSheetAtFairValueDetail" ], "lang": { "en-us": { "role": { "label": "Contingent Consideration Type [Domain]", "documentation": "Description of contingent payment arrangement." } } }, "auth_ref": [] }, "ctcx_ConversionOfCommonStockAndPreferredStockInConnectionWithMerger": { "xbrltype": "monetaryItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "ConversionOfCommonStockAndPreferredStockInConnectionWithMerger", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Conversion of Common Stock and Preferred Stock In Connection With Merger", "terseLabel": "Conversion of common stock and preferred stock in connection with the Business Combination", "documentation": "Conversion of common stock and preferred stock in connection with merger." } } }, "auth_ref": [] }, "ctcx_ConversionOfConvertibleNotesAndAccruedNotesToSeriesC2PreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "ConversionOfConvertibleNotesAndAccruedNotesToSeriesC2PreferredStock", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Conversion Of Convertible Notes And Accrued Notes To Series C2 Preferred Stock", "terseLabel": "Conversion of convertible notes and accrued notes to Series C-2 preferred stock", "documentation": "Conversion of convertible notes and accrued notes to series C2 preferred stock." } } }, "auth_ref": [] }, "ctcx_ConversionOfInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "ConversionOfInterestMember", "presentation": [ "http://www.carmellrx.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Conversion of Interest [Member]", "documentation": "Conversion of Interest Member" } } }, "auth_ref": [] }, "us-gaap_ConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebt", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Convertible Debt", "terseLabel": "Convertible Debt", "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company." } } }, "auth_ref": [ "r28", "r211", "r1073" ] }, "us-gaap_ConvertibleDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebtCurrent", "crdr": "credit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 21.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Convertible Debt, Current", "terseLabel": "Convertible notes payable", "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": [ "r155" ] }, "us-gaap_ConvertibleDebtFairValueDisclosures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebtFairValueDisclosures", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Convertible Debt, Fair Value Disclosures", "terseLabel": "Notes fair value", "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock." } } }, "auth_ref": [] }, "us-gaap_ConvertibleDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebtMember", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Convertible Debt [Member]", "verboseLabel": "Notes [Member]", "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock." } } }, "auth_ref": [ "r191", "r459", "r460", "r470", "r471", "r472", "r476", "r477", "r478", "r479", "r480", "r919", "r920", "r921", "r922", "r923" ] }, "us-gaap_ConvertibleDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebtSecuritiesMember", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfTheSecuritiesThatWereExcludedFromTheDilutedPerShareDetail" ], "lang": { "en-us": { "role": { "label": "Convertible Debt Securities [Member]", "terseLabel": "Convertible Notes (if converted) [Member]", "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder." } } }, "auth_ref": [ "r1023" ] }, "ctcx_ConvertibleNoteWarrantsOrRightsIssuedDuringPeriodFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "ConvertibleNoteWarrantsOrRightsIssuedDuringPeriodFairValue", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Convertible note warrants or rights issued during period fair value", "documentation": "Convertible note warrants or rights issued during the period fair value" } } }, "auth_ref": [] }, "ctcx_ConvertibleNotesAndConvertibleNoteWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "ConvertibleNotesAndConvertibleNoteWarrantsMember", "presentation": [ "http://www.carmellrx.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Convertible Notes and Convertible Note Warrants [Member]", "documentation": "Convertible notes and convertible note warrants." } } }, "auth_ref": [] }, "ctcx_ConvertibleNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "ConvertibleNotesMember", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfFairValueOfEmbeddedDerivativesInTheConvertibleNotesDetail" ], "lang": { "en-us": { "role": { "label": "Convertible Notes [Member]", "documentation": "Convertible Notes [Member]" } } }, "auth_ref": [] }, "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertiblePreferredStockSharesIssuedUponConversion", "presentation": [ "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Convertible Preferred Stock, Shares Issued upon Conversion", "verboseLabel": "Convertible preferred stock, shares issued upon conversion", "documentation": "Number of shares issued for each share of convertible preferred stock that is converted." } } }, "auth_ref": [ "r29", "r87", "r158", "r195", "r496" ] }, "us-gaap_CostOfSalesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfSalesPolicyTextBlock", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Cost of Goods and Service [Policy Text Block]", "terseLabel": "Cost of Revenue", "documentation": "Disclosure of accounting policy for cost of product sold and service rendered." } } }, "auth_ref": [ "r963" ] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CounterpartyNameAxis", "presentation": [ "http://www.carmellrx.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r291", "r292", "r462", "r488", "r689", "r908", "r910" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "ctcx_CumulativeDividendsRatePerAnnum": { "xbrltype": "percentItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "CumulativeDividendsRatePerAnnum", "presentation": [ "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Cumulative Dividends Rate Per Annum", "terseLabel": "Cumulative dividends rate per annum", "documentation": "Cumulative dividends rate per annum." } } }, "auth_ref": [] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerConcentrationRiskMember", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesConcentrationsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r59", "r351" ] }, "us-gaap_CustomerContractsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerContractsMember", "presentation": [ "http://www.carmellrx.com/role/GoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetail", "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Customer Contracts [Member]", "documentation": "Entity's established relationships with its customers through contracts." } } }, "auth_ref": [ "r109" ] }, "ctcx_CustomerOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "CustomerOneMember", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesConcentrationsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Customer One [Member]", "documentation": "Customer one." } } }, "auth_ref": [] }, "us-gaap_DebtConversionByUniqueDescriptionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtConversionByUniqueDescriptionAxis", "presentation": [ "http://www.carmellrx.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Debt Conversion Description [Axis]", "documentation": "Information by description of debt issuances converted in a noncash or part noncash transaction." } } }, "auth_ref": [ "r54", "r55" ] }, "us-gaap_DebtConversionConvertedInstrumentAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtConversionConvertedInstrumentAmount1", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Debt Conversion, Converted Instrument, Amount", "terseLabel": "Debt conversion Amount", "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r54", "r55" ] }, "us-gaap_DebtConversionConvertedInstrumentIssuanceDateDayMonthAndYear": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtConversionConvertedInstrumentIssuanceDateDayMonthAndYear", "presentation": [ "http://www.carmellrx.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Debt Conversion, Converted Instrument, Issuance Date", "terseLabel": "Conversion Date", "documentation": "Date the financial instrument was issued in exchange for the original debt being converted in a noncash or part noncash transaction, in YYYY-MM-DD format." } } }, "auth_ref": [ "r54", "r55" ] }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtConversionConvertedInstrumentSharesIssued1", "presentation": [ "http://www.carmellrx.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Debt Conversion, Converted Instrument, Shares Issued", "terseLabel": "Number of Share Issued", "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period." } } }, "auth_ref": [ "r54", "r55" ] }, "us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1", "presentation": [ "http://www.carmellrx.com/role/DebtAdditionalInformationDetail", "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Debt Conversion, Converted Instrument, Warrants or Options Issued", "terseLabel": "Debt conversion, converted instrument, warrants or options issued", "verboseLabel": "Warrants issued", "documentation": "The number of warrants issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r54", "r55" ] }, "us-gaap_DebtConversionNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtConversionNameDomain", "presentation": [ "http://www.carmellrx.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Debt Conversion, Name [Domain]", "documentation": "The name of the original debt issue that has been converted in a noncash (or part noncash) transaction during the accounting period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r54", "r55" ] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://www.carmellrx.com/role/Debt" ], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Text Block]", "terseLabel": "Debt", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r190", "r285", "r458", "r464", "r465", "r466", "r467", "r468", "r469", "r474", "r481", "r482", "r484" ] }, "ctcx_DebtDiscountRecordedInConnectionWithLoansPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "DebtDiscountRecordedInConnectionWithLoansPayable", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Debt Discount Recorded In Connection With Loans Payable", "terseLabel": "Debt discount recorded in connection with loans payable", "documentation": "Debt discount recorded in connection with loans payable." } } }, "auth_ref": [] }, "ctcx_DebtInstrumentAccruedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "DebtInstrumentAccruedInterest", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Debt Instrument Accrued Interest", "terseLabel": "Debt instrument accrued interest", "documentation": "Debt Instrument Accrued InterestDebt instrument accrued interest." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.carmellrx.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.carmellrx.com/role/DebtAdditionalInformationDetail", "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfFairValueOfEmbeddedDerivativesInTheConvertibleNotesDetail" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r28", "r155", "r156", "r210", "r211", "r293", "r459", "r460", "r461", "r462", "r463", "r465", "r470", "r471", "r472", "r473", "r475", "r476", "r477", "r478", "r479", "r480", "r665", "r919", "r920", "r921", "r922", "r923", "r983" ] }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleConversionPrice1", "presentation": [ "http://www.carmellrx.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Convertible, Conversion Price", "terseLabel": "Debt instrument conversion price per share", "documentation": "The price per share of the conversion feature embedded in the debt instrument." } } }, "auth_ref": [ "r192", "r461" ] }, "us-gaap_DebtInstrumentConvertibleConversionRatio1": { "xbrltype": "pureItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleConversionRatio1", "presentation": [ "http://www.carmellrx.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Convertible, Conversion Ratio", "terseLabel": "Conversion Ratio", "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount." } } }, "auth_ref": [ "r39", "r87", "r195", "r196", "r461" ] }, "us-gaap_DebtInstrumentDateOfFirstRequiredPayment1": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentDateOfFirstRequiredPayment1", "presentation": [ "http://www.carmellrx.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Date of First Required Payment", "terseLabel": "Debt instrument date of first required payment", "documentation": "Date the debt agreement requires the first payment to be made, in YYYY-MM-DD format." } } }, "auth_ref": [ "r40", "r130" ] }, "ctcx_DebtInstrumentDiscountPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "DebtInstrumentDiscountPercentage", "presentation": [ "http://www.carmellrx.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Debt Instrument Discount Percentage", "terseLabel": "Debt instrument discount percentage on conversion price", "documentation": "Debt instrument discount percentage." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Face Amount", "verboseLabel": "Debt instrument, face amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r121", "r123", "r459", "r665", "r920", "r921" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://www.carmellrx.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Interest Rate", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r38", "r460" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentLineItems", "presentation": [ "http://www.carmellrx.com/role/DebtAdditionalInformationDetail", "http://www.carmellrx.com/role/GoingConcernAndManagementsLiquidityPlansAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r293", "r459", "r460", "r461", "r462", "r463", "r465", "r470", "r471", "r472", "r473", "r475", "r476", "r477", "r478", "r479", "r480", "r483", "r665", "r919", "r920", "r921", "r922", "r923", "r983" ] }, "us-gaap_DebtInstrumentMaturityDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentMaturityDate", "presentation": [ "http://www.carmellrx.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Maturity Date", "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format." } } }, "auth_ref": [ "r240", "r919", "r1058" ] }, "ctcx_DebtInstrumentMaturityYear": { "xbrltype": "gYearItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "DebtInstrumentMaturityYear", "presentation": [ "http://www.carmellrx.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Maturity Year", "terseLabel": "Debt instrument maturity and payable year", "documentation": "Debt instrument, maturity year." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.carmellrx.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.carmellrx.com/role/DebtAdditionalInformationDetail", "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfFairValueOfEmbeddedDerivativesInTheConvertibleNotesDetail" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r40", "r293", "r459", "r460", "r461", "r462", "r463", "r465", "r470", "r471", "r472", "r473", "r475", "r476", "r477", "r478", "r479", "r480", "r665", "r919", "r920", "r921", "r922", "r923", "r983" ] }, "us-gaap_DebtInstrumentPeriodicPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentPeriodicPayment", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Periodic Payment", "terseLabel": "Payment of principal and interest", "documentation": "Amount of the required periodic payments including both interest and principal payments." } } }, "auth_ref": [ "r40", "r130" ] }, "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentPeriodicPaymentPrincipal", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Periodic Payment, Principal", "terseLabel": "Debt instrument monthly payment", "documentation": "Amount of the required periodic payments applied to principal." } } }, "auth_ref": [ "r40" ] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTable", "presentation": [ "http://www.carmellrx.com/role/DebtAdditionalInformationDetail", "http://www.carmellrx.com/role/GoingConcernAndManagementsLiquidityPlansAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r40", "r87", "r90", "r120", "r121", "r123", "r129", "r194", "r196", "r293", "r459", "r460", "r461", "r462", "r463", "r465", "r470", "r471", "r472", "r473", "r475", "r476", "r477", "r478", "r479", "r480", "r483", "r665", "r919", "r920", "r921", "r922", "r923", "r983" ] }, "us-gaap_DebtInstrumentTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTerm", "presentation": [ "http://www.carmellrx.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Term", "terseLabel": "Debt instrument, term", "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentUnamortizedDiscount", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Unamortized Discount", "terseLabel": "Unamortized debt discount", "documentation": "Amount, after accumulated amortization, of debt discount." } } }, "auth_ref": [ "r120", "r123", "r1020" ] }, "us-gaap_DeferredCostsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredCostsCurrent", "crdr": "debit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Deferred Costs, Current", "terseLabel": "Deferred offering costs", "documentation": "Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r976" ] }, "us-gaap_DeferredOfferingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredOfferingCosts", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Deferred Offering Costs", "terseLabel": "Deferred offering costs", "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period." } } }, "auth_ref": [ "r997" ] }, "us-gaap_DeferredTaxAssetInterestCarryforward": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetInterestCarryforward", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/IncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetail" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Asset, Interest Carryforward", "terseLabel": "Accrued interest", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible interest carryforward." } } }, "auth_ref": [ "r1053" ] }, "ctcx_DeferredTaxAssetsAccruedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "DeferredTaxAssetsAccruedCompensation", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/IncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetail" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets Accrued Compensation", "terseLabel": "Accrued compensation", "documentation": "Deferred tax assets accrued compensation." } } }, "auth_ref": [] }, "ctcx_DeferredTaxAssetsAmortizationOfResearchExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "DeferredTaxAssetsAmortizationOfResearchExpense", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/IncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetail" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets Amortization of Research Expense", "terseLabel": "Amortization of research expense", "documentation": "Deferred tax assets amortization of research expense." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsDerivativeInstruments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsDerivativeInstruments", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/IncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetail" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Derivative Instruments", "terseLabel": "Change in fair value of derivative liabilities", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from derivative instruments." } } }, "auth_ref": [ "r101", "r1053" ] }, "us-gaap_DeferredTaxAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsGross", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/IncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetail" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Gross", "totalLabel": "Gross deferred tax asset", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r576" ] }, "us-gaap_DeferredTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsNet", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/IncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetail" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Net of Valuation Allowance", "totalLabel": "Net deferred income tax assets", "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r1052" ] }, "us-gaap_DeferredTaxAssetsNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsNetAbstract", "presentation": [ "http://www.carmellrx.com/role/IncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetail" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Net [Abstract]", "terseLabel": "Deferred income tax assets:" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/IncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetail" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Operating Loss Carryforwards", "terseLabel": "Net operating losses", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards." } } }, "auth_ref": [ "r101", "r1053" ] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Operating Loss Carryforwards, Domestic", "terseLabel": "Federal net operating loss carryforwards", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards." } } }, "auth_ref": [ "r101", "r1053" ] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local", "terseLabel": "State net operating loss carryforwards", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards." } } }, "auth_ref": [ "r101", "r1053" ] }, "ctcx_DeferredTaxAssetsRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "DeferredTaxAssetsRightOfUseAsset", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/IncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetail" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets Right of Use Asset", "terseLabel": "Right of use asset", "documentation": "Deferred tax assets right of use asset." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/IncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetail" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research", "terseLabel": "Federal research and development tax credits", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards." } } }, "auth_ref": [ "r100", "r101", "r1053" ] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/IncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetail" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost", "terseLabel": "Non-qualified deferred compensation", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation." } } }, "auth_ref": [ "r101", "r1053" ] }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/IncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetail" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Valuation allowance", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": [ "r577" ] }, "us-gaap_DefinedBenefitPlanAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanAbstract", "lang": { "en-us": { "role": { "label": "Defined Benefit Plan [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanTextBlock", "presentation": [ "http://www.carmellrx.com/role/ProfitSharingPlan" ], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan [Text Block]", "terseLabel": "Profit-Sharing Plan", "documentation": "The entire disclosure for defined benefit plan." } } }, "auth_ref": [ "r516", "r725", "r929" ] }, "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/ProfitSharingPlanAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount", "terseLabel": "401(k) Profit sharing plans, employer contribution", "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan." } } }, "auth_ref": [] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Depreciation", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/PropertyAndEquipmentAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Depreciation", "terseLabel": "Depreciation expense", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r11", "r71" ] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 }, "http://www.carmellrx.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows", "http://www.carmellrx.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization of intangible assets", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r11", "r333" ] }, "us-gaap_DerivativeAssetMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeAssetMeasurementInput", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Derivative Asset, Measurement Input", "terseLabel": "Derivative Asset, Measurement Input", "documentation": "Value of input used to measure derivative asset." } } }, "auth_ref": [ "r642" ] }, "us-gaap_DerivativeAssetValuationTechniqueExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeAssetValuationTechniqueExtensibleList", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Derivative Asset, Valuation Technique [Extensible Enumeration]", "documentation": "Indicates valuation technique for measuring derivative asset." } } }, "auth_ref": [ "r641" ] }, "ctcx_DerivativeEquitySecurityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "DerivativeEquitySecurityMember", "presentation": [ "http://www.carmellrx.com/role/NatureOfTheOrganizationAndBusinessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Derivative Equity Security [Member]", "terseLabel": "Derivative Equity Security [Member]", "documentation": "Derivative equity security." } } }, "auth_ref": [] }, "us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeFinancialInstrumentsLiabilitiesMember", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfChangesInFairValueOfLevel3FinancialAssetsAndLiabilitiesDetail" ], "lang": { "en-us": { "role": { "label": "Derivative Financial Instruments, Liabilities [Member]", "terseLabel": "Derivative Liabilities [Member]", "documentation": "This item represents derivative instrument obligations meeting the definition of a liability which are reported as of the balance sheet date. Derivative instrument obligations are generally measured at fair value, and adjustments to the carrying amount of hedged items reflect changes in their fair value (that is, losses) that are attributable to the risk being hedged and that arise while the hedge is in effect." } } }, "auth_ref": [] }, "us-gaap_DerivativeFloorPrice": { "xbrltype": "perUnitItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeFloorPrice", "presentation": [ "http://www.carmellrx.com/role/NatureOfTheOrganizationAndBusinessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Derivative, Floor Price", "terseLabel": "Derivative, floor price", "documentation": "Floor rate on a price risk derivative such as a floor or a collar. A payment or receipt is triggered if the market rate falls below the floor rate on the contract." } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentsAndHedgesLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsAndHedgesLiabilities", "crdr": "credit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 22.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Derivative Instruments and Hedges, Liabilities", "terseLabel": "Derivative liabilities", "documentation": "Sum as of the balance sheet date of the (a) fair values of all liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments, and (b) the carrying amounts of the liabilities arising from financial instruments or contracts used to mitigate a specified risk (hedge), and which are expected to be extinguished or otherwise disposed of within a year or the normal operating cycle, if longer, net of the effects of master netting arrangements." } } }, "auth_ref": [ "r36" ] }, "us-gaap_DerivativeLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLiabilities", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfOtherFinancialAssetsAndLiabilitiesRecordedInBalanceSheetAtFairValueDetail" ], "lang": { "en-us": { "role": { "label": "Derivative Liabilities", "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r267", "r268", "r648", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r841", "r843", "r844", "r882", "r883", "r884", "r886", "r887", "r888", "r889", "r910", "r1079" ] }, "us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfOtherFinancialAssetsAndLiabilitiesRecordedInBalanceSheetAtFairValueDetail" ], "lang": { "en-us": { "role": { "label": "Derivative Liability, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes derivative liability." } } }, "auth_ref": [ "r610" ] }, "ctcx_DerivativeResetPrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "DerivativeResetPrice", "presentation": [ "http://www.carmellrx.com/role/NatureOfTheOrganizationAndBusinessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Derivative Reset Price", "terseLabel": "Derivative reset price", "documentation": "Derivative reset price." } } }, "auth_ref": [] }, "us-gaap_DerivativeTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeTermOfContract", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Derivative, Term of Contract", "terseLabel": "Derivative Asset, term", "documentation": "Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans", "presentation": [ "http://www.carmellrx.com/role/ProfitSharingPlanAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Defined Contribution Plan, Description", "terseLabel": "Profit Sharing 401(k) Plans Description", "documentation": "Description of defined contribution pension and other postretirement plans." } } }, "auth_ref": [] }, "ctcx_DisclosureOfAccruedExpensesAndOtherLiabilitiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "DisclosureOfAccruedExpensesAndOtherLiabilitiesTextBlock", "presentation": [ "http://www.carmellrx.com/role/AccruedExpensesAndOtherLiabilities" ], "lang": { "en-us": { "role": { "label": "Disclosure Of Accrued Expenses And Other Liabilities [Text Block]", "terseLabel": "Accrued Expenses and Other Liabilities", "documentation": "Disclosure of accrued expenses and other liabilities." } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/DiscontinuedOperationsSummaryOfDiscontinuedOperationsInConsolidatedStatementsOfIncomeDetail" ], "lang": { "en-us": { "role": { "label": "Discontinued Operation, Gain (Loss) from Disposal of Discontinued Operation, before Income Tax", "totalLabel": "Loss before income taxes", "documentation": "Amount before tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation." } } }, "auth_ref": [ "r138", "r140", "r142" ] }, "us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/DiscontinuedOperationsSummaryOfDiscontinuedOperationsInConsolidatedStatementsOfIncomeDetail" ], "lang": { "en-us": { "role": { "label": "Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax", "totalLabel": "Discontinued operations, net", "documentation": "Amount after tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation." } } }, "auth_ref": [ "r138", "r140", "r142", "r151" ] }, "us-gaap_DiscontinuedOperationGainLossOnDisposalStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DiscontinuedOperationGainLossOnDisposalStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration", "presentation": [ "http://www.carmellrx.com/role/DiscontinuedOperationsSummaryOfDiscontinuedOperationsInConsolidatedStatementsOfIncomeDetail" ], "lang": { "en-us": { "role": { "label": "Discontinued Operation, Gain (Loss) on Disposal, Statement of Income or Comprehensive Income [Extensible Enumeration]", "documentation": "Indicates line item in statement of income or comprehensive income that includes gain (loss) from disposal of discontinued operation." } } }, "auth_ref": [ "r248" ] }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare", "calculation": { "http://www.carmellrx.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_EarningsPerShareBasic", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share", "terseLabel": "Discontinued operations, net of tax - basic", "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation." } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare", "calculation": { "http://www.carmellrx.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_EarningsPerShareDiluted", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Diluted Share", "terseLabel": "Discontinued operations, net of tax - diluted", "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation." } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/DiscontinuedOperationsSummaryOfDiscontinuedOperationsInConsolidatedStatementsOfIncomeDetail" ], "lang": { "en-us": { "role": { "label": "Discontinued Operation, Tax Effect of Gain (Loss) from Disposal of Discontinued Operation", "terseLabel": "Income tax benefit, deferred", "documentation": "Amount of tax expense (benefit) on gain (loss) not previously recognized resulting from the disposal of a discontinued operation." } } }, "auth_ref": [ "r140", "r142", "r151", "r1055" ] }, "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract", "lang": { "en-us": { "role": { "label": "Discontinued Operations and Disposal Groups [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationsDisposedOfBySaleMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DiscontinuedOperationsDisposedOfBySaleMember", "presentation": [ "http://www.carmellrx.com/role/DiscontinuedOperationsSummaryOfAssetsAndLiabilitiesClassifiedAsAvailableForSaleDetail" ], "lang": { "en-us": { "role": { "label": "Discontinued Operations, Disposed of by Sale [Member]", "documentation": "Component or group of components disposed of by sale and representing a strategic shift that has or will have a major effect on operations and financial results." } } }, "auth_ref": [ "r7" ] }, "us-gaap_DiscontinuedOperationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DiscontinuedOperationsPolicyTextBlock", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Discontinued Operations, Policy [Policy Text Block]", "terseLabel": "Discontinued Operations", "documentation": "Disclosure of accounting policy for discontinued operations. Includes, but is not limited to, method of interest allocation to a discontinued operation." } } }, "auth_ref": [ "r14", "r33" ] }, "us-gaap_DisposalGroupClassificationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupClassificationAxis", "presentation": [ "http://www.carmellrx.com/role/DiscontinuedOperationsSummaryOfAssetsAndLiabilitiesClassifiedAsAvailableForSaleDetail" ], "lang": { "en-us": { "role": { "label": "Disposal Group Classification [Axis]", "documentation": "Information by disposal group classification." } } }, "auth_ref": [ "r249" ] }, "us-gaap_DisposalGroupClassificationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupClassificationDomain", "presentation": [ "http://www.carmellrx.com/role/DiscontinuedOperationsSummaryOfAssetsAndLiabilitiesClassifiedAsAvailableForSaleDetail" ], "lang": { "en-us": { "role": { "label": "Disposal Group Classification [Domain]", "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations." } } }, "auth_ref": [] }, "ctcx_DisposalGroupIncludingDiscontinuedOperatingExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "DisposalGroupIncludingDiscontinuedOperatingExpenseAbstract", "presentation": [ "http://www.carmellrx.com/role/DiscontinuedOperationsSummaryOfDiscontinuedOperationsInConsolidatedStatementsOfIncomeDetail" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operating Expense [Abstract]", "terseLabel": "Operating expenses:", "documentation": "Disposal Group, Including Discontinued Operating Expense." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/DiscontinuedOperationsSummaryOfAssetsAndLiabilitiesClassifiedAsAvailableForSaleDetail" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net", "terseLabel": "Accounts receivable, net", "documentation": "Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r5", "r134", "r149", "r186" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/DiscontinuedOperationsSummaryOfAssetsAndLiabilitiesClassifiedAsAvailableForSaleDetail" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Accounts Payable, Current", "terseLabel": "Accounts payable", "documentation": "Amount classified as accounts payable attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r5", "r134", "r149", "r184", "r186" ] }, "ctcx_DisposalGroupIncludingDiscontinuedOperationAccruedInterestCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "DisposalGroupIncludingDiscontinuedOperationAccruedInterestCurrent", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/DiscontinuedOperationsSummaryOfAssetsAndLiabilitiesClassifiedAsAvailableForSaleDetail" ], "lang": { "en-us": { "role": { "label": "Disposal Group Including Discontinued Operation Accrued Interest Current", "terseLabel": "Accrued interest", "documentation": "Disposal group including discontinued operation accrued interest current." } } }, "auth_ref": [] }, "ctcx_DisposalGroupIncludingDiscontinuedOperationAccruedInterestRelatedPartyCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "DisposalGroupIncludingDiscontinuedOperationAccruedInterestRelatedPartyCurrent", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/DiscontinuedOperationsSummaryOfAssetsAndLiabilitiesClassifiedAsAvailableForSaleDetail" ], "lang": { "en-us": { "role": { "label": "Disposal Group Including Discontinued Operation Accrued Interest, Related Party Current", "terseLabel": "Accrued interest, related party", "documentation": "Disposal group including discontinued operation accrued interest, related party current." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/DiscontinuedOperationsSummaryOfAssetsAndLiabilitiesClassifiedAsAvailableForSaleDetail" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents", "terseLabel": "Cash and cash equivalents", "documentation": "Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r5", "r134", "r149", "r186" ] }, "ctcx_DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfEarnoutLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfEarnoutLiabilities", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/DiscontinuedOperationsSummaryOfDiscontinuedOperationsInConsolidatedStatementsOfIncomeDetail" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Change in fair value of earnout liabilities", "terseLabel": "Chane in fair value of earnout liability", "documentation": "Disposal Group, Including Discontinued Operation, Change in fair value of earnout liabilities" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/DiscontinuedOperationsSummaryOfDiscontinuedOperationsInConsolidatedStatementsOfIncomeDetail" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Costs of Goods Sold", "terseLabel": "Cost of sales", "documentation": "Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r148", "r250" ] }, "ctcx_DisposalGroupIncludingDiscontinuedOperationDeferredIncomeTaxesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "DisposalGroupIncludingDiscontinuedOperationDeferredIncomeTaxesCurrent", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/DiscontinuedOperationsSummaryOfAssetsAndLiabilitiesClassifiedAsAvailableForSaleDetail" ], "lang": { "en-us": { "role": { "label": "Disposal Group Including Discontinued Operation Deferred Income Taxes Current", "terseLabel": "Deferred income taxes", "documentation": "Disposal group including discontinued operation deferred income taxes current." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/DiscontinuedOperationsSummaryOfDiscontinuedOperationsInConsolidatedStatementsOfIncomeDetail" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Depreciation and Amortization", "terseLabel": "Depreciation and amortization", "documentation": "Amount of depreciation and amortization expense attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r148" ] }, "ctcx_DisposalGroupIncludingDiscontinuedOperationEarnoutLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "DisposalGroupIncludingDiscontinuedOperationEarnoutLiabilityCurrent", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/DiscontinuedOperationsSummaryOfAssetsAndLiabilitiesClassifiedAsAvailableForSaleDetail" ], "lang": { "en-us": { "role": { "label": "Disposal Group Including Discontinued Operation Earnout Liability Current", "terseLabel": "Earnout liability", "documentation": "Disposal Group Including Discontinued Operation Earnout Liability Current." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/DiscontinuedOperationsSummaryOfDiscontinuedOperationsInConsolidatedStatementsOfIncomeDetail" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, General and Administrative Expense", "terseLabel": "General and administrative", "documentation": "Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r148" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/DiscontinuedOperationsSummaryOfAssetsAndLiabilitiesClassifiedAsAvailableForSaleDetail" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Goodwill, Current", "terseLabel": "Goodwill", "documentation": "Amount classified as goodwill attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r5", "r134", "r149", "r184", "r186" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/DiscontinuedOperationsSummaryOfDiscontinuedOperationsInConsolidatedStatementsOfIncomeDetail" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Gross Profit (Loss)", "totalLabel": "Gross profit", "documentation": "Amount of gross profit attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r148", "r250" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/DiscontinuedOperationsSummaryOfAssetsAndLiabilitiesClassifiedAsAvailableForSaleDetail" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Intangible Assets, Current", "terseLabel": "Intangible assets, net", "documentation": "Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r5", "r134", "r149", "r184", "r186" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationInterestExpense", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/DiscontinuedOperationsSummaryOfDiscontinuedOperationsInConsolidatedStatementsOfIncomeDetail" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Interest Expense", "negatedLabel": "Interest expense", "documentation": "Amount of interest expense attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r30", "r31", "r33", "r148" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationInventoryCurrent", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/DiscontinuedOperationsSummaryOfAssetsAndLiabilitiesClassifiedAsAvailableForSaleDetail" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Inventory, Current", "terseLabel": "Inventories", "documentation": "Amount classified as inventory attributable to disposal group, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r5", "r134", "r149", "r184", "r186" ] }, "ctcx_DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown": { "xbrltype": "monetaryItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/DiscontinuedOperationsSummaryOfDiscontinuedOperationsInConsolidatedStatementsOfIncomeDetail" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Inventory write-down", "negatedLabel": "Inventory write-down", "documentation": "Disposal Group, Including Discontinued Operation, Inventory write-down" } } }, "auth_ref": [] }, "ctcx_DisposalGroupIncludingDiscontinuedOperationLoansPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "DisposalGroupIncludingDiscontinuedOperationLoansPayableCurrent", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/DiscontinuedOperationsSummaryOfAssetsAndLiabilitiesClassifiedAsAvailableForSaleDetail" ], "lang": { "en-us": { "role": { "label": "Disposal Group Including Discontinued Operation Loans Payable, Current", "terseLabel": "Loans payable, current", "documentation": "Disposal group including discontinued operation loans payable, current." } } }, "auth_ref": [] }, "ctcx_DisposalGroupIncludingDiscontinuedOperationNonOperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "DisposalGroupIncludingDiscontinuedOperationNonOperatingIncomeExpense", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/DiscontinuedOperationsSummaryOfDiscontinuedOperationsInConsolidatedStatementsOfIncomeDetail" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Non operating Income Expense", "totalLabel": "Total other (expense) income", "documentation": "Disposal Group, Including Discontinued Operation, Non operating Income Expense." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingExpense", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/DiscontinuedOperationsSummaryOfDiscontinuedOperationsInConsolidatedStatementsOfIncomeDetail" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Operating Expense", "totalLabel": "Total operating expenses", "documentation": "Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r148" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/DiscontinuedOperationsSummaryOfDiscontinuedOperationsInConsolidatedStatementsOfIncomeDetail" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Operating Income (Loss)", "totalLabel": "Loss from operations", "documentation": "Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r148" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/DiscontinuedOperationsSummaryOfAssetsAndLiabilitiesClassifiedAsAvailableForSaleDetail" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Other Liabilities, Current", "terseLabel": "Other accrued expenses", "documentation": "Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r5", "r134", "r149", "r184", "r186" ] }, "ctcx_DisposalGroupIncludingDiscontinuedOperationOtherExpenseIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "DisposalGroupIncludingDiscontinuedOperationOtherExpenseIncomeAbstract", "presentation": [ "http://www.carmellrx.com/role/DiscontinuedOperationsSummaryOfDiscontinuedOperationsInConsolidatedStatementsOfIncomeDetail" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Other (expense) income [Abstract]", "terseLabel": "Other income (expense):", "documentation": "Disposal Group, Including Discontinued Operation, Other (expense) income." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationOtherIncome", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/DiscontinuedOperationsSummaryOfDiscontinuedOperationsInConsolidatedStatementsOfIncomeDetail" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Other Income", "negatedLabel": "Other income", "documentation": "Amount of other income attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r148" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/DiscontinuedOperationsSummaryOfAssetsAndLiabilitiesClassifiedAsAvailableForSaleDetail" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current", "terseLabel": "Prepaid expenses", "documentation": "Amount classified as prepaid and other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r5", "r134", "r149", "r184", "r186" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/DiscontinuedOperationsSummaryOfAssetsAndLiabilitiesClassifiedAsAvailableForSaleDetail" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Current", "terseLabel": "Property and equipment, net", "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r5", "r134", "r149", "r184", "r186" ] }, "ctcx_DisposalGroupIncludingDiscontinuedOperationRelatedPartyLoansCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "DisposalGroupIncludingDiscontinuedOperationRelatedPartyLoansCurrent", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/DiscontinuedOperationsSummaryOfAssetsAndLiabilitiesClassifiedAsAvailableForSaleDetail" ], "lang": { "en-us": { "role": { "label": "Disposal Group Including Discontinued Operation Related Party Loans, Current", "terseLabel": "Related party loans, current", "documentation": "Disposal group including discontinued operation related party loans, current." } } }, "auth_ref": [] }, "ctcx_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/DiscontinuedOperationsSummaryOfDiscontinuedOperationsInConsolidatedStatementsOfIncomeDetail" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Research and development", "terseLabel": "Research and development", "documentation": "Disposal Group, Including Discontinued Operation, Research and development." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/DiscontinuedOperationsSummaryOfDiscontinuedOperationsInConsolidatedStatementsOfIncomeDetail" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Revenue", "terseLabel": "Revenue", "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r148", "r250" ] }, "ctcx_DisposalGroupIncludingDiscontinuedOperationSellingAndMarketing": { "xbrltype": "monetaryItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "DisposalGroupIncludingDiscontinuedOperationSellingAndMarketing", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/DiscontinuedOperationsSummaryOfDiscontinuedOperationsInConsolidatedStatementsOfIncomeDetail" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Selling and marketing", "terseLabel": "Selling and marketing", "documentation": "Disposal Group, Including Discontinued Operation, Selling and marketing." } } }, "auth_ref": [] }, "ctcx_DisposalGroupIncludingDiscontinuedOperationsAmortizationOfDebtDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "DisposalGroupIncludingDiscontinuedOperationsAmortizationOfDebtDiscount", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/DiscontinuedOperationsSummaryOfDiscontinuedOperationsInConsolidatedStatementsOfIncomeDetail" ], "lang": { "en-us": { "role": { "label": "Disposal Group Including Discontinued Operations Amortization of Debt Discount", "negatedLabel": "Amortization of debt discount", "documentation": "Disposal group including discontinued operations amortization of debt discount." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "presentation": [ "http://www.carmellrx.com/role/DiscontinuedOperations" ], "lang": { "en-us": { "role": { "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]", "terseLabel": "Discontinued Operations", "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r133", "r183" ] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "presentation": [ "http://www.carmellrx.com/role/DiscontinuedOperationsSummaryOfAssetsAndLiabilitiesClassifiedAsAvailableForSaleDetail", "http://www.carmellrx.com/role/DiscontinuedOperationsSummaryOfDiscontinuedOperationsInConsolidatedStatementsOfIncomeDetail", "http://www.carmellrx.com/role/NatureOfTheOrganizationAndBusinessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Disposal Group Name [Domain]", "documentation": "Name of disposal group." } } }, "auth_ref": [ "r930", "r931" ] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationLineItems", "presentation": [ "http://www.carmellrx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationTable", "presentation": [ "http://www.carmellrx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.carmellrx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_DomesticCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DomesticCountryMember", "presentation": [ "http://www.carmellrx.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Domestic Tax Authority [Member]", "terseLabel": "Domestic Tax Authority [Member]", "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Net (loss) income per common share - basic and diluted:" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "calculation": { "http://www.carmellrx.com/role/ConsolidatedStatementsOfOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic", "totalLabel": "Net loss per common share - basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r276", "r302", "r303", "r305", "r306", "r308", "r314", "r317", "r321", "r322", "r323", "r325", "r634", "r635", "r745", "r764", "r912" ] }, "us-gaap_EarningsPerShareBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasicAbstract", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic [Abstract]", "terseLabel": "Basic" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "calculation": { "http://www.carmellrx.com/role/ConsolidatedStatementsOfOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted", "totalLabel": "Net loss per common share - diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r276", "r302", "r303", "r305", "r306", "r308", "r317", "r321", "r322", "r323", "r325", "r634", "r635", "r745", "r764", "r912" ] }, "us-gaap_EarningsPerShareDilutedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDilutedAbstract", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted [Abstract]", "terseLabel": "Diluted" } } }, "auth_ref": [] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Loss Per Share", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r56", "r57" ] }, "ctcx_EarnoutLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "EarnoutLiabilitiesMember", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfChangesInFairValueOfLevel3FinancialAssetsAndLiabilitiesDetail" ], "lang": { "en-us": { "role": { "label": "Earnout Liabilities [Member]", "terseLabel": "Earnout Liabilities [Member]", "documentation": "Earnout liabilities." } } }, "auth_ref": [] }, "ctcx_EarnoutLiabilityAndDeferredConsiderationPayableIncurredInConnectionWithAcquisition": { "xbrltype": "monetaryItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "EarnoutLiabilityAndDeferredConsiderationPayableIncurredInConnectionWithAcquisition", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Earnout Liability and Deferred Consideration Payable Incurred in Connection With Acquisition", "terseLabel": "Earnout liability and deferred consideration payable in connection with AxoBio Acquisition", "documentation": "Earnout liability and deferred consideration payable incurred in connection with acquisition." } } }, "auth_ref": [] }, "ctcx_EarnoutLiabilityPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "EarnoutLiabilityPolicyTextBlock", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Earnout Liability [Policy Text Block]", "terseLabel": "Earnout Liability", "documentation": "Earnout liability." } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": [ "http://www.carmellrx.com/role/IncomeTaxesComponentsOfIncomeTaxRateDetail" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Percent", "totalLabel": "Effective rate", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r569" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "presentation": [ "http://www.carmellrx.com/role/IncomeTaxesComponentsOfIncomeTaxRateDetail" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "U.S. federal statutory rate", "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)." } } }, "auth_ref": [ "r288", "r569", "r588" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "presentation": [ "http://www.carmellrx.com/role/IncomeTaxesComponentsOfIncomeTaxRateDetail" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent", "terseLabel": "Valuation allowance", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets." } } }, "auth_ref": [ "r1050", "r1054" ] }, "ctcx_EffectiveIncomeTaxRateReconciliationGainOnLoanForgiveness": { "xbrltype": "percentItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "EffectiveIncomeTaxRateReconciliationGainOnLoanForgiveness", "presentation": [ "http://www.carmellrx.com/role/IncomeTaxesComponentsOfIncomeTaxRateDetail" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation Gain on Loan Forgiveness", "terseLabel": "Gain on loan forgiveness", "documentation": "Effective income tax rate reconciliation gain on loan forgiveness." } } }, "auth_ref": [] }, "ctcx_EffectiveIncomeTaxRateReconciliationLossOnForwardPurchaseAgreement": { "xbrltype": "percentItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "EffectiveIncomeTaxRateReconciliationLossOnForwardPurchaseAgreement", "presentation": [ "http://www.carmellrx.com/role/IncomeTaxesComponentsOfIncomeTaxRateDetail" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation Loss On Forward Purchase Agreement", "terseLabel": "Loss on forward purchase agreement", "documentation": "Effective income tax rate reconciliation loss on forward purchase agreement." } } }, "auth_ref": [] }, "ctcx_EffectiveIncomeTaxRateReconciliationNetOperatingLossPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "EffectiveIncomeTaxRateReconciliationNetOperatingLossPercent", "presentation": [ "http://www.carmellrx.com/role/IncomeTaxesComponentsOfIncomeTaxRateDetail" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation Net Operating Loss Percent", "terseLabel": "Net operating loss\u00a0true-up", "documentation": "Effective income tax rate reconciliation net operating loss percent." } } }, "auth_ref": [] }, "ctcx_EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseCapitalizedTransactionCosts": { "xbrltype": "percentItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseCapitalizedTransactionCosts", "presentation": [ "http://www.carmellrx.com/role/IncomeTaxesComponentsOfIncomeTaxRateDetail" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation Non Deductible Expense Capitalized Transaction Costs", "terseLabel": "Capitalized transaction costs", "documentation": "Effective income tax rate reconciliation non deductible expense capitalized transaction costs." } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther", "presentation": [ "http://www.carmellrx.com/role/IncomeTaxesComponentsOfIncomeTaxRateDetail" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent", "terseLabel": "Other", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses." } } }, "auth_ref": [ "r1050", "r1054" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment", "presentation": [ "http://www.carmellrx.com/role/IncomeTaxesComponentsOfIncomeTaxRateDetail" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent", "terseLabel": "Research and development expenses, net", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense." } } }, "auth_ref": [ "r1050", "r1054" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost", "presentation": [ "http://www.carmellrx.com/role/IncomeTaxesComponentsOfIncomeTaxRateDetail" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent", "terseLabel": "Stock based compensation", "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement." } } }, "auth_ref": [ "r1050", "r1054" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "presentation": [ "http://www.carmellrx.com/role/IncomeTaxesComponentsOfIncomeTaxRateDetail" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent", "terseLabel": "State taxes, net of federal benefit", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)." } } }, "auth_ref": [ "r1050", "r1054" ] }, "us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Embedded Derivative, Fair Value of Embedded Derivative Liability", "terseLabel": "Fair value of derivative upon conversion of convertible debt", "documentation": "Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability." } } }, "auth_ref": [ "r113" ] }, "us-gaap_EmbeddedDerivativeLiabilityMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmbeddedDerivativeLiabilityMeasurementInput", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfFairValueOfEmbeddedDerivativesInTheConvertibleNotesDetail" ], "lang": { "en-us": { "role": { "label": "Embedded Derivative Liability, Measurement Input", "terseLabel": "Embedded derivative liability, measurement input", "documentation": "Value of input used to measure embedded derivative liability." } } }, "auth_ref": [ "r1058" ] }, "ctcx_EmergingGrowthCompanyStatusPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "EmergingGrowthCompanyStatusPolicyTextBlock", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Emerging Growth Company Status [Policy Text Block]", "verboseLabel": "Emerging Growth Company Status", "documentation": "Disclosure of accounting policy for emerging growth company status." } } }, "auth_ref": [] }, "us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeRelatedLiabilitiesCurrentAndNoncurrent", "crdr": "credit", "calculation": { "http://www.carmellrx.com/role/AccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetail": { "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.carmellrx.com/role/AccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetail" ], "lang": { "en-us": { "role": { "label": "Employee-related Liabilities", "verboseLabel": "Accrued stock-based compensation", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": [ "r127", "r1072" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized compensation expense", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r556" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Estimated weighted average period over which expense is expected to be recognized", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r556" ] }, "us-gaap_EmployeeSeveranceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeSeveranceMember", "presentation": [ "http://www.carmellrx.com/role/GoingConcernAndManagementsLiquidityPlansAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Employee Severance [Member]", "terseLabel": "Workforce Reduction [Member]", "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfTheSecuritiesThatWereExcludedFromTheDilutedPerShareDetail" ], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Stock Options [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.carmellrx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.carmellrx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.carmellrx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.carmellrx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.carmellrx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityAddressesAddressTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressesAddressTypeAxis", "presentation": [ "http://www.carmellrx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Addresses, Address Type [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.carmellrx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r951" ] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://www.carmellrx.com/role/BusinessCombinationsAdditionalInformationDetail", "http://www.carmellrx.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.carmellrx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r951" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://www.carmellrx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r954" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://www.carmellrx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r951" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.carmellrx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://www.carmellrx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r953" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.carmellrx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r951" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://www.carmellrx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r951" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.carmellrx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r951" ] }, "us-gaap_EquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquipmentMember", "presentation": [ "http://www.carmellrx.com/role/PropertyAndEquipmentScheduleOfPropertyPlantAndEquipmentIncludeInContinuingOperationsDetail", "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Equipment [Member]", "verboseLabel": "Equipment [Member]", "terseLabel": "Lab Equipment [Member]", "documentation": "Tangible personal property used to produce goods and services." } } }, "auth_ref": [] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://www.carmellrx.com/role/BusinessCombinationsAdditionalInformationDetail", "http://www.carmellrx.com/role/BusinessCombinationsSummaryOfFairValueOfPurchaseConsiderationTransferredDetail", "http://www.carmellrx.com/role/BusinessCombinationsSummaryOfFairValueOfPurchaseConsiderationTransferredParentheticalDetail", "http://www.carmellrx.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.carmellrx.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit", "http://www.carmellrx.com/role/CoverPage", "http://www.carmellrx.com/role/DebtAdditionalInformationDetail", "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitAdditionalInformationDetail", "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitSummaryOfInformationRelatedToCommonStockWarrantsDetail", "http://www.carmellrx.com/role/NatureOfTheOrganizationAndBusinessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r18", "r245", "r272", "r273", "r274", "r294", "r295", "r296", "r299", "r309", "r311", "r326", "r396", "r403", "r503", "r557", "r558", "r559", "r583", "r584", "r615", "r617", "r618", "r619", "r620", "r622", "r633", "r655", "r656", "r657", "r658", "r659", "r660", "r685", "r776", "r777", "r778", "r797", "r871" ] }, "srt_EquityMethodInvesteeNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "EquityMethodInvesteeNameDomain", "presentation": [ "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Domain]" } } }, "auth_ref": [ "r387", "r388", "r389" ] }, "ctcx_EquityValuationMinimumForConsummationOfBusinessCombination": { "xbrltype": "monetaryItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "EquityValuationMinimumForConsummationOfBusinessCombination", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Minimum For Consummation Of Business Combination", "terseLabel": "Equity valuation minimum for consummation of business combination", "documentation": "Equity valuation minimum for consummation of business combination." } } }, "auth_ref": [] }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EstimateOfFairValueFairValueDisclosureMember", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfOtherFinancialAssetsAndLiabilitiesRecordedInBalanceSheetAtFairValueDetail" ], "lang": { "en-us": { "role": { "label": "Estimate of Fair Value Measurement [Member]", "terseLabel": "Estimated Fair Value [Member]", "documentation": "Measured as an estimate of fair value." } } }, "auth_ref": [ "r472", "r648", "r920", "r921" ] }, "ctcx_EstimatedFairValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "EstimatedFairValuePerShare", "presentation": [ "http://www.carmellrx.com/role/BusinessCombinationsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Estimated Fair Value Per Share", "terseLabel": "Estimated fair value per share", "documentation": "Estimated fair value per share." } } }, "auth_ref": [] }, "ctcx_ExchangeRatio": { "xbrltype": "pureItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "ExchangeRatio", "presentation": [ "http://www.carmellrx.com/role/NatureOfTheOrganizationAndBusinessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Exchange Ratio", "terseLabel": "Exchange ratio", "documentation": "Exchange ratio." } } }, "auth_ref": [] }, "ctcx_ExpectedGainLossFromRestructuringActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "ExpectedGainLossFromRestructuringActivities", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/GoingConcernAndManagementsLiquidityPlansAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Expected Gain (Loss) from Restructuring Activities", "terseLabel": "Expected annual savings from restructuring activities", "documentation": "Expected gain (loss) from restructuring activities." } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfFairValueOfEmbeddedDerivativesInTheConvertibleNotesDetail" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfFairValueOfEmbeddedDerivativesInTheConvertibleNotesDetail" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]", "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": [ "r19" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "terseLabel": "Schedule of Fair Value of the Overallotment Liability", "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": [ "r19" ] }, "ctcx_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfChangesInFairValueOfLevel3FinancialAssetsAndLiabilitiesDetail" ], "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "documentation": "Fair value, assets and liabilities measured on recurring basis, unobservable input reconciliation." } } }, "auth_ref": [] }, "ctcx_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "xbrltype": "stringItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfChangesInFairValueOfLevel3FinancialAssetsAndLiabilitiesDetail" ], "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "documentation": "Fair value, assets and liabilities measured on recurring basis, unobservable input reconciliation." } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfChangesInFairValueOfLevel3FinancialAssetsAndLiabilitiesDetail" ], "lang": { "en-us": { "role": { "label": "Asset Class [Domain]", "documentation": "Class of asset." } } }, "auth_ref": [ "r20" ] }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfOtherFinancialAssetsAndLiabilitiesRecordedInBalanceSheetAtFairValueDetail" ], "lang": { "en-us": { "role": { "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_FairValueByAssetClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByAssetClassAxis", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfChangesInFairValueOfLevel3FinancialAssetsAndLiabilitiesDetail" ], "lang": { "en-us": { "role": { "label": "Asset Class [Axis]", "documentation": "Information by class of asset." } } }, "auth_ref": [ "r114", "r115" ] }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByBalanceSheetGroupingTable", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfOtherFinancialAssetsAndLiabilitiesRecordedInBalanceSheetAtFairValueDetail" ], "lang": { "en-us": { "role": { "label": "Fair Value, by Balance Sheet Grouping [Table]", "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities." } } }, "auth_ref": [ "r114", "r116", "r117" ] }, "us-gaap_FairValueByBalanceSheetGroupingTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByBalanceSheetGroupingTextBlock", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]", "terseLabel": "Schedule of Other Financial Assets and Liabilities Recorded in Balance Sheet at Fair Value", "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities." } } }, "auth_ref": [ "r114", "r116" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfOtherFinancialAssetsAndLiabilitiesRecordedInBalanceSheetAtFairValueDetail" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r472", "r518", "r519", "r520", "r521", "r522", "r523", "r639", "r696", "r697", "r698", "r920", "r921", "r927", "r928", "r929" ] }, "us-gaap_FairValueByLiabilityClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByLiabilityClassAxis", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfChangesInFairValueOfLevel3FinancialAssetsAndLiabilitiesDetail", "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfOtherFinancialAssetsAndLiabilitiesRecordedInBalanceSheetAtFairValueDetail" ], "lang": { "en-us": { "role": { "label": "Liability Class [Axis]", "documentation": "Information by class of liability." } } }, "auth_ref": [ "r115", "r208" ] }, "us-gaap_FairValueByMeasurementBasisAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByMeasurementBasisAxis", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfOtherFinancialAssetsAndLiabilitiesRecordedInBalanceSheetAtFairValueDetail" ], "lang": { "en-us": { "role": { "label": "Measurement Basis [Axis]", "documentation": "Information by measurement basis." } } }, "auth_ref": [ "r25", "r114", "r472", "r920", "r921" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfOtherFinancialAssetsAndLiabilitiesRecordedInBalanceSheetAtFairValueDetail", "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfFairValueOfEmbeddedDerivativesInTheConvertibleNotesDetail" ], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r638", "r639", "r641", "r642", "r644" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfOtherFinancialAssetsAndLiabilitiesRecordedInBalanceSheetAtFairValueDetail" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r472", "r518", "r523", "r639", "r697", "r920", "r921", "r927", "r928", "r929" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfOtherFinancialAssetsAndLiabilitiesRecordedInBalanceSheetAtFairValueDetail" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r472", "r518", "r519", "r520", "r521", "r522", "r523", "r639", "r698", "r920", "r921", "r927", "r928", "r929" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfChangesInFairValueOfLevel3FinancialAssetsAndLiabilitiesDetail", "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfOtherFinancialAssetsAndLiabilitiesRecordedInBalanceSheetAtFairValueDetail" ], "lang": { "en-us": { "role": { "label": "Fair Value by Liability Class [Domain]", "documentation": "Represents classes of liabilities measured and disclosed at fair value." } } }, "auth_ref": [ "r20" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Schedule of Changes in Fair Value of Level 3 Financial Assets and Liabilities", "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability." } } }, "auth_ref": [ "r20", "r115" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfOtherFinancialAssetsAndLiabilitiesRecordedInBalanceSheetAtFairValueDetail", "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfFairValueOfEmbeddedDerivativesInTheConvertibleNotesDetail" ], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair Value Measurements and Fair Value of Financial Instruments", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfChangesInFairValueOfLevel3FinancialAssetsAndLiabilitiesDetail" ], "lang": { "en-us": { "role": { "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings", "terseLabel": "Change in fair value, Assets", "documentation": "Amount of gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3)." } } }, "auth_ref": [ "r643" ] }, "ctcx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetInitialRecognitionOfAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetInitialRecognitionOfAssets", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfChangesInFairValueOfLevel3FinancialAssetsAndLiabilitiesDetail" ], "lang": { "en-us": { "role": { "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Initial Recognition of Assets", "terseLabel": "Initial recognition, Assets", "documentation": "Fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, initial recognition of assets." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfChangesInFairValueOfLevel3FinancialAssetsAndLiabilitiesDetail" ], "lang": { "en-us": { "role": { "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value", "periodEndLabel": "Balance, end of period, Assets", "periodStartLabel": "Balance, beginning of year, Assets", "documentation": "Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r20" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfChangesInFairValueOfLevel3FinancialAssetsAndLiabilitiesDetail" ], "lang": { "en-us": { "role": { "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "terseLabel": "Change in fair value, Liabilities", "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)." } } }, "auth_ref": [ "r643" ] }, "ctcx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognitionOfLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialRecognitionOfLiabilities", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfChangesInFairValueOfLevel3FinancialAssetsAndLiabilitiesDetail" ], "lang": { "en-us": { "role": { "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Initial Recognition of Liabilities", "terseLabel": "Initial recognition of liability", "documentation": "Fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, initial recognition of liabilities." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfChangesInFairValueOfLevel3FinancialAssetsAndLiabilitiesDetail" ], "lang": { "en-us": { "role": { "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "periodEndLabel": "Balance, end of period, Liabilities", "periodStartLabel": "Balance, beginning of year, Liabilities", "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r20" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfOtherFinancialAssetsAndLiabilitiesRecordedInBalanceSheetAtFairValueDetail" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r472", "r518", "r519", "r520", "r521", "r522", "r523", "r696", "r697", "r698", "r920", "r921", "r927", "r928", "r929" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfFairValueOfEmbeddedDerivativesInTheConvertibleNotesDetail" ], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r637", "r644" ] }, "ctcx_FairValueOfSharesIssuedUponConversionOfConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "FairValueOfSharesIssuedUponConversionOfConvertibleDebt", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Fair Value Of Shares Issued Upon Conversion Of Convertible Debt", "terseLabel": "Fair value of shares issued upon conversion of convertible debt", "documentation": "Fair value of shares issued upon conversion of convertible debt." } } }, "auth_ref": [] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialInstrumentAxis", "presentation": [ "http://www.carmellrx.com/role/NatureOfTheOrganizationAndBusinessAdditionalInformationDetail", "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r483", "r499", "r623", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r763", "r917", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r992", "r993", "r994", "r995" ] }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": [ "http://www.carmellrx.com/role/GoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetail", "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Finite-lived intangible assets, amortization period", "verboseLabel": "Amortization Period", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "calculation": { "http://www.carmellrx.com/role/GoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetail": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.carmellrx.com/role/GoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetail" ], "lang": { "en-us": { "role": { "label": "Accumulated Amortization", "verboseLabel": "Finite lived intangible asset accumulated depreciation", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r258", "r433" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/GoodwillAndIntangibleAssetsSummaryOfAmortizationExpenseRelatedToIntangibleAssetsDetail" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five", "verboseLabel": "Thereafter", "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/GoodwillAndIntangibleAssetsSummaryOfAmortizationExpenseRelatedToIntangibleAssetsDetail" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "terseLabel": "2024", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r182" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/GoodwillAndIntangibleAssetsSummaryOfAmortizationExpenseRelatedToIntangibleAssetsDetail" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five", "verboseLabel": "2028", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r182" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/GoodwillAndIntangibleAssetsSummaryOfAmortizationExpenseRelatedToIntangibleAssetsDetail" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "terseLabel": "2027", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r182" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/GoodwillAndIntangibleAssetsSummaryOfAmortizationExpenseRelatedToIntangibleAssetsDetail" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "terseLabel": "2026", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r182" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/GoodwillAndIntangibleAssetsSummaryOfAmortizationExpenseRelatedToIntangibleAssetsDetail" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "terseLabel": "2025", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r182" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.carmellrx.com/role/BusinessCombinationsAdditionalInformationDetail", "http://www.carmellrx.com/role/GoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetail", "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r431", "r432", "r433", "r434", "r727", "r731" ] }, "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract", "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "calculation": { "http://www.carmellrx.com/role/GoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetail": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.carmellrx.com/role/GoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetail" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Gross Carrying Value", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r181", "r731" ] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://www.carmellrx.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetail", "http://www.carmellrx.com/role/GoodwillAndIntangibleAssetsSummaryOfAmortizationExpenseRelatedToIntangibleAssetsDetail", "http://www.carmellrx.com/role/GoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetail" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r727" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.carmellrx.com/role/BusinessCombinationsAdditionalInformationDetail", "http://www.carmellrx.com/role/GoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetail", "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r68", "r69" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 }, "http://www.carmellrx.com/role/GoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetail": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedBalanceSheets", "http://www.carmellrx.com/role/GoodwillAndIntangibleAssetsSummaryOfAmortizationExpenseRelatedToIntangibleAssetsDetail", "http://www.carmellrx.com/role/GoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetail" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Net", "terseLabel": "Intangible assets, net of accumulated amortization of $46,560 and $42,044, respectively", "totalLabel": "Net Book Value", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r181", "r727" ] }, "us-gaap_FiniteLivedPatentsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedPatentsGross", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Patents, Gross", "terseLabel": "Gross patent costs", "documentation": "Gross carrying amount before accumulated amortization as of the balance sheet date of the costs pertaining to the exclusive legal rights granted to the owner of the patent to exploit an invention or a process for a period of time specified by law. Such costs may have been expended to directly apply and receive patent rights, or to acquire such rights." } } }, "auth_ref": [ "r181" ] }, "ctcx_FormationGeneralAndAdministrativeExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "FormationGeneralAndAdministrativeExpenses", "crdr": "debit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Formation, General And Administrative Expenses", "terseLabel": "General and administrative", "documentation": "Formation, general and administrative expenses." } } }, "auth_ref": [] }, "ctcx_ForwardPurchaseAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "ForwardPurchaseAgreement", "crdr": "debit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedBalanceSheets", "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfOtherFinancialAssetsAndLiabilitiesRecordedInBalanceSheetAtFairValueDetail" ], "lang": { "en-us": { "role": { "label": "Forward Purchase Agreement", "terseLabel": "Forward purchase agreement", "documentation": "Forward purchase agreement." } } }, "auth_ref": [] }, "ctcx_ForwardPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "ForwardPurchaseAgreementMember", "presentation": [ "http://www.carmellrx.com/role/NatureOfTheOrganizationAndBusinessAdditionalInformationDetail", "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfChangesInFairValueOfLevel3FinancialAssetsAndLiabilitiesDetail" ], "lang": { "en-us": { "role": { "label": "Forward Purchase Agreement [Member]", "terseLabel": "Forward Purchase Agreement [Member]", "documentation": "Forward Purchase Agreement Member" } } }, "auth_ref": [] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FurnitureAndFixturesMember", "presentation": [ "http://www.carmellrx.com/role/PropertyAndEquipmentScheduleOfPropertyPlantAndEquipmentIncludeInContinuingOperationsDetail", "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and Fixtures [Member]", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [] }, "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnDerivativeInstrumentsNetPretax", "crdr": "credit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 16.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Gain (Loss) on Derivative Instruments, Net, Pretax", "negatedLabel": "Change in fair value of derivative liabilities", "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects." } } }, "auth_ref": [ "r112" ] }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainsLossesOnExtinguishmentOfDebt", "crdr": "credit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 20.0 }, "http://www.carmellrx.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows", "http://www.carmellrx.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Gain (Loss) on Extinguishment of Debt", "verboseLabel": "Loss on debt extinguishment", "negatedLabel": "Loss on extinguishment of debt", "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity." } } }, "auth_ref": [ "r11", "r77", "r78" ] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Goodwill", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/BusinessCombinationsSummaryOfAllocationOfPurchasePriceDetail", "http://www.carmellrx.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetail", "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfGoodwillDetail" ], "lang": { "en-us": { "role": { "label": "Goodwill", "periodEndLabel": "Goodwill, Ending Balance", "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r257", "r418", "r744", "r918", "r937", "r999", "r1006" ] }, "us-gaap_GoodwillAcquiredDuringPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAcquiredDuringPeriod", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfGoodwillDetail" ], "lang": { "en-us": { "role": { "label": "Goodwill, Acquired During Period", "terseLabel": "AxoBio Acquisition", "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination." } } }, "auth_ref": [ "r421", "r918" ] }, "us-gaap_GoodwillAndIntangibleAssetImpairment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetImpairment", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Asset Impairment", "terseLabel": "Goodwill or intangible asset impairment charges recognized", "documentation": "Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill." } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]", "terseLabel": "Goodwill and Intangible Assets", "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets." } } }, "auth_ref": [ "r15", "r66" ] }, "us-gaap_GoodwillLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillLineItems", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfGoodwillDetail" ], "lang": { "en-us": { "role": { "label": "Goodwill [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r918" ] }, "us-gaap_IPOMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IPOMember", "presentation": [ "http://www.carmellrx.com/role/NatureOfTheOrganizationAndBusinessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "IPO [Member]", "documentation": "First sale of stock by a private company to the public." } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperations", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/GoingConcernAndManagementsLiquidityPlansAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent", "terseLabel": "Net loss from continuing operations", "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent." } } }, "auth_ref": [ "r111", "r168", "r175", "r302", "r303", "r305", "r306", "r319", "r323" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Loss from continuing operations before provision for income taxes", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r0", "r166", "r214", "r329", "r342", "r346", "r348", "r746", "r759", "r914" ] }, "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Loss from continuing operations", "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r207", "r287", "r298", "r329", "r342", "r346", "r348", "r390", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r635", "r649", "r759", "r914", "r1017" ] }, "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsPerBasicShare", "calculation": { "http://www.carmellrx.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_EarningsPerShareBasic", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations, Per Basic Share", "terseLabel": "Net loss from continuing operations - basic", "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r165", "r213", "r215", "r276", "r298", "r302", "r303", "r305", "r306", "r317", "r321", "r322", "r635", "r745", "r1075" ] }, "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsPerDilutedShare", "calculation": { "http://www.carmellrx.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_EarningsPerShareDiluted", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations, Per Diluted Share", "terseLabel": "Net loss from continuing operations - diluted", "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r165", "r276", "r298", "r302", "r303", "r305", "r306", "r317", "r321", "r322", "r323", "r635", "r745", "r1075" ] }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax", "crdr": "credit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 }, "http://www.carmellrx.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 22.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows", "http://www.carmellrx.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "verboseLabel": "Income from discontinued operations attributable to common shareholders", "terseLabel": "Discontinued operations, net of tax", "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal." } } }, "auth_ref": [ "r138", "r139", "r140", "r141", "r142", "r151", "r250", "r590", "r760" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "presentation": [ "http://www.carmellrx.com/role/DiscontinuedOperationsSummaryOfAssetsAndLiabilitiesClassifiedAsAvailableForSaleDetail", "http://www.carmellrx.com/role/DiscontinuedOperationsSummaryOfDiscontinuedOperationsInConsolidatedStatementsOfIncomeDetail", "http://www.carmellrx.com/role/NatureOfTheOrganizationAndBusinessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Disposal Group Name [Axis]", "documentation": "Information by name of disposal group." } } }, "auth_ref": [ "r930", "r931" ] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "presentation": [ "http://www.carmellrx.com/role/DiscontinuedOperationsSummaryOfAssetsAndLiabilitiesClassifiedAsAvailableForSaleDetail", "http://www.carmellrx.com/role/DiscontinuedOperationsSummaryOfDiscontinuedOperationsInConsolidatedStatementsOfIncomeDetail" ], "lang": { "en-us": { "role": { "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "presentation": [ "http://www.carmellrx.com/role/DiscontinuedOperationsSummaryOfAssetsAndLiabilitiesClassifiedAsAvailableForSaleDetail", "http://www.carmellrx.com/role/DiscontinuedOperationsSummaryOfDiscontinuedOperationsInConsolidatedStatementsOfIncomeDetail" ], "lang": { "en-us": { "role": { "label": "Disposal Groups, Including Discontinued Operations [Table]", "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r14", "r24", "r32", "r134", "r143", "r144", "r145", "r146", "r147", "r150", "r152", "r153", "r187" ] }, "us-gaap_IncomeTaxAuthorityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityAxis", "presentation": [ "http://www.carmellrx.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Income Tax Authority [Axis]", "documentation": "Information by tax jurisdiction." } } }, "auth_ref": [ "r17" ] }, "us-gaap_IncomeTaxAuthorityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityDomain", "presentation": [ "http://www.carmellrx.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Income Tax Authority [Domain]", "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.carmellrx.com/role/IncomeTaxes" ], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r288", "r564", "r570", "r573", "r579", "r586", "r589", "r591", "r592", "r795" ] }, "us-gaap_IncomeTaxExaminationYearUnderExamination": { "xbrltype": "gYearListItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExaminationYearUnderExamination", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Income Tax Examination, Year under Examination", "terseLabel": "Income tax examination, years under examination", "documentation": "Tax year being audited in the income tax examination, in YYYY format." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": -1.0, "order": 21.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Income Tax Expense (Benefit)", "terseLabel": "Provision for income taxes", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r222", "r239", "r310", "r311", "r334", "r568", "r587", "r766" ] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Income Tax, Policy [Policy Text Block]", "verboseLabel": "Income Taxes", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r271", "r566", "r567", "r573", "r574", "r578", "r580", "r789" ] }, "ctcx_IncomeTaxesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "IncomeTaxesLineItems", "presentation": [ "http://www.carmellrx.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Income Taxes [Line Items]", "documentation": "Income Taxes Line Items" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Income Taxes Paid, Net", "terseLabel": "Income tax paid", "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes." } } }, "auth_ref": [ "r53" ] }, "us-gaap_IncomeTaxesReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxesReceivable", "crdr": "debit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Income Taxes Receivable, Current", "terseLabel": "Income taxes receivable", "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes." } } }, "auth_ref": [ "r126", "r974" ] }, "ctcx_IncomeTaxesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "IncomeTaxesTable", "presentation": [ "http://www.carmellrx.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Income Taxes [Table]", "documentation": "Income Taxes Table" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 15.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r10" ] }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "crdr": "debit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 24.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Income Taxes Payable", "terseLabel": "Income tax payable", "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction." } } }, "auth_ref": [ "r10" ] }, "ctcx_IncreaseDecreaseInAccruedInterestPayableRelatedAndThirdParty": { "xbrltype": "monetaryItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "IncreaseDecreaseInAccruedInterestPayableRelatedAndThirdParty", "crdr": "debit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 21.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accrued Interest Payable, Related and Third Party", "terseLabel": "Accrued interest - related and third-party", "documentation": "Increase (Decrease) in Accrued Interest Payable, Related and Third Party" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "crdr": "debit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 17.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities", "terseLabel": "Accrued expenses and other liabilities", "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other." } } }, "auth_ref": [ "r980" ] }, "us-gaap_IncreaseDecreaseInAssetsHeldForSale": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAssetsHeldForSale", "crdr": "credit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Asset, Held-for-Sale", "negatedLabel": "Assets available for sale", "documentation": "The increase (decrease) during the period in book value of long-lived assets that the reporting entity plans to sell within one year (or one business cycle)." } } }, "auth_ref": [ "r10" ] }, "us-gaap_IncreaseDecreaseInIncomeTaxesReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInIncomeTaxesReceivable", "crdr": "credit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Income Taxes Receivable", "negatedLabel": "Income taxes receivable", "documentation": "The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid." } } }, "auth_ref": [ "r10" ] }, "ctcx_IncreaseDecreaseInLiabilitiesAvailableForSales": { "xbrltype": "monetaryItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "IncreaseDecreaseInLiabilitiesAvailableForSales", "crdr": "debit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 23.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Liabilities Available for Sales", "terseLabel": "Liabilities available for sales", "documentation": "Increase (decrease) in liabilities available for sales." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 19.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Lease Liability", "terseLabel": "Lease liability", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": [ "r961", "r980" ] }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherCurrentAssets", "crdr": "credit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 13.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Other Current Assets", "negatedLabel": "Other current assets", "documentation": "Amount of increase (decrease) in current assets classified as other." } } }, "auth_ref": [ "r980" ] }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidExpense", "crdr": "credit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Prepaid Expense", "negatedLabel": "Prepaid expenses", "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods." } } }, "auth_ref": [ "r10" ] }, "ctcx_InitialRecognitionOfDerivativeLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "InitialRecognitionOfDerivativeLiabilities", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Initial Recognition Of Derivative Liabilities", "terseLabel": "Initial recognition of derivative liabilities", "documentation": "Initial recognition of derivative liabilities." } } }, "auth_ref": [] }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsDisclosureTextBlock", "presentation": [ "http://www.carmellrx.com/role/GoodwillAndIntangibleAssets" ], "lang": { "en-us": { "role": { "label": "Intangible Assets Disclosure [Text Block]", "terseLabel": "Goodwill and Intangible Assets", "documentation": "The entire disclosure for all or part of the information related to intangible assets." } } }, "auth_ref": [ "r430" ] }, "us-gaap_IntellectualPropertyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntellectualPropertyMember", "presentation": [ "http://www.carmellrx.com/role/BusinessCombinationsAdditionalInformationDetail", "http://www.carmellrx.com/role/GoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetail", "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Intellectual Property [Member]", "terseLabel": "Intellectual Property [Member]", "documentation": "Intangible asset arising from original creative thought. Include, but is not limited to, trademarks, patents, and copyrights." } } }, "auth_ref": [ "r26" ] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Interest Expense", "terseLabel": "Interest expense incurred", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": [ "r122", "r217", "r275", "r332", "r664", "r856", "r948", "r1081" ] }, "us-gaap_InterestExpenseDebtExcludingAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpenseDebtExcludingAmortization", "crdr": "debit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 16.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfOperations", "http://www.carmellrx.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Interest Expense, Debt, Excluding Amortization", "negatedLabel": "Interest expense", "terseLabel": "Interest expense on convertible debt", "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs." } } }, "auth_ref": [ "r171", "r479", "r922", "r923" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Interest paid", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r278", "r281", "r282" ] }, "us-gaap_InterestPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPayableCurrent", "crdr": "credit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 16.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Interest Payable, Current", "terseLabel": "Accrued interest", "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r36" ] }, "ctcx_InterestRecognizedUponDefault": { "xbrltype": "monetaryItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "InterestRecognizedUponDefault", "crdr": "debit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 22.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Interest Recognized Upon Default", "terseLabel": "Interest recognized upon default", "documentation": "Interest recognized upon default." } } }, "auth_ref": [] }, "us-gaap_InventoryPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryPolicyTextBlock", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventories", "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost." } } }, "auth_ref": [ "r224", "r253", "r263", "r412", "r413", "r415", "r724", "r911" ] }, "us-gaap_InventoryValuationReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryValuationReserves", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Inventory Valuation Reserves", "terseLabel": "Reserve for inventory obsolescense", "documentation": "Amount of valuation reserve for inventory." } } }, "auth_ref": [ "r65", "r975" ] }, "us-gaap_InventoryWriteDown": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryWriteDown", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Inventory Write-down", "terseLabel": "Loss on the write-down", "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels." } } }, "auth_ref": [ "r414" ] }, "ctcx_IssuanceOfSeriesAPreferredStockAndCommonStockInConnectionWithAcquisition": { "xbrltype": "monetaryItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "IssuanceOfSeriesAPreferredStockAndCommonStockInConnectionWithAcquisition", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Issuance of Series A Preferred Stock and Common Stock in Connection With Acquisition", "terseLabel": "Issuance of Series A preferred stock and common stock in connection with AxoBio Acquisition", "documentation": "Issuance of series A preferred stock and common stock in connection with acquisition." } } }, "auth_ref": [] }, "ctcx_JanuaryTwoThousandAndTwentyTwoConvertibleNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "JanuaryTwoThousandAndTwentyTwoConvertibleNotesMember", "presentation": [ "http://www.carmellrx.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.carmellrx.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "January Two Thousand And Twenty Two Convertible Notes [Member]", "terseLabel": "January 2022 convertible notes [Member]", "documentation": "January Two Thousand And Twenty Two Convertible Notes Member" } } }, "auth_ref": [] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCost", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/LeasesSummaryOfNetLeaseCostAndOtherSupplementalLeaseInformationDetail" ], "lang": { "en-us": { "role": { "label": "Lease, Cost", "totalLabel": "Net lease cost", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": [ "r674", "r936" ] }, "us-gaap_LeaseCostAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCostAbstract", "presentation": [ "http://www.carmellrx.com/role/LeasesSummaryOfNetLeaseCostAndOtherSupplementalLeaseInformationDetail" ], "lang": { "en-us": { "role": { "label": "Lease, Cost [Abstract]", "terseLabel": "Lease cost:" } } }, "auth_ref": [] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://www.carmellrx.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "label": "Lease, Cost [Table Text Block]", "terseLabel": "Summary of Net Lease Cost and Other Supplemental Lease Information", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r1060" ] }, "us-gaap_LeaseExpirationDate1": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseExpirationDate1", "presentation": [ "http://www.carmellrx.com/role/LeasesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Lease Expiration Date", "terseLabel": "Lease expiration date", "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://www.carmellrx.com/role/PropertyAndEquipmentScheduleOfPropertyPlantAndEquipmentIncludeInContinuingOperationsDetail", "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [ "r185" ] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LeasesOfLesseeDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeasesOfLesseeDisclosureTextBlock", "presentation": [ "http://www.carmellrx.com/role/Leases" ], "lang": { "en-us": { "role": { "label": "Leases of Lessee Disclosure [Text Block]", "terseLabel": "Leases", "documentation": "The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing." } } }, "auth_ref": [ "r221" ] }, "ctcx_LegacyCarmellCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "LegacyCarmellCommonStockMember", "presentation": [ "http://www.carmellrx.com/role/NatureOfTheOrganizationAndBusinessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Legacy Carmell Common Stock [Member]", "documentation": "Legacy carmell common stock." } } }, "auth_ref": [] }, "ctcx_LegacyCarmellMember": { "xbrltype": "domainItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "LegacyCarmellMember", "presentation": [ "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Legacy Carmell [Member]", "documentation": "Legacy Carmell." } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://www.carmellrx.com/role/BusinessCombinationsAdditionalInformationDetail", "http://www.carmellrx.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "ctcx_LenderAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "LenderAxis", "presentation": [ "http://www.carmellrx.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.carmellrx.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Lender [Axis]", "documentation": "Lender Axis" } } }, "auth_ref": [] }, "ctcx_LenderDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "LenderDomain", "presentation": [ "http://www.carmellrx.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.carmellrx.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Lender [Domain]", "documentation": "Lender Domain" } } }, "auth_ref": [] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeasesPolicyTextBlock", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": [ "r673" ] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.carmellrx.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "terseLabel": "Schedule of Estimated Future Minimum Lease Payments, Excluding Non-Lease Components", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r1061" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/LeasesScheduleOfEstimatedFutureMinimumLeasePaymentsExcludingNonLeaseComponentsDetail" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total future minimum annual lease payments", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r680" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/LeasesScheduleOfEstimatedFutureMinimumLeasePaymentsExcludingNonLeaseComponentsDetail" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2024", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r680" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/LeasesScheduleOfEstimatedFutureMinimumLeasePaymentsExcludingNonLeaseComponentsDetail" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "terseLabel": "2028", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r680" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/LeasesScheduleOfEstimatedFutureMinimumLeasePaymentsExcludingNonLeaseComponentsDetail" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2027", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r680" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/LeasesScheduleOfEstimatedFutureMinimumLeasePaymentsExcludingNonLeaseComponentsDetail" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2026", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r680" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/LeasesScheduleOfEstimatedFutureMinimumLeasePaymentsExcludingNonLeaseComponentsDetail" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2025", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r680" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/LeasesScheduleOfEstimatedFutureMinimumLeasePaymentsExcludingNonLeaseComponentsDetail" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: Imputed interest", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r680" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities", "totalLabel": "Total liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r35", "r287", "r390", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r605", "r608", "r609", "r649", "r825", "r913", "r950", "r1017", "r1063", "r1064" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities and Equity", "totalLabel": "Total liabilities, mezzanine equity and stockholders' equity (deficit)", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r164", "r212", "r755", "r937", "r984", "r996", "r1059" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "verboseLabel": "Liabilities, Mezzanine Equity and Shareholders' Equity (Deficit)" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities, Current", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r37", "r252", "r287", "r390", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r605", "r608", "r609", "r649", "r937", "r1017", "r1063", "r1064" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "verboseLabel": "Current liabilities:" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesNoncurrentAbstract", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities, Noncurrent [Abstract]", "terseLabel": "Long-term liabilities:" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "crdr": "credit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedBalanceSheets", "http://www.carmellrx.com/role/DiscontinuedOperationsSummaryOfAssetsAndLiabilitiesClassifiedAsAvailableForSaleDetail" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current", "terseLabel": "Liabilities available for sale", "totalLabel": "Total liabilities available for sale", "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r5", "r134", "r149", "r184", "r186", "r249", "r250" ] }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract", "presentation": [ "http://www.carmellrx.com/role/DiscontinuedOperationsSummaryOfAssetsAndLiabilitiesClassifiedAsAvailableForSaleDetail" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current [Abstract]", "terseLabel": "Liabilities available for sale" } } }, "auth_ref": [] }, "us-gaap_LitigationStatusAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LitigationStatusAxis", "presentation": [ "http://www.carmellrx.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Litigation Status [Axis]", "documentation": "Information by status of pending, threatened, or settled litigation." } } }, "auth_ref": [ "r1012" ] }, "us-gaap_LitigationStatusDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LitigationStatusDomain", "presentation": [ "http://www.carmellrx.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Litigation Status [Domain]", "documentation": "Status of pending, threatened, or settled litigation." } } }, "auth_ref": [ "r1012" ] }, "us-gaap_LoansPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LoansPayableCurrent", "crdr": "credit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 18.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Loans Payable, Current", "terseLabel": "Loans payable", "documentation": "Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer." } } }, "auth_ref": [ "r36" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.carmellrx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "ctcx_LongTermDebtCommissionPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "LongTermDebtCommissionPercentage", "presentation": [ "http://www.carmellrx.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Long Term Debt Commission Percentage", "terseLabel": "Long term debt commission percentage", "documentation": "Long term debt commission percentage." } } }, "auth_ref": [] }, "ctcx_LongTermDebtDiscountPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "LongTermDebtDiscountPercentage", "presentation": [ "http://www.carmellrx.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Long Term Debt Discount Percentage", "terseLabel": "Long term debt discount percentage", "documentation": "Long term debt discount percentage." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtFairValue", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Fair Value", "terseLabel": "Fair value", "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission." } } }, "auth_ref": [] }, "ctcx_LongTermDebtFixedInterestRatePercentageInCaseOfDefault": { "xbrltype": "percentItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "LongTermDebtFixedInterestRatePercentageInCaseOfDefault", "presentation": [ "http://www.carmellrx.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Long Term Debt Fixed Interest Rate Percentage In Case Of Default", "terseLabel": "Long term debt fixed interest rate percentage in case of default", "documentation": "Long term debt fixed interest rate percentage in case of default." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtPercentageBearingFixedInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtPercentageBearingFixedInterestRate", "presentation": [ "http://www.carmellrx.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Percentage Bearing Fixed Interest, Percentage Rate", "terseLabel": "Long term debt bearing fixed interest rate percentage", "documentation": "The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a set, unchanging rate." } } }, "auth_ref": [ "r38" ] }, "ctcx_LongTermDebtPercentageIncreaseInOutstandingPrincipalDueToDefault": { "xbrltype": "percentItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "LongTermDebtPercentageIncreaseInOutstandingPrincipalDueToDefault", "presentation": [ "http://www.carmellrx.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Long Term Debt Percentage Increase In Outstanding Principal Due To Default", "terseLabel": "Long term debt percentage increase in outstanding principal due to default", "documentation": "Long term debt percentage increase in outstanding principal due to default." } } }, "auth_ref": [] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://www.carmellrx.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.carmellrx.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.carmellrx.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit", "http://www.carmellrx.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r40" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://www.carmellrx.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.carmellrx.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.carmellrx.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit", "http://www.carmellrx.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r40", "r75" ] }, "us-gaap_LossContingenciesByNatureOfContingencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingenciesByNatureOfContingencyAxis", "presentation": [ "http://www.carmellrx.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Loss Contingency Nature [Axis]", "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur." } } }, "auth_ref": [ "r443", "r444", "r445", "r448", "r1013", "r1014" ] }, "us-gaap_LossContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingenciesLineItems", "presentation": [ "http://www.carmellrx.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Loss Contingencies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r443", "r444", "r445", "r448", "r1013", "r1014" ] }, "us-gaap_LossContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingenciesTable", "presentation": [ "http://www.carmellrx.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Loss Contingencies [Table]", "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations." } } }, "auth_ref": [ "r443", "r444", "r445", "r448", "r1013", "r1014" ] }, "us-gaap_LossContingencyDamagesSoughtValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingencyDamagesSoughtValue", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Loss Contingency, Damages Sought, Value", "terseLabel": "Total claim amount", "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter." } } }, "auth_ref": [ "r1012", "r1013", "r1014" ] }, "us-gaap_LossContingencyLawsuitFilingDate": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingencyLawsuitFilingDate", "presentation": [ "http://www.carmellrx.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Loss Contingency, Lawsuit Filing Date", "terseLabel": "Litigation filed date", "documentation": "States the date the complaint was formally filed in a court of law, in arbitration or mediation." } } }, "auth_ref": [ "r73", "r74", "r189" ] }, "us-gaap_LossContingencyNameOfPlaintiff": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingencyNameOfPlaintiff", "presentation": [ "http://www.carmellrx.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Loss Contingency, Name of Plaintiff", "terseLabel": "Litigation plaintiff name", "documentation": "Identifies the plaintiff in the lawsuit." } } }, "auth_ref": [ "r73", "r74", "r189" ] }, "us-gaap_LossContingencyNatureDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingencyNatureDomain", "presentation": [ "http://www.carmellrx.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Loss Contingency, Nature [Domain]", "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability." } } }, "auth_ref": [ "r443", "r444", "r445", "r448", "r1013", "r1014" ] }, "ctcx_LossOnForwardPurchaseAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "LossOnForwardPurchaseAgreement", "crdr": "debit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 18.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Loss On Forward Purchase Agreement", "negatedLabel": "Loss on forward purchase agreement", "documentation": "Loss on forward purchase agreement." } } }, "auth_ref": [] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MajorCustomersAxis", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesConcentrationsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "auth_ref": [ "r351", "r926", "r1022", "r1076", "r1077" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://www.carmellrx.com/role/BusinessCombinationsAdditionalInformationDetail", "http://www.carmellrx.com/role/DebtAdditionalInformationDetail", "http://www.carmellrx.com/role/GoingConcernAndManagementsLiquidityPlansAdditionalInformationDetail", "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelDetail", "http://www.carmellrx.com/role/NatureOfTheOrganizationAndBusinessAdditionalInformationDetail", "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum [Member]" } } }, "auth_ref": [ "r444", "r445", "r446", "r447", "r525", "r723", "r773", "r817", "r818", "r878", "r879", "r880", "r881", "r890", "r902", "r903", "r916", "r924", "r932", "r939", "r1019", "r1065", "r1066", "r1067", "r1068", "r1069", "r1070" ] }, "ctcx_MeasurementInputDebtRateMember": { "xbrltype": "domainItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "MeasurementInputDebtRateMember", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Debt Rate [Member]", "terseLabel": "Debt Rate [Member]", "documentation": "Measurement input, debt rate." } } }, "auth_ref": [] }, "us-gaap_MeasurementInputExpectedTermMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputExpectedTermMember", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfFairValueOfEmbeddedDerivativesInTheConvertibleNotesDetail" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Expected Term [Member]", "terseLabel": "Expected Term (years) [Member]", "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date." } } }, "auth_ref": [ "r1057" ] }, "us-gaap_MeasurementInputPriceVolatilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputPriceVolatilityMember", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfFairValueOfEmbeddedDerivativesInTheConvertibleNotesDetail" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Price Volatility [Member]", "terseLabel": "Volatility [Member]", "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns." } } }, "auth_ref": [ "r1057" ] }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputRiskFreeInterestRateMember", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfFairValueOfEmbeddedDerivativesInTheConvertibleNotesDetail" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Risk Free Interest Rate [Member]", "terseLabel": "Risk-free Interest Rate [Member]", "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss." } } }, "auth_ref": [ "r1057" ] }, "us-gaap_MeasurementInputSharePriceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputSharePriceMember", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfFairValueOfEmbeddedDerivativesInTheConvertibleNotesDetail" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Share Price [Member]", "verboseLabel": "Share Price [Member]", "terseLabel": "Stock price [Member]", "documentation": "Measurement input using share price of saleable stock." } } }, "auth_ref": [ "r1057" ] }, "ctcx_MeasurementInputTerminationFeeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "MeasurementInputTerminationFeeMember", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Termination Fee [Member]", "terseLabel": "Termination Fee [Member]", "documentation": "Measurement input, termination fee." } } }, "auth_ref": [] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeAxis", "presentation": [ "http://www.carmellrx.com/role/DebtAdditionalInformationDetail", "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfFairValueOfEmbeddedDerivativesInTheConvertibleNotesDetail" ], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r640" ] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeDomain", "presentation": [ "http://www.carmellrx.com/role/DebtAdditionalInformationDetail", "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfFairValueOfEmbeddedDerivativesInTheConvertibleNotesDetail" ], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Domain]", "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth_ref": [] }, "ctcx_MeteoraMember": { "xbrltype": "domainItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "MeteoraMember", "presentation": [ "http://www.carmellrx.com/role/NatureOfTheOrganizationAndBusinessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Meteora [Member]", "documentation": "Meteora." } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://www.carmellrx.com/role/DebtAdditionalInformationDetail", "http://www.carmellrx.com/role/GoingConcernAndManagementsLiquidityPlansAdditionalInformationDetail", "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitAdditionalInformationDetail", "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelDetail", "http://www.carmellrx.com/role/NatureOfTheOrganizationAndBusinessAdditionalInformationDetail", "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum [Member]" } } }, "auth_ref": [ "r444", "r445", "r446", "r447", "r525", "r723", "r773", "r817", "r818", "r878", "r879", "r880", "r881", "r890", "r902", "r903", "r916", "r924", "r932", "r939", "r1019", "r1065", "r1066", "r1067", "r1068", "r1069", "r1070" ] }, "ctcx_MonteCarloModelMember": { "xbrltype": "domainItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "MonteCarloModelMember", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfFairValueOfEmbeddedDerivativesInTheConvertibleNotesDetail" ], "lang": { "en-us": { "role": { "label": "Monte-Carlo Model [Member]", "documentation": "Monte-Carlo Model [Member]" } } }, "auth_ref": [] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesConcentrationsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]" } } }, "auth_ref": [ "r351", "r926", "r1022", "r1076", "r1077" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 25.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r280" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "verboseLabel": "Cash Flows from Financing Activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r280" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows", "http://www.carmellrx.com/role/GoingConcernAndManagementsLiquidityPlansAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities", "negatedLabel": "Net cash used in operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r173", "r174", "r175" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "Cash Flows from Operating Activities:" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.carmellrx.com/role/BusinessCombinationsSummaryOfBusinessCombinationsUnauditedProFromaStatementsOfOperationsDetail", "http://www.carmellrx.com/role/ConsolidatedStatementsOfOperations", "http://www.carmellrx.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Net loss from continuing operations", "totalLabel": "Net loss", "terseLabel": "Net loss", "verboseLabel": "Net loss from consolidated statements of operations", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r167", "r175", "r216", "r250", "r269", "r270", "r274", "r287", "r298", "r302", "r303", "r305", "r306", "r310", "r311", "r319", "r329", "r342", "r346", "r348", "r390", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r635", "r649", "r762", "r848", "r869", "r870", "r914", "r948", "r1017" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedStatementsOfOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Basic", "totalLabel": "Net loss attributable to common stockholders", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r277", "r302", "r303", "r305", "r306", "r314", "r315", "r320", "r323", "r329", "r342", "r346", "r348", "r914" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "verboseLabel": "Recently Adopted Accounting Guidance", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "Non-cash financing activity:" } } }, "auth_ref": [] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income (expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r169" ] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other income (expense):" } } }, "auth_ref": [] }, "us-gaap_NonrelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonrelatedPartyMember", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfOperations", "http://www.carmellrx.com/role/DiscontinuedOperationsSummaryOfDiscontinuedOperationsInConsolidatedStatementsOfIncomeDetail" ], "lang": { "en-us": { "role": { "label": "Nonrelated Party [Member]", "verboseLabel": "Nonrelated Party [Member]", "documentation": "Party not related to reporting entity." } } }, "auth_ref": [ "r985", "r986" ] }, "ctcx_NumberOfCustomers": { "xbrltype": "integerItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "NumberOfCustomers", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesConcentrationsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Number of Customers", "documentation": "Number of customers." } } }, "auth_ref": [] }, "ctcx_NumberOfFreelyTradeableShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "NumberOfFreelyTradeableShares", "presentation": [ "http://www.carmellrx.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Number Of Freely Tradeable Shares", "terseLabel": "Number of freely tradeable shares", "documentation": "Number of freely tradeable shares." } } }, "auth_ref": [] }, "ctcx_NumberOfFreelyTransferrableSharesWithdrawn": { "xbrltype": "sharesItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "NumberOfFreelyTransferrableSharesWithdrawn", "presentation": [ "http://www.carmellrx.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Number Of Freely Transferrable Shares Withdrawn", "terseLabel": "Number of freely transferrable shares withdrawn", "documentation": "Number of freely transferrable shares withdrawn." } } }, "auth_ref": [] }, "ctcx_NumberOfOfficeLeases": { "xbrltype": "integerItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "NumberOfOfficeLeases", "presentation": [ "http://www.carmellrx.com/role/LeasesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Number of office leases", "documentation": "Number of office leases" } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfOperatingSegments", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Number of Operating Segments", "terseLabel": "Number of operating segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r991" ] }, "us-gaap_NumberOfReportingUnits": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfReportingUnits", "presentation": [ "http://www.carmellrx.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Number of Reporting Units", "terseLabel": "Number of reporting units", "documentation": "Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment." } } }, "auth_ref": [] }, "ctcx_OfferingCostsAssociatedWithPublicOfferingPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "OfferingCostsAssociatedWithPublicOfferingPolicyTextBlock", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Offering Costs Associated with Public Offering [Policy Text Block]", "terseLabel": "Offering Costs Associated with a Public Offering", "documentation": "Offering costs associated with public offering." } } }, "auth_ref": [] }, "us-gaap_OperatingCostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingCostsAndExpenses", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/OtherRelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Operating Costs and Expenses", "terseLabel": "Related party expense", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Operating Expenses", "totalLabel": "Total operating expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Operating Income (Loss)", "totalLabel": "Loss from operations", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r329", "r342", "r346", "r348", "r914" ] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/LeasesSummaryOfNetLeaseCostAndOtherSupplementalLeaseInformationDetail" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Cost", "terseLabel": "Operating lease cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r675", "r936" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/LeasesScheduleOfEstimatedFutureMinimumLeasePaymentsExcludingNonLeaseComponentsDetail" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability", "totalLabel": "Present value of lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r671" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 19.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r671" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liability, net of current portion", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r671" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/LeasesSummaryOfNetLeaseCostAndOtherSupplementalLeaseInformationDetail" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Payments", "negatedLabel": "Cash paid for operating lease liabilities", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r672", "r677" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right of use asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r670" ] }, "ctcx_OperatingLeaseRightOfUseAssetAmortizationExpenseReversal": { "xbrltype": "monetaryItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "OperatingLeaseRightOfUseAssetAmortizationExpenseReversal", "crdr": "debit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Operating Lease Right Of Use Asset Amortization Expense (Reversal)", "terseLabel": "Amortization of right of use assets", "documentation": "Operating lease right of use asset amortization expense (reversal)." } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.carmellrx.com/role/LeasesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted average incremental borrowing rate", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r679", "r936" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.carmellrx.com/role/LeasesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r678", "r936" ] }, "us-gaap_OperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwards", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Operating Loss Carryforwards", "terseLabel": "Net operating loss carryovers", "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r100" ] }, "us-gaap_OperatingLossCarryforwardsLimitationsOnUse": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwardsLimitationsOnUse", "presentation": [ "http://www.carmellrx.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Operating Loss Carryforwards, Limitations on Use", "terseLabel": "Operating loss carryforwards, limitations on use", "documentation": "A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income." } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "ctcx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems", "presentation": [ "http://www.carmellrx.com/role/NatureOfTheOrganizationAndBusinessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Organization Consolidation And Presentation Of Financial Statements [Line Items]", "documentation": "Organization consolidation and presentation of financial statements." } } }, "auth_ref": [] }, "ctcx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsTable", "presentation": [ "http://www.carmellrx.com/role/NatureOfTheOrganizationAndBusinessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Organization Consolidation And Presentation Of Financial Statements [Table]", "documentation": "Organization consolidation and presentation of financial statements." } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "presentation": [ "http://www.carmellrx.com/role/NatureOfTheOrganizationAndBusiness" ], "lang": { "en-us": { "role": { "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]", "terseLabel": "Nature of the Organization and Business", "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles." } } }, "auth_ref": [ "r176", "r177", "r178", "r206" ] }, "ctcx_OrthoExMember": { "xbrltype": "domainItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "OrthoExMember", "presentation": [ "http://www.carmellrx.com/role/OtherRelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Ortho Ex [Member]", "documentation": "OrthoEx Member" } } }, "auth_ref": [] }, "ctcx_OrthoSpineCompaniesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "OrthoSpineCompaniesMember", "presentation": [ "http://www.carmellrx.com/role/OtherRelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Ortho Spine Companies [Member]", "verboseLabel": "Ortho Spine [Member]", "documentation": "Ortho Spine Companies." } } }, "auth_ref": [] }, "us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAccruedLiabilitiesCurrentAndNoncurrent", "crdr": "credit", "calculation": { "http://www.carmellrx.com/role/AccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetail": { "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.carmellrx.com/role/AccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetail" ], "lang": { "en-us": { "role": { "label": "Other Accrued Liabilities", "terseLabel": "Other accrued expenses", "documentation": "Amount of expenses incurred but not yet paid classified as other." } } }, "auth_ref": [ "r127" ] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other Assets, Current", "terseLabel": "Other current assets", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r265", "r937" ] }, "ctcx_OtherConvertibleNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "OtherConvertibleNotesMember", "presentation": [ "http://www.carmellrx.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Other Convertible Notes [Member]", "terseLabel": "Other convertible notes [member]", "documentation": "Other Convertible Notes Member" } } }, "auth_ref": [] }, "us-gaap_OtherIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherIncome", "crdr": "credit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 15.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Other Income", "terseLabel": "Other income", "documentation": "Amount of revenue and income classified as other." } } }, "auth_ref": [ "r765", "r850", "r891", "r892", "r893" ] }, "ctcx_OtherRelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "OtherRelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Other Related Party Transactions [Abstract]", "documentation": "Other related party transactions." } } }, "auth_ref": [] }, "ctcx_OtherRelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "OtherRelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://www.carmellrx.com/role/OtherRelatedPartyTransactions" ], "lang": { "en-us": { "role": { "label": "Other Related Party Transactions Disclosure [Text Block]", "terseLabel": "Other Related Party Transactions", "documentation": "Other related party transactions." } } }, "auth_ref": [] }, "ctcx_OutstandingLoan": { "xbrltype": "monetaryItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "OutstandingLoan", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Outstanding Loan", "terseLabel": "Outstanding loan", "documentation": "Outstanding loan." } } }, "auth_ref": [] }, "ctcx_OverduePaymentsInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "OverduePaymentsInterestRate", "presentation": [ "http://www.carmellrx.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Overdue Payments Interest Rate", "terseLabel": "Overdue payments interest rate", "documentation": "Overdue payments interest rate." } } }, "auth_ref": [] }, "us-gaap_PaidInKindInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaidInKindInterest", "crdr": "debit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 18.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Paid-in-Kind Interest", "terseLabel": "Non-cash interest expense", "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r11" ] }, "us-gaap_PatentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PatentsMember", "presentation": [ "http://www.carmellrx.com/role/GoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetail", "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Patents [Member]", "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law." } } }, "auth_ref": [ "r204" ] }, "ctcx_PayableToRelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "PayableToRelatedParty", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/OtherRelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Payable To Related Party", "verboseLabel": "Payable to related party", "documentation": "Payable To Related Party" } } }, "auth_ref": [] }, "ctcx_PaymentsDuePeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "PaymentsDuePeriod", "presentation": [ "http://www.carmellrx.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Payments Due Period", "terseLabel": "Payments due period", "documentation": "Payments due period." } } }, "auth_ref": [] }, "us-gaap_PaymentsForLoans": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForLoans", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Payments for Loans", "terseLabel": "Amount paid at closing date", "documentation": "Cash payments for and related to principal collection on loans related to operating activities." } } }, "auth_ref": [ "r9" ] }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 35.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments for Repurchase of Common Stock", "negatedLabel": "Repurchase of common stock", "documentation": "The cash outflow to reacquire common stock during the period." } } }, "auth_ref": [ "r47" ] }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfDebtIssuanceCosts", "crdr": "credit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 36.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments of Debt Issuance Costs", "negatedLabel": "Payment of debt financing fee", "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt." } } }, "auth_ref": [ "r49" ] }, "us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfMergerRelatedCostsFinancingActivities", "crdr": "credit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 27.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments of Merger Related Costs, Financing Activities", "negatedLabel": "Transaction costs paid in connection with the Business Combination", "documentation": "The cash outflow for financing costs associated with business combinations." } } }, "auth_ref": [ "r46" ] }, "us-gaap_PaymentsOfStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfStockIssuanceCosts", "crdr": "credit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 37.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments of Stock Issuance Costs", "negatedLabel": "Payment of offering costs", "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security." } } }, "auth_ref": [ "r46" ] }, "us-gaap_PaymentsToAcquireBusinessesGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireBusinessesGross", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/NatureOfTheOrganizationAndBusinessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Payments to Acquire Businesses, Gross", "terseLabel": "Payments to acquire businesses, gross", "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price." } } }, "auth_ref": [ "r44", "r600" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r172" ] }, "us-gaap_PendingLitigationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PendingLitigationMember", "presentation": [ "http://www.carmellrx.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Pending Litigation [Member]", "documentation": "Risk of loss associated with the outcome of pending litigation against the entity, for example, but not limited to, litigation in arbitration or within the trial process." } } }, "auth_ref": [ "r1012" ] }, "ctcx_PercentageOfIncreasingInOutstandingPrincipal": { "xbrltype": "percentItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "PercentageOfIncreasingInOutstandingPrincipal", "presentation": [ "http://www.carmellrx.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Percentage Of Increasing In Outstanding Principal", "terseLabel": "Percentage of increasing in outstanding principal", "documentation": "Percentage of increasing in outstanding principal." } } }, "auth_ref": [] }, "ctcx_PercentageOfOutstandingCommonStock": { "xbrltype": "percentItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "PercentageOfOutstandingCommonStock", "presentation": [ "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Percentage of Outstanding Common Stock", "terseLabel": "Percentage of outstanding common stock", "documentation": "Percentage of outstanding common stock." } } }, "auth_ref": [] }, "ctcx_PercentageOfStockOwnedByIndividual": { "xbrltype": "percentItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "PercentageOfStockOwnedByIndividual", "presentation": [ "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Percentage Of Stock Owned By Individual", "terseLabel": "Percentage of stock owned by individual", "documentation": "Percentage of stock owned by individual." } } }, "auth_ref": [] }, "ctcx_PerformanceBasedSharesEarnoutMember": { "xbrltype": "domainItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "PerformanceBasedSharesEarnoutMember", "presentation": [ "http://www.carmellrx.com/role/NatureOfTheOrganizationAndBusinessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Performance Based Shares Earnout [Member]", "documentation": "Performance Based Shares Earnout." } } }, "auth_ref": [] }, "ctcx_PinnacleTransplantTechnologiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "PinnacleTransplantTechnologiesMember", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesConcentrationsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Pinnacle Transplant Technologies [Member]", "documentation": "Pinnacle Transplant Technologies." } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameAxis", "presentation": [ "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r1024", "r1025", "r1026", "r1027", "r1028", "r1029", "r1030", "r1031", "r1032", "r1033", "r1034", "r1035", "r1036", "r1037", "r1038", "r1039", "r1040", "r1041", "r1042", "r1043", "r1044", "r1045", "r1046", "r1047", "r1048", "r1049" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameDomain", "presentation": [ "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r1024", "r1025", "r1026", "r1027", "r1028", "r1029", "r1030", "r1031", "r1032", "r1033", "r1034", "r1035", "r1036", "r1037", "r1038", "r1039", "r1040", "r1041", "r1042", "r1043", "r1044", "r1045", "r1046", "r1047", "r1048", "r1049" ] }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PortionAtFairValueFairValueDisclosureMember", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfOtherFinancialAssetsAndLiabilitiesRecordedInBalanceSheetAtFairValueDetail" ], "lang": { "en-us": { "role": { "label": "Portion at Fair Value Measurement [Member]", "documentation": "Measured at fair value for financial reporting purposes." } } }, "auth_ref": [ "r647" ] }, "ctcx_PreferredSeriesC2Member": { "xbrltype": "domainItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "PreferredSeriesC2Member", "presentation": [ "http://www.carmellrx.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Preferred Series C 2 [Member]", "documentation": "Preferred Series C 2 Member" } } }, "auth_ref": [] }, "us-gaap_PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockMember", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit", "http://www.carmellrx.com/role/NatureOfTheOrganizationAndBusinessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Preferred Stock [Member]", "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company." } } }, "auth_ref": [ "r940", "r941", "r944", "r945", "r946", "r947", "r1078", "r1082" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Par or Stated Value Per Share", "verboseLabel": "Preferred stock par or stated value per share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r158", "r486" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Authorized", "verboseLabel": "Preferred stock shares authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r158", "r827" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Issued", "verboseLabel": "Preferred stock shares issued", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": [ "r158", "r486" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Outstanding", "verboseLabel": "Preferred stock shares outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r158", "r827", "r846", "r1082", "r1083" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 24.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Value, Issued", "terseLabel": "Series A convertible voting preferred stock, $0.001 par value; 4,243 and -0- shares authorized, issued and outstanding at December 31, 2023, and December 31, 2022, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r158", "r751", "r937" ] }, "ctcx_PreferredStockWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "PreferredStockWarrantsMember", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfTheSecuritiesThatWereExcludedFromTheDilutedPerShareDetail" ], "lang": { "en-us": { "role": { "label": "Preferred Stock Warrants [Member]", "terseLabel": "Preferred Stock Warrants [Member]", "documentation": "Preferred Stock Warrants [Member]" } } }, "auth_ref": [] }, "ctcx_PremiumFinancingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "PremiumFinancingMember", "presentation": [ "http://www.carmellrx.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Premium Financing [Member]", "terseLabel": "Premium Financing [Member]", "documentation": "Premium financing." } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Prepaid Expense, Current", "terseLabel": "Prepaid expenses", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r264", "r416", "r417", "r907" ] }, "ctcx_PricePerShareOfSharesWithdrawn": { "xbrltype": "perShareItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "PricePerShareOfSharesWithdrawn", "presentation": [ "http://www.carmellrx.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Price Per Share Of Shares Withdrawn", "terseLabel": "Price per share of shares withdrawn", "documentation": "Price per share of shares withdrawn." } } }, "auth_ref": [] }, "ctcx_PrincipalConversionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "PrincipalConversionMember", "presentation": [ "http://www.carmellrx.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Principal Conversion [Member]", "documentation": "Principal Conversion Member" } } }, "auth_ref": [] }, "ctcx_PrivatePlacementWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "PrivatePlacementWarrantsMember", "presentation": [ "http://www.carmellrx.com/role/NatureOfTheOrganizationAndBusinessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Private Placement Warrants [Member]", "documentation": "Private placement warrants." } } }, "auth_ref": [] }, "ctcx_ProFormaNetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "ProFormaNetIncomeLoss", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/BusinessCombinationsSummaryOfBusinessCombinationsUnauditedProFromaStatementsOfOperationsDetail" ], "lang": { "en-us": { "role": { "label": "Pro Forma Net Income Loss", "totalLabel": "Unaudited pro forma net loss", "documentation": "Pro forma net income loss." } } }, "auth_ref": [] }, "ctcx_ProFormaRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "ProFormaRevenue", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/BusinessCombinationsSummaryOfBusinessCombinationsUnauditedProFromaStatementsOfOperationsDetail" ], "lang": { "en-us": { "role": { "label": "Pro Forma Revenue", "totalLabel": "Unaudited pro forma revenue", "documentation": "Pro Forma revenue." } } }, "auth_ref": [] }, "ctcx_ProbabilityOfAChangeInControlEventMember": { "xbrltype": "domainItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "ProbabilityOfAChangeInControlEventMember", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfFairValueOfEmbeddedDerivativesInTheConvertibleNotesDetail" ], "lang": { "en-us": { "role": { "label": "Probability of a Change in Control Event [Member]", "terseLabel": "Probability of a Change in Control Event [Member]", "documentation": "Probability of a Change in Control Event [Member]" } } }, "auth_ref": [] }, "ctcx_ProbabilityOfQualifiedFinancingOrIpoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "ProbabilityOfQualifiedFinancingOrIpoMember", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfFairValueOfEmbeddedDerivativesInTheConvertibleNotesDetail" ], "lang": { "en-us": { "role": { "label": "Probability of Qualified Financing or IPO [Member]", "terseLabel": "Probability of Qualified Financing or IPO [Member]", "documentation": "Probability of Qualified Financing or IPO [Member]" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromConvertibleDebt", "crdr": "debit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 33.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Convertible Debt", "terseLabel": "Proceeds from convertible notes", "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": [ "r45" ] }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfLongTermDebt", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Long-Term Debt", "terseLabel": "Procees from notes", "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer." } } }, "auth_ref": [ "r45", "r790" ] }, "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock", "crdr": "debit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 34.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Preferred Stock and Preference Stock", "terseLabel": "Issuance of Series C-1 preferred stock", "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation." } } }, "auth_ref": [ "r6" ] }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfWarrants", "crdr": "debit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 30.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Warrants", "terseLabel": "Proceeds from issuance of loans and related warrants", "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)." } } }, "auth_ref": [ "r6" ] }, "us-gaap_ProceedsFromLoans": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromLoans", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.carmellrx.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Proceeds from Loans", "terseLabel": "Proceeds from loan", "documentation": "Cash received from principal payments made on loans related to operating activities." } } }, "auth_ref": [ "r50" ] }, "ctcx_ProceedsFromMerger": { "xbrltype": "monetaryItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "ProceedsFromMerger", "crdr": "debit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 26.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds From Merger", "verboseLabel": "Gross proceeds from Business Combination", "documentation": "Proceeds from merger." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 29.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Stock Options Exercised", "verboseLabel": "Proceeds from common stock option exercises", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r6", "r23" ] }, "ctcx_ProceedsFromTemporaryEquityAcquisitionsEquivalentToAmountRemittedUnderOTCEquityPrepaidForwardTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "ProceedsFromTemporaryEquityAcquisitionsEquivalentToAmountRemittedUnderOTCEquityPrepaidForwardTransaction", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/NatureOfTheOrganizationAndBusinessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Proceeds From Temporary Equity Acquisitions Equivalent To Amount Remitted Under OTC Equity Prepaid Forward Transaction", "terseLabel": "Proceeds from temporary equity acquisitions equivalent to amount remitted under otc equity prepaid forward transaction", "documentation": "Proceeds from temporary equity acquisitions equivalent to amount remitted under otc equity prepaid forward transaction." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromWarrantExercises": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromWarrantExercises", "crdr": "debit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 38.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Warrant Exercises", "terseLabel": "Proceeds from warrant exercise", "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants." } } }, "auth_ref": [ "r978" ] }, "us-gaap_ProductConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductConcentrationRiskMember", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesConcentrationsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Product Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence." } } }, "auth_ref": [ "r60" ] }, "us-gaap_ProductInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductInformationLineItems", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesConcentrationsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Product Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesConcentrationsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r349", "r726", "r767", "r768", "r769", "r770", "r771", "r772", "r905", "r925", "r938", "r962", "r1015", "r1016", "r1022", "r1076" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesConcentrationsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r349", "r726", "r767", "r768", "r769", "r770", "r771", "r772", "r905", "r925", "r938", "r962", "r1015", "r1016", "r1022", "r1076" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss from continuing operations attributable to common stockholders", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r250", "r269", "r270", "r279", "r287", "r298", "r310", "r311", "r329", "r342", "r346", "r348", "r390", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r603", "r606", "r607", "r635", "r649", "r746", "r761", "r796", "r848", "r869", "r870", "r914", "r934", "r935", "r949", "r977", "r1017" ] }, "ctcx_PromissoryNotesOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "PromissoryNotesOutstanding", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Promissory Notes Outstanding", "terseLabel": "Promissory notes outstanding", "documentation": "Promissory notes outstanding." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://www.carmellrx.com/role/PropertyAndEquipmentScheduleOfPropertyPlantAndEquipmentIncludeInContinuingOperationsDetail", "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r12" ] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://www.carmellrx.com/role/PropertyAndEquipment" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property and Equipment", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r183", "r228", "r233", "r234" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://www.carmellrx.com/role/PropertyAndEquipmentScheduleOfPropertyPlantAndEquipmentIncludeInContinuingOperationsDetail": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.carmellrx.com/role/PropertyAndEquipmentScheduleOfPropertyPlantAndEquipmentIncludeInContinuingOperationsDetail" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property and equipment, gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r185", "r255", "r758" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://www.carmellrx.com/role/PropertyAndEquipmentAdditionalInformationDetail", "http://www.carmellrx.com/role/PropertyAndEquipmentScheduleOfPropertyPlantAndEquipmentIncludeInContinuingOperationsDetail" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property Plant And Equipment", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 }, "http://www.carmellrx.com/role/PropertyAndEquipmentScheduleOfPropertyPlantAndEquipmentIncludeInContinuingOperationsDetail": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedBalanceSheets", "http://www.carmellrx.com/role/PropertyAndEquipmentScheduleOfPropertyPlantAndEquipmentIncludeInContinuingOperationsDetail" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net of accumulated depreciation of $622,714 and $530,116, respectively", "totalLabel": "Property and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r12", "r747", "r758", "r937" ] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property and Equipment", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r12", "r228", "r233", "r756" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://www.carmellrx.com/role/PropertyAndEquipmentTables" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of Property Plant and Equipment Include In Continuing Operations", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r12" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://www.carmellrx.com/role/PropertyAndEquipmentScheduleOfPropertyPlantAndEquipmentIncludeInContinuingOperationsDetail", "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r185" ] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Property and equipment estimated useful lives", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "ctcx_PublicWarrantsAssumedInBusinessCombinationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "PublicWarrantsAssumedInBusinessCombinationMember", "presentation": [ "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitSummaryOfInformationRelatedToCommonStockWarrantsDetail" ], "lang": { "en-us": { "role": { "label": "Public Warrants Assumed In Business Combination [Member]", "terseLabel": "Public Warrants Assumed in Business Combination [Member]", "documentation": "Public warrants assumed in business combination." } } }, "auth_ref": [] }, "ctcx_PublicWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "PublicWarrantsMember", "presentation": [ "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitAdditionalInformationDetail", "http://www.carmellrx.com/role/NatureOfTheOrganizationAndBusinessAdditionalInformationDetail", "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfTheSecuritiesThatWereExcludedFromTheDilutedPerShareDetail" ], "lang": { "en-us": { "role": { "label": "Public Warrants [Member]", "terseLabel": "Public Warrants [Member]", "documentation": "Public warrants." } } }, "auth_ref": [] }, "ctcx_PuritanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "PuritanMember", "presentation": [ "http://www.carmellrx.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.carmellrx.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Puritan [Member]", "terseLabel": "Puritan [Member]", "documentation": "Puritan." } } }, "auth_ref": [] }, "ctcx_PuritanPartnersLimitedLiabilityCompanyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "PuritanPartnersLimitedLiabilityCompanyMember", "presentation": [ "http://www.carmellrx.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Puritan Partners Limited Liability Company [Member]", "terseLabel": "Puritan Partners LLC [Member]", "documentation": "Puritan Partners Limited Liability Company." } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://www.carmellrx.com/role/BusinessCombinationsAdditionalInformationDetail", "http://www.carmellrx.com/role/DebtAdditionalInformationDetail", "http://www.carmellrx.com/role/GoingConcernAndManagementsLiquidityPlansAdditionalInformationDetail", "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitAdditionalInformationDetail", "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelDetail", "http://www.carmellrx.com/role/NatureOfTheOrganizationAndBusinessAdditionalInformationDetail", "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r444", "r445", "r446", "r447", "r517", "r525", "r551", "r552", "r553", "r699", "r723", "r773", "r817", "r818", "r878", "r879", "r880", "r881", "r890", "r902", "r903", "r916", "r924", "r932", "r939", "r942", "r1009", "r1019", "r1066", "r1067", "r1068", "r1069", "r1070" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://www.carmellrx.com/role/BusinessCombinationsAdditionalInformationDetail", "http://www.carmellrx.com/role/DebtAdditionalInformationDetail", "http://www.carmellrx.com/role/GoingConcernAndManagementsLiquidityPlansAdditionalInformationDetail", "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitAdditionalInformationDetail", "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelDetail", "http://www.carmellrx.com/role/NatureOfTheOrganizationAndBusinessAdditionalInformationDetail", "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r444", "r445", "r446", "r447", "r517", "r525", "r551", "r552", "r553", "r699", "r723", "r773", "r817", "r818", "r878", "r879", "r880", "r881", "r890", "r902", "r903", "r916", "r924", "r932", "r939", "r942", "r1009", "r1019", "r1066", "r1067", "r1068", "r1069", "r1070" ] }, "us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RedeemableNoncontrollingInterestEquityPreferredCarryingAmount", "crdr": "credit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 28.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Redeemable Noncontrolling Interest, Equity, Preferred, Carrying Amount", "terseLabel": "Redeemable convertible preferred stock", "documentation": "As of the reporting date, the carrying amount of noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. The noncontrolling interest holder's ownership (or holders' ownership) may be in the form of preferred shares (regardless of class), preferred partnership units (regardless of class), preferential membership interests, or any other form of preferred equity regardless of investee entity legal form." } } }, "auth_ref": [ "r81", "r82", "r83", "r84" ] }, "ctcx_RedemptionWarrantsTriggerPriceAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "RedemptionWarrantsTriggerPriceAxis", "presentation": [ "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Redemption Warrants Trigger Price [Axis]", "documentation": "Redemption Warrants Trigger Price Axis" } } }, "auth_ref": [] }, "ctcx_RedemptionWarrantsTriggerPriceDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "RedemptionWarrantsTriggerPriceDomain", "presentation": [ "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Redemption Warrants Trigger Price [Domain]", "documentation": "Redemption Warrants Trigger Price Domain" } } }, "auth_ref": [] }, "ctcx_ReimbursmentOfExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "ReimbursmentOfExpenses", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Reimbursment Of Expenses", "terseLabel": "Reimbursment of expenses", "documentation": "Reimbursment of expenses." } } }, "auth_ref": [] }, "ctcx_ReimbursmentOfExpensesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "ReimbursmentOfExpensesPayable", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Reimbursment Of Expenses Payable", "terseLabel": "Reimbursment of expenses payable", "documentation": "Reimbursment of expenses payable." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyDomain", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedBalanceSheets", "http://www.carmellrx.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.carmellrx.com/role/ConsolidatedStatementsOfOperations", "http://www.carmellrx.com/role/DiscontinuedOperationsSummaryOfDiscontinuedOperationsInConsolidatedStatementsOfIncomeDetail", "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitAdditionalInformationDetail", "http://www.carmellrx.com/role/NatureOfTheOrganizationAndBusinessAdditionalInformationDetail", "http://www.carmellrx.com/role/OtherRelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Related Party [Domain]", "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r524", "r686", "r687", "r820", "r821", "r822", "r823", "r824", "r845", "r847", "r877" ] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyMember", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfOperations", "http://www.carmellrx.com/role/DiscontinuedOperationsSummaryOfDiscontinuedOperationsInConsolidatedStatementsOfIncomeDetail" ], "lang": { "en-us": { "role": { "label": "Related Party [Member]", "terseLabel": "Related Party [Member]", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": [ "r289", "r290", "r686", "r687", "r688", "r689", "r820", "r821", "r822", "r823", "r824", "r845", "r847", "r877" ] }, "us-gaap_RelatedPartyTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionAxis", "presentation": [ "http://www.carmellrx.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Axis]", "documentation": "Information by type of related party transaction." } } }, "auth_ref": [ "r686", "r687", "r1062" ] }, "us-gaap_RelatedPartyTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionDomain", "presentation": [ "http://www.carmellrx.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Domain]", "documentation": "Transaction between related party." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionLineItems", "presentation": [ "http://www.carmellrx.com/role/OtherRelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r853", "r854", "r855" ] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedBalanceSheets", "http://www.carmellrx.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.carmellrx.com/role/ConsolidatedStatementsOfOperations", "http://www.carmellrx.com/role/DiscontinuedOperationsSummaryOfDiscontinuedOperationsInConsolidatedStatementsOfIncomeDetail", "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitAdditionalInformationDetail", "http://www.carmellrx.com/role/NatureOfTheOrganizationAndBusinessAdditionalInformationDetail", "http://www.carmellrx.com/role/OtherRelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Related Party [Axis]", "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r524", "r686", "r687", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r820", "r821", "r822", "r823", "r824", "r845", "r847", "r877", "r1062" ] }, "us-gaap_RepaymentOfNotesReceivableFromRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentOfNotesReceivableFromRelatedParties", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Repayment of Notes Receivable from Related Parties", "verboseLabel": "Repayment of notes receivable from related parties of borrowings", "documentation": "The cash inflow from a loan, supported by a promissory note, granted to related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth." } } }, "auth_ref": [ "r43" ] }, "us-gaap_RepaymentsOfConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfConvertibleDebt", "crdr": "credit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 32.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Repayments of Convertible Debt", "negatedLabel": "Payment of convertible notes", "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": [ "r48" ] }, "us-gaap_RepaymentsOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfDebt", "crdr": "credit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 31.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Repayments of Debt", "negatedLabel": "Payment of loans", "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation." } } }, "auth_ref": [ "r979" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.carmellrx.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]" } } }, "auth_ref": [ "r291", "r292", "r462", "r488", "r689", "r909", "r910" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense", "terseLabel": "Research and development", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r132", "r563", "r1071" ] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development Expenses", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": [ "r562" ] }, "us-gaap_ResearchMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchMember", "presentation": [ "http://www.carmellrx.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Research Tax Credit Carryforward [Member]", "terseLabel": "Research Tax Credit Carryforward [Member]", "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes." } } }, "auth_ref": [ "r99" ] }, "srt_RestatementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RestatementAxis", "presentation": [ "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Axis]" } } }, "auth_ref": [ "r246", "r294", "r295", "r296", "r298", "r299", "r302", "r303", "r304", "r305", "r307", "r308", "r309", "r310", "r311", "r313", "r325", "r398", "r399", "r584", "r629", "r633", "r634", "r635", "r669", "r684", "r685", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r787" ] }, "srt_RestatementDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RestatementDomain", "presentation": [ "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Domain]" } } }, "auth_ref": [ "r246", "r294", "r295", "r296", "r298", "r299", "r302", "r303", "r304", "r305", "r307", "r308", "r309", "r310", "r311", "r313", "r325", "r398", "r399", "r584", "r629", "r633", "r634", "r635", "r669", "r684", "r685", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r787" ] }, "us-gaap_RestructuringCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringCharges", "crdr": "debit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Restructuring Charges", "verboseLabel": "Restructuring charges", "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r11", "r438", "r439", "r1010" ] }, "ctcx_RestructuringChargesPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "RestructuringChargesPolicyPolicyTextBlock", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Restructuring Charges Policy [Policy Text Block]", "terseLabel": "Restructuring Charges", "documentation": "Restructuring charges policy." } } }, "auth_ref": [] }, "us-gaap_RestructuringCostAndReserveAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringCostAndReserveAxis", "presentation": [ "http://www.carmellrx.com/role/GoingConcernAndManagementsLiquidityPlansAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Restructuring Type [Axis]", "documentation": "Information by type of restructuring cost." } } }, "auth_ref": [ "r436", "r437", "r439", "r440" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 27.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedBalanceSheets", "http://www.carmellrx.com/role/GoingConcernAndManagementsLiquidityPlansAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Retained Earnings (Accumulated Deficit)", "verboseLabel": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r161", "r197", "r754", "r780", "r785", "r794", "r828", "r937" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r245", "r294", "r295", "r296", "r299", "r309", "r311", "r396", "r403", "r557", "r558", "r559", "r583", "r584", "r615", "r618", "r619", "r622", "r633", "r776", "r778", "r797", "r1082" ] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/BusinessCombinationsSummaryOfBusinessCombinationsUnauditedProFromaStatementsOfOperationsDetail" ], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "verboseLabel": "Revenue included in discontinued operations in the consolidated statements of operations", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r330", "r331", "r341", "r344", "r345", "r349", "r350", "r351", "r514", "r515", "r726" ] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue Recognition", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": [ "r241", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r904" ] }, "us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenuePerformanceObligationDescriptionOfPaymentTerms", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Revenue, Performance Obligation, Description of Payment Terms", "terseLabel": "Revenue, performance obligation, description of payment terms", "documentation": "Description of payment terms in contract with customer. Includes, but is not limited to, timing of payment, existence of financing component, variability of consideration and constraint on variable consideration." } } }, "auth_ref": [ "r505" ] }, "us-gaap_RevenuePerformanceObligationDescriptionOfTiming": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenuePerformanceObligationDescriptionOfTiming", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Revenue, Performance Obligation, Description of Timing", "terseLabel": "Revenue, performance obligation, description of timing", "documentation": "Description of timing for satisfying performance obligation in contract with customer. Includes, but is not limited to, as services are rendered, and upon shipment, delivery or completion of service." } } }, "auth_ref": [ "r504" ] }, "us-gaap_RevenueRemainingPerformanceObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRemainingPerformanceObligation", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Revenue, Remaining Performance Obligation, Amount", "terseLabel": "Services accounted for consideration payable and reduction of transaction price", "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue." } } }, "auth_ref": [ "r231" ] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period", "terseLabel": "Revenue, remaining performance obligation, expected timing of satisfaction, period", "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r232" ] }, "ctcx_RoyaltiesPayablePercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "RoyaltiesPayablePercentage", "presentation": [ "http://www.carmellrx.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Royalties Payable Percentage", "terseLabel": "Royalities payable percentage", "documentation": "Royalities payable percentage." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitAdditionalInformationDetail", "http://www.carmellrx.com/role/NatureOfTheOrganizationAndBusinessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_SalesRevenueNetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalesRevenueNetMember", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesConcentrationsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Revenue Benchmark [Member]", "terseLabel": "Revenue [Member]", "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r351", "r956" ] }, "ctcx_ScheduleOfAccruedExpensesAndOtherLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "ScheduleOfAccruedExpensesAndOtherLiabilitiesTableTextBlock", "presentation": [ "http://www.carmellrx.com/role/AccruedExpensesAndOtherLiabilitiesTables" ], "lang": { "en-us": { "role": { "label": "Schedule Of Accrued Expenses And Other Liabilities [Table Text Block]", "terseLabel": "Schedule of Accrued Expenses and Other Liabilities", "documentation": "Schedule of accrued expenses and other liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfTheSecuritiesThatWereExcludedFromTheDilutedPerShareDetail" ], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities." } } }, "auth_ref": [ "r56" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Summary of Securities that were Excluded from the Diluted Per Share", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r56" ] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "presentation": [ "http://www.carmellrx.com/role/BusinessCombinationsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]", "terseLabel": "Summary of Fair Value of the Purchase Consideration Transferred", "documentation": "Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "presentation": [ "http://www.carmellrx.com/role/BusinessCombinationsAdditionalInformationDetail", "http://www.carmellrx.com/role/BusinessCombinationsSummaryOfAllocationOfPurchasePriceDetail", "http://www.carmellrx.com/role/BusinessCombinationsSummaryOfBusinessCombinationsUnauditedProFromaStatementsOfOperationsDetail", "http://www.carmellrx.com/role/BusinessCombinationsSummaryOfBusinessCombinationsUnauditedProFromaStatementsOfOperationsParentheticalDetail", "http://www.carmellrx.com/role/BusinessCombinationsSummaryOfFairValueOfPurchaseConsiderationTransferredDetail", "http://www.carmellrx.com/role/BusinessCombinationsSummaryOfFairValueOfPurchaseConsiderationTransferredParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities." } } }, "auth_ref": [ "r103", "r105", "r595" ] }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": [ "http://www.carmellrx.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Significant Components of Deferred Tax Assets", "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets." } } }, "auth_ref": [ "r201" ] }, "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "presentation": [ "http://www.carmellrx.com/role/DiscontinuedOperationsTables" ], "lang": { "en-us": { "role": { "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]", "terseLabel": "Schedule of Discontinued Operations", "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r14", "r24", "r32", "r134", "r143", "r144", "r145", "r146", "r147", "r150", "r152", "r153", "r187" ] }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": [ "http://www.carmellrx.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Components of Income Tax Rate", "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r200" ] }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": [ "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]" } } }, "auth_ref": [ "r387", "r388", "r389" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": [ "http://www.carmellrx.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetail", "http://www.carmellrx.com/role/GoodwillAndIntangibleAssetsSummaryOfAmortizationExpenseRelatedToIntangibleAssetsDetail", "http://www.carmellrx.com/role/GoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetail" ], "lang": { "en-us": { "role": { "label": "Schedule of Finite-Lived Intangible Assets [Table]", "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r68", "r69", "r727" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": [ "http://www.carmellrx.com/role/GoodwillAndIntangibleAssetsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Summary of Intangible Assets", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": [ "r68", "r69" ] }, "us-gaap_ScheduleOfGoodwillTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfGoodwillTable", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfGoodwillDetail" ], "lang": { "en-us": { "role": { "label": "Schedule of Goodwill [Table]", "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons." } } }, "auth_ref": [ "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r918" ] }, "us-gaap_ScheduleOfGoodwillTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfGoodwillTextBlock", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Summary of Goodwill", "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule." } } }, "auth_ref": [ "r918", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008" ] }, "us-gaap_ScheduleOfProductInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfProductInformationTable", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesConcentrationsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Schedule of Product Information [Table]", "documentation": "Schedule detailing quantitative information concerning products or product lines by product or product line." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://www.carmellrx.com/role/PropertyAndEquipmentAdditionalInformationDetail", "http://www.carmellrx.com/role/PropertyAndEquipmentScheduleOfPropertyPlantAndEquipmentIncludeInContinuingOperationsDetail" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r12" ] }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "presentation": [ "http://www.carmellrx.com/role/BusinessCombinationsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "verboseLabel": "Summary of Allocation of the Purchase Price", "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree." } } }, "auth_ref": [ "r203" ] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": [ "http://www.carmellrx.com/role/OtherRelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Schedule of Related Party TransactionsTable]", "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r124", "r125", "r853", "r854", "r855" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelDetail" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r526", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitTables" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Summary of Option Activity", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r21", "r22", "r96" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of Assumptions used in Black Scholes Option Pricing Model", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r199" ] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Schedule of Stock by Class [Table]", "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity." } } }, "auth_ref": [ "r80", "r85", "r86", "r87", "r88", "r89", "r90", "r194", "r196", "r197", "r260", "r261", "r262", "r327", "r486", "r487", "r488", "r490", "r493", "r499", "r501", "r790", "r791", "r792", "r793", "r924", "r955", "r982" ] }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "presentation": [ "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]", "terseLabel": "Summary Of Information Related To Common Stock Warrants", "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": [ "r93" ] }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "presentation": [ "http://www.carmellrx.com/role/GoodwillAndIntangibleAssetsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "verboseLabel": "Summary of Amortization Expense Related to Intangible Assets", "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets." } } }, "auth_ref": [ "r69" ] }, "us-gaap_SegmentContinuingOperationsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentContinuingOperationsMember", "presentation": [ "http://www.carmellrx.com/role/AccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetail", "http://www.carmellrx.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetail", "http://www.carmellrx.com/role/GoodwillAndIntangibleAssetsSummaryOfAmortizationExpenseRelatedToIntangibleAssetsDetail", "http://www.carmellrx.com/role/GoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetail", "http://www.carmellrx.com/role/PropertyAndEquipmentAdditionalInformationDetail", "http://www.carmellrx.com/role/PropertyAndEquipmentScheduleOfPropertyPlantAndEquipmentIncludeInContinuingOperationsDetail" ], "lang": { "en-us": { "role": { "label": "Continuing Operations [Member]", "documentation": "Component of an entity expected to operate in the foreseeable future." } } }, "auth_ref": [] }, "us-gaap_SegmentDiscontinuedOperationsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentDiscontinuedOperationsMember", "presentation": [ "http://www.carmellrx.com/role/AccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetail", "http://www.carmellrx.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetail", "http://www.carmellrx.com/role/GoodwillAndIntangibleAssetsSummaryOfAmortizationExpenseRelatedToIntangibleAssetsDetail", "http://www.carmellrx.com/role/GoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetail", "http://www.carmellrx.com/role/PropertyAndEquipmentAdditionalInformationDetail", "http://www.carmellrx.com/role/PropertyAndEquipmentScheduleOfPropertyPlantAndEquipmentIncludeInContinuingOperationsDetail" ], "lang": { "en-us": { "role": { "label": "Discontinued Operations [Member]", "documentation": "Component or group of components disposed of or classified as held-for-sale and representing a strategic shift that has or will have a major effect on operations and financial results. Includes a business or nonprofit activity on acquisition classified as held-for-sale." } } }, "auth_ref": [ "r8", "r135", "r136", "r137" ] }, "us-gaap_SegmentOperatingActivitiesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentOperatingActivitiesDomain", "presentation": [ "http://www.carmellrx.com/role/AccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetail", "http://www.carmellrx.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetail", "http://www.carmellrx.com/role/GoodwillAndIntangibleAssetsSummaryOfAmortizationExpenseRelatedToIntangibleAssetsDetail", "http://www.carmellrx.com/role/GoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetail", "http://www.carmellrx.com/role/PropertyAndEquipmentAdditionalInformationDetail", "http://www.carmellrx.com/role/PropertyAndEquipmentScheduleOfPropertyPlantAndEquipmentIncludeInContinuingOperationsDetail" ], "lang": { "en-us": { "role": { "label": "Operating Activities [Domain]", "documentation": "Operations of an entity including continuing and discontinued operations." } } }, "auth_ref": [] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Segment Reporting", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": [ "r335", "r336", "r337", "r338", "r339", "r340", "r350", "r915" ] }, "us-gaap_SellingAndMarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingAndMarketingExpense", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Selling and Marketing Expense", "terseLabel": "Sales and marketing expenses", "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services." } } }, "auth_ref": [] }, "ctcx_SellingAndMarketingExpensesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "SellingAndMarketingExpensesPolicyTextBlock", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Selling and Marketing Expenses [Policy Text Block]", "terseLabel": "Selling and Marketing Expenses", "documentation": "Selling and marketing expenses." } } }, "auth_ref": [] }, "ctcx_SeriesACOneAndCTwoConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "SeriesACOneAndCTwoConvertiblePreferredStockMember", "presentation": [ "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Series A, C-One and C-Two Convertible Preferred Stock [Member]", "terseLabel": "Series A, C-1 and C-2 Convertible Preferred Stock [Member]", "documentation": "Series A, C-one and C-two convertible preferred stock." } } }, "auth_ref": [] }, "ctcx_SeriesAConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "SeriesAConvertiblePreferredStockMember", "presentation": [ "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitAdditionalInformationDetail", "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitRedeemableConvertiblePreferredStockDetail" ], "lang": { "en-us": { "role": { "label": "Series A Convertible Preferred Stock [Member]", "documentation": "Series A convertible preferred stock." } } }, "auth_ref": [] }, "ctcx_SeriesAConvertibleVotingPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "SeriesAConvertibleVotingPreferredStockMember", "presentation": [ "http://www.carmellrx.com/role/BusinessCombinationsSummaryOfFairValueOfPurchaseConsiderationTransferredDetail", "http://www.carmellrx.com/role/BusinessCombinationsSummaryOfFairValueOfPurchaseConsiderationTransferredParentheticalDetail", "http://www.carmellrx.com/role/NatureOfTheOrganizationAndBusinessAdditionalInformationDetail", "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Series A Convertible Voting Preferred Stock [Member]", "terseLabel": "Series A Convertible Voting Preferred Stock [Member]", "documentation": "Series A Convertible Voting Preferred Stock." } } }, "auth_ref": [] }, "us-gaap_SeriesAPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeriesAPreferredStockMember", "presentation": [ "http://www.carmellrx.com/role/BusinessCombinationsAdditionalInformationDetail", "http://www.carmellrx.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.carmellrx.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit", "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitAdditionalInformationDetail", "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfTheSecuritiesThatWereExcludedFromTheDilutedPerShareDetail" ], "lang": { "en-us": { "role": { "label": "Series A Preferred Stock [Member]", "terseLabel": "Series A Preferred Stock [Member]", "verboseLabel": "Series A Preferred Stock (if converted) [Member]", "documentation": "Series A preferred stock." } } }, "auth_ref": [ "r972", "r973", "r1021" ] }, "ctcx_SeriesARedeemableConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "SeriesARedeemableConvertiblePreferredStockMember", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedBalanceSheets", "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfTheSecuritiesThatWereExcludedFromTheDilutedPerShareDetail" ], "lang": { "en-us": { "role": { "label": "Series A Redeemable Convertible Preferred Stock [Member]", "terseLabel": "Series A Redeemable Convertible Preferred Stock [Member]", "verboseLabel": "Series A Preferred Stock (if converted) [Member]", "documentation": "Series A Redeemable Convertible Preferred Stock [Member]." } } }, "auth_ref": [] }, "ctcx_SeriesBConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "SeriesBConvertiblePreferredStockMember", "presentation": [ "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitRedeemableConvertiblePreferredStockDetail" ], "lang": { "en-us": { "role": { "label": "Series B Convertible Preferred Stock [Member]", "documentation": "Series b convertible preferred stock." } } }, "auth_ref": [] }, "us-gaap_SeriesBPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeriesBPreferredStockMember", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Series B Preferred Stock [Member]", "terseLabel": "Series B Preferred Stock [Member]", "documentation": "Series B preferred stock." } } }, "auth_ref": [ "r972", "r973", "r1021" ] }, "ctcx_SeriesBRedeemableConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "SeriesBRedeemableConvertiblePreferredStockMember", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedBalanceSheets", "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfTheSecuritiesThatWereExcludedFromTheDilutedPerShareDetail" ], "lang": { "en-us": { "role": { "label": "Series B Preferred Stock (if converted) [Member]", "terseLabel": "Series B Redeemable Convertible Preferred Stock [Member]", "documentation": "Series B Redeemable Convertible Preferred Stock [Member]." } } }, "auth_ref": [] }, "ctcx_SeriesCOneConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "SeriesCOneConvertiblePreferredStockMember", "presentation": [ "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitAdditionalInformationDetail", "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitRedeemableConvertiblePreferredStockDetail" ], "lang": { "en-us": { "role": { "label": "Series C One Convertible Preferred Stock [Member]", "terseLabel": "Series C-1 Convertible Preferred Stock [Member]", "documentation": "Series C one convertible preferred stock." } } }, "auth_ref": [] }, "ctcx_SeriesCOnePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "SeriesCOnePreferredStockMember", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.carmellrx.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Series C One Preferred Stock [Member]", "verboseLabel": "Series C-1 Preferred Stock [Member]", "documentation": "Series C one preferred stock." } } }, "auth_ref": [] }, "ctcx_SeriesCOneRedeemableConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "SeriesCOneRedeemableConvertiblePreferredStockMember", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedBalanceSheets", "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfTheSecuritiesThatWereExcludedFromTheDilutedPerShareDetail" ], "lang": { "en-us": { "role": { "label": "Series C-1 Preferred Stock (if converted) [Member]", "terseLabel": "Series C-1 Redeemable Convertible Preferred Stock [Member]", "documentation": "Series C One Redeemable Convertible Preferred Stock [Member]." } } }, "auth_ref": [] }, "ctcx_SeriesCTwoConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "SeriesCTwoConvertiblePreferredStockMember", "presentation": [ "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitAdditionalInformationDetail", "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitRedeemableConvertiblePreferredStockDetail" ], "lang": { "en-us": { "role": { "label": "Series C Two Convertible Preferred Stock [Member]", "terseLabel": "Series C-2 Convertible Preferred Stock [Member]", "documentation": "Series C two convertible preferred stock." } } }, "auth_ref": [] }, "ctcx_SeriesCTwoPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "SeriesCTwoPreferredStockMember", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.carmellrx.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Series C Two Preferred Stock [Member]", "verboseLabel": "Series C-2 Preferred Stock [Member]", "documentation": "Series C two preferred stock." } } }, "auth_ref": [] }, "ctcx_SeriesCTwoRedeemableConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "SeriesCTwoRedeemableConvertiblePreferredStockMember", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedBalanceSheets", "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfTheSecuritiesThatWereExcludedFromTheDilutedPerShareDetail" ], "lang": { "en-us": { "role": { "label": "Series C-2 Preferred Stock (if converted) [Member]", "terseLabel": "Series C-2 Redeemable Convertible Preferred Stock [Member]", "documentation": "Series C Two Redeemable Convertible Preferred Stock [Member]." } } }, "auth_ref": [] }, "ctcx_SeriesOneConvertibleNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "SeriesOneConvertibleNotesMember", "presentation": [ "http://www.carmellrx.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Series One Convertible Notes [Member]", "documentation": "Series One Convertible Notes Member" } } }, "auth_ref": [] }, "ctcx_SeriesTwoConvertibleNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "SeriesTwoConvertibleNotesMember", "presentation": [ "http://www.carmellrx.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Series Two Convertible Notes [Member]", "documentation": "Series Two Convertible Notes [Member]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r10" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "terseLabel": "Stock option, vesting period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r933" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelDetail" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Dividend yield", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r552" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "presentation": [ "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelDetail" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum", "terseLabel": "Expected volatility rate, Maximum", "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "presentation": [ "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelDetail" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum", "terseLabel": "Expected volatility rate, Minimum", "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "presentation": [ "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelDetail" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum", "terseLabel": "Range of risk-free interest rate, Maximum", "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "presentation": [ "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelDetail" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum", "terseLabel": "Range of risk-free interest rate, Minimum", "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelDetail" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r526", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554" ] }, "ctcx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumStockIssuedDescription": { "xbrltype": "stringItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumStockIssuedDescription", "presentation": [ "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award Maximum Stock Issued Description", "terseLabel": "Share based compensation arrangement by share based payment award maximum stock issued description", "documentation": "Share based compensation arrangement by share based payment award maximum stock issued description." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitSummaryOfOptionActivityDetail" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "periodEndLabel": "Number of options, vested/exercisable, ending balance", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r534" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitSummaryOfOptionActivityDetail" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "periodEndLabel": "Weighted average exercise price, vested/exercisable, ending balance", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r534" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "presentation": [ "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitSummaryOfOptionActivityDetail" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period", "negatedLabel": "Number of options, expired/cancelled", "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements." } } }, "auth_ref": [ "r539" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitSummaryOfOptionActivityDetail" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Number of options, granted", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r536" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitSummaryOfOptionActivityDetail" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "periodEndLabel": "Aggregate intrinsic value, options outstanding, ending balance", "periodStartLabel": "Aggregate intrinsic value, options outstanding, beginning balance", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r94" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitSummaryOfOptionActivityDetail" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Number of options, outstanding, ending balance", "periodStartLabel": "Number of options, outstanding, beginning balance", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r532", "r533" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitSummaryOfOptionActivityDetail" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted average exercise price, outstanding, ending balance", "periodStartLabel": "Weighted average exercise price, outstanding, beginning balance", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r532", "r533" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitSummaryOfOptionActivityDetail" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price, exercised", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r537" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitSummaryOfOptionActivityDetail" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price, expired/cancelled", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired." } } }, "auth_ref": [ "r539" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitSummaryOfOptionActivityDetail" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "verboseLabel": "Weighted average exercise price granted", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r536" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "presentation": [ "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage", "terseLabel": "Share-based compensation arrangement by share-based percentage award, award vesting rights, percentage", "documentation": "Percentage of vesting of award under share-based payment arrangement." } } }, "auth_ref": [ "r1024" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelDetail" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected term of option", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r550" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitSummaryOfOptionActivityDetail" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "periodEndLabel": "Aggregate intrinsic value, Options vested/exercisable", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": [ "r94" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitSummaryOfOptionActivityDetail" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Options vested/exercisable, Weighted average remaining life in years", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r94" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitSummaryOfOptionActivityDetail" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Options outstanding, weighted average remaining life in years", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r198" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "presentation": [ "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent", "terseLabel": "Percentage of exercise price per share from fair market value", "documentation": "Purchase price of common stock expressed as a percentage of its fair value." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesOutstanding", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Shares, Outstanding", "periodEndLabel": "Ending Balance (in Shares)", "periodStartLabel": "Beginning Balance (in Shares)", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_ShortTermLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermLeaseCost", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/LeasesSummaryOfNetLeaseCostAndOtherSupplementalLeaseInformationDetail" ], "lang": { "en-us": { "role": { "label": "Short-Term Lease, Cost", "terseLabel": "Short term lease cost", "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less." } } }, "auth_ref": [ "r676", "r936" ] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r176", "r284" ] }, "ctcx_SmallBusinessAdministrationLoan": { "xbrltype": "monetaryItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "SmallBusinessAdministrationLoan", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfOtherFinancialAssetsAndLiabilitiesRecordedInBalanceSheetAtFairValueDetail" ], "lang": { "en-us": { "role": { "label": "Small Business Administration Loan", "terseLabel": "SBA Loan", "documentation": "Small business administration loan." } } }, "auth_ref": [] }, "ctcx_SponsorMember": { "xbrltype": "domainItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "SponsorMember", "presentation": [ "http://www.carmellrx.com/role/NatureOfTheOrganizationAndBusinessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Sponsor [Member]", "documentation": "Sponsor." } } }, "auth_ref": [] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.carmellrx.com/role/BusinessCombinationsAdditionalInformationDetail", "http://www.carmellrx.com/role/BusinessCombinationsSummaryOfFairValueOfPurchaseConsiderationTransferredDetail", "http://www.carmellrx.com/role/BusinessCombinationsSummaryOfFairValueOfPurchaseConsiderationTransferredParentheticalDetail", "http://www.carmellrx.com/role/ConsolidatedBalanceSheets", "http://www.carmellrx.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.carmellrx.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit", "http://www.carmellrx.com/role/CoverPage", "http://www.carmellrx.com/role/DebtAdditionalInformationDetail", "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitAdditionalInformationDetail", "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitRedeemableConvertiblePreferredStockDetail", "http://www.carmellrx.com/role/NatureOfTheOrganizationAndBusinessAdditionalInformationDetail", "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfTheSecuritiesThatWereExcludedFromTheDilutedPerShareDetail" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r242", "r260", "r261", "r262", "r287", "r317", "r318", "r321", "r323", "r327", "r328", "r390", "r449", "r451", "r452", "r453", "r456", "r457", "r486", "r487", "r490", "r493", "r501", "r649", "r790", "r791", "r792", "r793", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r809", "r827", "r849", "r871", "r894", "r895", "r896", "r897", "r898", "r955", "r982", "r990" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.carmellrx.com/role/BusinessCombinationsAdditionalInformationDetail", "http://www.carmellrx.com/role/BusinessCombinationsSummaryOfFairValueOfPurchaseConsiderationTransferredDetail", "http://www.carmellrx.com/role/BusinessCombinationsSummaryOfFairValueOfPurchaseConsiderationTransferredParentheticalDetail", "http://www.carmellrx.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.carmellrx.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit", "http://www.carmellrx.com/role/CoverPage", "http://www.carmellrx.com/role/DebtAdditionalInformationDetail", "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitAdditionalInformationDetail", "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitSummaryOfInformationRelatedToCommonStockWarrantsDetail", "http://www.carmellrx.com/role/NatureOfTheOrganizationAndBusinessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r18", "r42", "r245", "r272", "r273", "r274", "r294", "r295", "r296", "r299", "r309", "r311", "r326", "r396", "r403", "r503", "r557", "r558", "r559", "r583", "r584", "r615", "r617", "r618", "r619", "r620", "r622", "r633", "r655", "r656", "r657", "r658", "r659", "r660", "r685", "r776", "r777", "r778", "r797", "r871" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedBalanceSheets", "http://www.carmellrx.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.carmellrx.com/role/ConsolidatedStatementsOfOperations", "http://www.carmellrx.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit", "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r294", "r295", "r296", "r326", "r726", "r788", "r809", "r819", "r820", "r821", "r822", "r823", "r824", "r827", "r830", "r831", "r832", "r833", "r834", "r836", "r837", "r838", "r839", "r841", "r842", "r843", "r844", "r845", "r847", "r851", "r852", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r871", "r943" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOperatingActivitiesSegmentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOperatingActivitiesSegmentAxis", "presentation": [ "http://www.carmellrx.com/role/AccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetail", "http://www.carmellrx.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetail", "http://www.carmellrx.com/role/GoodwillAndIntangibleAssetsSummaryOfAmortizationExpenseRelatedToIntangibleAssetsDetail", "http://www.carmellrx.com/role/GoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetail", "http://www.carmellrx.com/role/PropertyAndEquipmentAdditionalInformationDetail", "http://www.carmellrx.com/role/PropertyAndEquipmentScheduleOfPropertyPlantAndEquipmentIncludeInContinuingOperationsDetail" ], "lang": { "en-us": { "role": { "label": "Operating Activities [Axis]", "documentation": "Information by continuing and discontinuing operations." } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedBalanceSheets", "http://www.carmellrx.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.carmellrx.com/role/ConsolidatedStatementsOfOperations", "http://www.carmellrx.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit", "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r294", "r295", "r296", "r326", "r726", "r788", "r809", "r819", "r820", "r821", "r822", "r823", "r824", "r827", "r830", "r831", "r832", "r833", "r834", "r836", "r837", "r838", "r839", "r841", "r842", "r843", "r844", "r845", "r847", "r851", "r852", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r871", "r943" ] }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesAcquisitions", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Acquisitions", "terseLabel": "Common and Series A Preferred stock issued in conjuction with AxBio Acquisition (in Shares)", "documentation": "Number of shares of stock issued during the period pursuant to acquisitions." } } }, "auth_ref": [ "r158", "r159", "r197" ] }, "ctcx_StockIssuedDuringPeriodSharesBusinessCombinationNetOfTransactionCosts": { "xbrltype": "sharesItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "StockIssuedDuringPeriodSharesBusinessCombinationNetOfTransactionCosts", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period Shares Business Combination Net Of Transaction Costs", "terseLabel": "Business Combination with Alpha, net of transaction costs (in Shares)", "documentation": "Stock issued during period shares business combination net of transaction costs." } } }, "auth_ref": [] }, "ctcx_StockIssuedDuringPeriodSharesCancellationOfCommonStock": { "xbrltype": "sharesItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "StockIssuedDuringPeriodSharesCancellationOfCommonStock", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Stock issued during period shares Cancellation of common stock", "terseLabel": "Cancellation of common stock (in Shares)", "documentation": "Stock issued during period shares Cancellation of common stock." } } }, "auth_ref": [] }, "ctcx_StockIssuedDuringPeriodSharesConvertibleNoteholdersUponMerger": { "xbrltype": "sharesItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "StockIssuedDuringPeriodSharesConvertibleNoteholdersUponMerger", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period Shares, Convertible Noteholders Upon Merger", "terseLabel": "Common stock issued to convertible noteholder at the Merger (in Shares)", "documentation": "Stock issued during period shares, convertible noteholders upon merger." } } }, "auth_ref": [] }, "ctcx_StockIssuedDuringPeriodSharesExerciseOfCommonStockPurchaseWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "StockIssuedDuringPeriodSharesExerciseOfCommonStockPurchaseWarrants", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period Shares Exercise of Common Stock Purchase Warrants", "terseLabel": "Exercise of common stock purchase warrants (in Shares)", "documentation": "Stock issued during period shares exercise of common stock purchase warrants." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Issued for Services", "verboseLabel": "Issuance of common stock for service (in Shares)", "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://www.carmellrx.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitAdditionalInformationDetail", "http://www.carmellrx.com/role/NatureOfTheOrganizationAndBusinessAdditionalInformationDetail", "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Stock issued to Puritan to rescind Acceleration Notice (in Shares)", "terseLabel": "Stock issued during period, shares, new issues", "verboseLabel": "Stock shares issued during the period shares", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r18", "r158", "r159", "r197", "r790", "r871", "r895" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit", "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitSummaryOfOptionActivityDetail" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "terseLabel": "Exercise of common stock options (in Shares)", "negatedLabel": "Number of options, exercised", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r18", "r158", "r159", "r197", "r537" ] }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueAcquisitions", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Acquisitions", "terseLabel": "Common and Series A Preferred stock issued in conjuction with AxBio Acquisition", "documentation": "Value of stock issued pursuant to acquisitions during the period." } } }, "auth_ref": [ "r18", "r42", "r197" ] }, "ctcx_StockIssuedDuringPeriodValueBusinessCombinationNetOfTransactionCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "StockIssuedDuringPeriodValueBusinessCombinationNetOfTransactionCosts", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period Value Business Combination Net Of Transaction Costs", "terseLabel": "Business Combination with Alpha, net of transaction costs", "documentation": "Stock issued during period value business combination net of transaction costs." } } }, "auth_ref": [] }, "ctcx_StockIssuedDuringPeriodValueCancellationOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "StockIssuedDuringPeriodValueCancellationOfCommonStock", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period Value Cancellation Of Common Stock", "terseLabel": "Cancellation of common stock", "documentation": "Stock Issued During Period Value Cancellation Of Common Stock." } } }, "auth_ref": [] }, "ctcx_StockIssuedDuringPeriodValueConvertibleNoteholdersUponMerger": { "xbrltype": "monetaryItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "StockIssuedDuringPeriodValueConvertibleNoteholdersUponMerger", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period Value, Convertible Noteholders Upon Merger", "terseLabel": "Common stock issued to convertible noteholder at the Merger", "documentation": "Stock issued during period value, convertible noteholders upon merger." } } }, "auth_ref": [] }, "ctcx_StockIssuedDuringPeriodValueExerciseOfCommonStockPurchaseWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "StockIssuedDuringPeriodValueExerciseOfCommonStockPurchaseWarrants", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period Value Exercise of Common Stock Purchase Warrants", "terseLabel": "Exercise of common stock purchase warrants", "documentation": "Stock issued during period value exercise of common stock purchase warrants." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueIssuedForServices", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Issued for Services", "verboseLabel": "Issuance of common stock for service", "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Exercise of common stock options", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r18", "r42", "r197" ] }, "us-gaap_StockRepurchasedDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchasedDuringPeriodShares", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Stock Repurchased During Period, Shares", "terseLabel": "Repurchase of common stock (in Shares)", "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": [ "r18", "r158", "r159", "r197", "r793", "r871", "r897" ] }, "us-gaap_StockRepurchasedDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchasedDuringPeriodValue", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Stock Repurchased During Period, Value", "negatedLabel": "Repurchase of common stock", "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": [ "r18", "r158", "r159", "r197", "r797", "r871", "r897", "r949" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 23.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedBalanceSheets", "http://www.carmellrx.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "Total stockholders' equity (deficit)", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r159", "r162", "r163", "r179", "r829", "r846", "r872", "r873", "r937", "r950", "r984", "r996", "r1059", "r1082" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "verboseLabel": "Stockholders' Equity (Deficit):" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note Disclosure [Text Block]", "verboseLabel": "Mezzanine Equity And Stockholders' Equity (Deficit)", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r193", "r286", "r485", "r487", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r497", "r498", "r500", "r503", "r624", "r874", "r876", "r899" ] }, "us-gaap_StockholdersEquityPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityPolicyTextBlock", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity, Policy [Policy Text Block]", "terseLabel": "Series A Voting Convertible Preferred Stock", "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income." } } }, "auth_ref": [ "r13", "r875" ] }, "ctcx_SublicenseFeesPaymentPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "SublicenseFeesPaymentPercentage", "presentation": [ "http://www.carmellrx.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Sublicense Fees Payment Percentage", "terseLabel": "Sublicense fees payment percentage", "documentation": "Sublicense fees payment percentage." } } }, "auth_ref": [] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": [ "http://www.carmellrx.com/role/NatureOfTheOrganizationAndBusinessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r661", "r691" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://www.carmellrx.com/role/NatureOfTheOrganizationAndBusinessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r661", "r691" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://www.carmellrx.com/role/NatureOfTheOrganizationAndBusinessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r661", "r691" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://www.carmellrx.com/role/SubsequentEvents" ], "lang": { "en-us": { "role": { "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r690", "r692" ] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitAdditionalInformationDetail", "http://www.carmellrx.com/role/NatureOfTheOrganizationAndBusinessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "ctcx_SubstantialDoubtAboutGoingConcernAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "SubstantialDoubtAboutGoingConcernAbstract", "lang": { "en-us": { "role": { "label": "Substantial Doubt About Going Concern [Abstract]", "documentation": "Substantial doubt about going concern." } } }, "auth_ref": [] }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "presentation": [ "http://www.carmellrx.com/role/GoingConcernAndManagementsLiquidityPlans" ], "lang": { "en-us": { "role": { "label": "Substantial Doubt about Going Concern [Text Block]", "terseLabel": "Going Concern and Managements Liquidity Plans", "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern." } } }, "auth_ref": [ "r154" ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental cash flow information:" } } }, "auth_ref": [] }, "us-gaap_TaxCreditCarryforwardAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxCreditCarryforwardAmount", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Tax Credit Carryforward, Amount", "terseLabel": "Tax credit carryforward, amount", "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r100" ] }, "us-gaap_TaxCreditCarryforwardAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxCreditCarryforwardAxis", "presentation": [ "http://www.carmellrx.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Tax Credit Carryforward [Axis]", "documentation": "Information by specific tax credit related to an unused tax credit." } } }, "auth_ref": [ "r99" ] }, "us-gaap_TaxCreditCarryforwardLimitationsOnUse": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxCreditCarryforwardLimitationsOnUse", "presentation": [ "http://www.carmellrx.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Tax Credit Carryforward, Limitations on Use", "terseLabel": "Tax credit carryforward, limitations on use", "documentation": "Description of the limitation related to use of the tax credit carryforward." } } }, "auth_ref": [] }, "us-gaap_TaxCreditCarryforwardNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxCreditCarryforwardNameDomain", "presentation": [ "http://www.carmellrx.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Tax Credit Carryforward, Name [Domain]", "documentation": "The name of the tax credit carryforward." } } }, "auth_ref": [ "r99" ] }, "us-gaap_TaxPeriodAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxPeriodAxis", "presentation": [ "http://www.carmellrx.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Tax Period [Axis]", "documentation": "Information about the period subject to enacted tax laws." } } }, "auth_ref": [] }, "us-gaap_TaxPeriodDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxPeriodDomain", "presentation": [ "http://www.carmellrx.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Tax Period [Domain]", "documentation": "Identified tax period." } } }, "auth_ref": [] }, "us-gaap_TaxYear2023Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxYear2023Member", "presentation": [ "http://www.carmellrx.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Tax Year 2023 [Member]", "documentation": "Identified as tax year 2023." } } }, "auth_ref": [ "r1051" ] }, "ctcx_TaxYear2028Member": { "xbrltype": "domainItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "TaxYear2028Member", "presentation": [ "http://www.carmellrx.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Tax Year 2028 [Member]", "terseLabel": "Tax Year 2028 [Member]", "documentation": "Tax year 2028." } } }, "auth_ref": [] }, "us-gaap_TemporaryEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquityAbstract", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Temporary Equity [Abstract]", "terseLabel": "Mezzanine equity:" } } }, "auth_ref": [] }, "us-gaap_TemporaryEquityAccretionOfDividends": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquityAccretionOfDividends", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit", "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Temporary Equity, Accretion of Dividends", "terseLabel": "Temporary equity accretion of dividends during the period", "documentation": "Value of accretion of temporary equity during the period due to unpaid dividends." } } }, "auth_ref": [] }, "ctcx_TemporaryEquityAccruedDividends": { "xbrltype": "monetaryItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "TemporaryEquityAccruedDividends", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Temporary Equity Accrued Dividends", "terseLabel": "Temporary equity accrued dividends", "documentation": "Temporary equity accrued dividends." } } }, "auth_ref": [] }, "us-gaap_TemporaryEquityAggregateAmountOfRedemptionRequirement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquityAggregateAmountOfRedemptionRequirement", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/NatureOfTheOrganizationAndBusinessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Temporary Equity, Aggregate Amount of Redemption Requirement", "terseLabel": "Temporary equity, aggregate redemption price", "documentation": "Aggregate amount of redemption requirements for each class or type of redeemable stock classified as temporary equity for each of the five years following the latest balance sheet date. The redemption requirement does not constitute an unconditional obligation that will be settled in a variable number of shares constituting a monetary value predominantly indexed to (a) a fixed monetary amount known at inception, (b) an amount inversely correlated with the residual value of the entity, or (c) an amount determined by reference to something other than the fair value of issuer's stock. Does not include mandatorily redeemable stock. The exception is if redemption is required upon liquidation or termination of the reporting entity." } } }, "auth_ref": [] }, "us-gaap_TemporaryEquityByClassOfStockTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquityByClassOfStockTable", "presentation": [ "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitRedeemableConvertiblePreferredStockDetail" ], "lang": { "en-us": { "role": { "label": "Temporary Equity, by Class of Stock [Table]", "documentation": "Table of capital stock that is classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. This table may include a description by series, value, shares authorized, shares issued and outstanding, redemption price per share and subscription receivable." } } }, "auth_ref": [ "r27", "r79" ] }, "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquityCarryingAmountAttributableToParent", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitRedeemableConvertiblePreferredStockDetail" ], "lang": { "en-us": { "role": { "label": "Temporary Equity, Carrying Amount, Attributable to Parent", "terseLabel": "Carrying Value", "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer." } } }, "auth_ref": [ "r449", "r451", "r452", "r453", "r456", "r457", "r560", "r753" ] }, "us-gaap_TemporaryEquityDividendsAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquityDividendsAdjustment", "crdr": "debit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0, "order": 23.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Temporary Equity, Dividends, Adjustment", "negatedLabel": "Dividends on Series A, Series C-1, and C-2 preferred stock", "documentation": "Accretion of temporary equity during the period due to cash, stock, and in-kind dividends. This item is an adjustment to net income necessary to derive net income apportioned to common stockholders and is to be distinguished from Temporary Equity, Accretion of Dividends (Temporary Equity, Accretion of Dividends)." } } }, "auth_ref": [] }, "us-gaap_TemporaryEquityLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquityLineItems", "presentation": [ "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitRedeemableConvertiblePreferredStockDetail" ], "lang": { "en-us": { "role": { "label": "Temporary Equity [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_TemporaryEquityLiquidationPreference": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquityLiquidationPreference", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitRedeemableConvertiblePreferredStockDetail" ], "lang": { "en-us": { "role": { "label": "Temporary Equity, Liquidation Preference", "terseLabel": "Liquidation Preference", "documentation": "The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer." } } }, "auth_ref": [] }, "us-gaap_TemporaryEquityParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquityParOrStatedValuePerShare", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitRedeemableConvertiblePreferredStockDetail" ], "lang": { "en-us": { "role": { "label": "Temporary Equity, Par or Stated Value Per Share", "terseLabel": "Issuance Price", "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable." } } }, "auth_ref": [ "r27", "r79" ] }, "us-gaap_TemporaryEquityRedemptionPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquityRedemptionPricePerShare", "presentation": [ "http://www.carmellrx.com/role/NatureOfTheOrganizationAndBusinessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Temporary Equity, Redemption Price Per Share", "terseLabel": "Temporary equity, redemption price per share", "documentation": "Amount to be paid per share that is classified as temporary equity by entity upon redemption. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer." } } }, "auth_ref": [ "r27", "r79" ] }, "us-gaap_TemporaryEquitySharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquitySharesAuthorized", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitRedeemableConvertiblePreferredStockDetail" ], "lang": { "en-us": { "role": { "label": "Temporary Equity, Shares Authorized", "terseLabel": "Temporary equity, shares authorized", "verboseLabel": "Shares Authorized", "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer." } } }, "auth_ref": [ "r157" ] }, "us-gaap_TemporaryEquitySharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquitySharesIssued", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitRedeemableConvertiblePreferredStockDetail" ], "lang": { "en-us": { "role": { "label": "Temporary Equity, Shares Issued", "terseLabel": "Temporary equity, shares issued", "verboseLabel": "Shares Issued", "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer." } } }, "auth_ref": [ "r157" ] }, "us-gaap_TemporaryEquitySharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquitySharesOutstanding", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitRedeemableConvertiblePreferredStockDetail", "http://www.carmellrx.com/role/NatureOfTheOrganizationAndBusinessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Shares Outstanding", "terseLabel": "Temporary equity, shares outstanding", "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer." } } }, "auth_ref": [ "r157" ] }, "us-gaap_TemporaryEquityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquityTableTextBlock", "presentation": [ "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitTables" ], "lang": { "en-us": { "role": { "label": "Temporary Equity [Table Text Block]", "terseLabel": "Schedule of Convertible Preferred Stock", "documentation": "Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer." } } }, "auth_ref": [ "r27", "r79" ] }, "ctcx_TerminationFeePayablePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "TerminationFeePayablePerShare", "presentation": [ "http://www.carmellrx.com/role/NatureOfTheOrganizationAndBusinessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Termination Fee Payable Per Share", "terseLabel": "Termination fee payable per share", "documentation": "Termination fee payable per share." } } }, "auth_ref": [] }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TradeAndOtherAccountsReceivablePolicy", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable [Policy Text Block]", "terseLabel": "Accounts Receivables, net", "documentation": "Disclosure of accounting policy for accounts receivable." } } }, "auth_ref": [ "r218", "r219", "r220", "r352", "r353", "r354" ] }, "us-gaap_TradeNamesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TradeNamesMember", "presentation": [ "http://www.carmellrx.com/role/BusinessCombinationsAdditionalInformationDetail", "http://www.carmellrx.com/role/GoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsDetail", "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Trade Names [Member]", "terseLabel": "Trade Name [Member]", "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof." } } }, "auth_ref": [ "r108" ] }, "ctcx_TrancheAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "TrancheAxis", "presentation": [ "http://www.carmellrx.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Tranche [Axis]", "documentation": "Tranche Axis" } } }, "auth_ref": [] }, "ctcx_TrancheDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "TrancheDomain", "presentation": [ "http://www.carmellrx.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Tranche [Domain]", "documentation": "Tranche Domain" } } }, "auth_ref": [] }, "ctcx_TrancheOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "TrancheOneMember", "presentation": [ "http://www.carmellrx.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Tranche One [Member]", "terseLabel": "Tranche 1 [member]", "documentation": "Tranche One Member" } } }, "auth_ref": [] }, "ctcx_TransactionsContemplatedDateOfClosed": { "xbrltype": "dateItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "TransactionsContemplatedDateOfClosed", "presentation": [ "http://www.carmellrx.com/role/NatureOfTheOrganizationAndBusinessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Transactions Contemplated Date of Closed", "terseLabel": "Transactions contemplated date of closed", "documentation": "Transactions contemplated date of closed." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://www.carmellrx.com/role/NatureOfTheOrganizationAndBusinessAdditionalInformationDetail", "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r483", "r499", "r623", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r763", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r992", "r993", "r994", "r995" ] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonMember", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Treasury Stock, Common [Member]", "terseLabel": "Treasury Stock [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r91" ] }, "ctcx_TwentySixZeroCouponPromisoryNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "TwentySixZeroCouponPromisoryNotesMember", "presentation": [ "http://www.carmellrx.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Twenty Six Zero Coupon Promisory Notes [Member]", "terseLabel": "26 Zero Coupon Promisory Notes [Member]", "documentation": "Twenty six zero couponpPromisory notes." } } }, "auth_ref": [] }, "ctcx_TwoThousandAndTwentyThreeIncentiveStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "TwoThousandAndTwentyThreeIncentiveStockOptionMember", "presentation": [ "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Two Thousand And Twenty Three Incentive Stock Option [member]", "terseLabel": "2023 Incentive stock option [member]", "documentation": "Two thousand and twenty three incentive stock option." } } }, "auth_ref": [] }, "ctcx_TwoThousandAndTwentyThreeLongTermIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "TwoThousandAndTwentyThreeLongTermIncentivePlanMember", "presentation": [ "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Two Thousand And Twenty Three Long-term Incentive Plan [member]", "terseLabel": "2023 Long-Term Incentive Plan [Member]", "documentation": "Two thousand and twenty three long-term incentive plan." } } }, "auth_ref": [] }, "ctcx_TwoThousandAndTwentyThreePromissoryNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "TwoThousandAndTwentyThreePromissoryNotesMember", "presentation": [ "http://www.carmellrx.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Two Thousand And Twenty Three Promissory Notes [Member]", "terseLabel": "Two thousand and twenty three promissory notes [Member]", "documentation": "Two thousand and twenty three promissory notes." } } }, "auth_ref": [] }, "us-gaap_TypeOfAdoptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfAdoptionMember", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Accounting Standards Update [Domain]", "documentation": "Amendment to accounting standards." } } }, "auth_ref": [ "r243", "r244", "r245", "r246", "r247", "r298", "r299", "r300", "r301", "r313", "r355", "r356", "r393", "r394", "r395", "r396", "r398", "r399", "r400", "r401", "r402", "r403", "r435", "r557", "r558", "r559", "r581", "r582", "r583", "r584", "r597", "r598", "r599", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r645", "r646", "r651", "r652", "r653", "r654", "r662", "r663", "r666", "r667", "r668", "r669", "r681", "r682", "r683", "r684", "r685", "r728", "r729", "r730", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785" ] }, "us-gaap_TypeOfRestructuringDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfRestructuringDomain", "presentation": [ "http://www.carmellrx.com/role/GoingConcernAndManagementsLiquidityPlansAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Type of Restructuring [Domain]", "documentation": "Identification of the types of restructuring costs." } } }, "auth_ref": [ "r436", "r437", "r439", "r440" ] }, "ctcx_USSmallBusinessAdministrationLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "USSmallBusinessAdministrationLoanMember", "presentation": [ "http://www.carmellrx.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "U.S. Small Business Administration Loan [Member]", "terseLabel": "U.S. Small Business Administration (SBA) Loan [Member]", "documentation": "U.S. small business administration loan." } } }, "auth_ref": [] }, "us-gaap_UnrealizedGainLossOnDerivatives": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrealizedGainLossOnDerivatives", "crdr": "credit", "calculation": { "http://www.carmellrx.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 19.0 } }, "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Unrealized Gain (Loss) on Derivatives", "terseLabel": "Change in fair value of derivative liabilities", "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period." } } }, "auth_ref": [ "r11", "r865", "r866", "r867", "r868", "r885" ] }, "us-gaap_UnrecognizedTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefits", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Unrecognized Tax Benefits", "terseLabel": "Unrecognized tax benefits", "documentation": "Amount of unrecognized tax benefits." } } }, "auth_ref": [ "r565", "r572" ] }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued", "terseLabel": "Accrued for interest and penalties", "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return." } } }, "auth_ref": [ "r571" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Use of Estimates, Policy [Policy Text Block]", "verboseLabel": "Use of Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r62", "r63", "r64", "r225", "r226", "r229", "r230" ] }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "negatedLabel": "Change in valuation allowance", "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset." } } }, "auth_ref": [ "r575" ] }, "us-gaap_ValuationTechniqueAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationTechniqueAxis", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfFairValueOfEmbeddedDerivativesInTheConvertibleNotesDetail" ], "lang": { "en-us": { "role": { "label": "Valuation Approach and Technique [Axis]", "documentation": "Information by valuation approach and technique." } } }, "auth_ref": [ "r19" ] }, "us-gaap_ValuationTechniqueDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationTechniqueDomain", "presentation": [ "http://www.carmellrx.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfFairValueOfEmbeddedDerivativesInTheConvertibleNotesDetail" ], "lang": { "en-us": { "role": { "label": "Valuation Approach and Technique [Domain]", "documentation": "Valuation approach and technique." } } }, "auth_ref": [ "r19" ] }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantsAndRightsOutstandingTerm", "presentation": [ "http://www.carmellrx.com/role/DebtAdditionalInformationDetail", "http://www.carmellrx.com/role/MezzanineEquityAndStockholdersEquityDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Warrants and Rights Outstanding, Term", "terseLabel": "Class of warrants or rights term", "verboseLabel": "Warrants and rights outstanding term", "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1058" ] }, "ctcx_WarrantsIssuedInConnectionWithConvertibleNotes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "WarrantsIssuedInConnectionWithConvertibleNotes", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Warrants Issued In Connection With Convertible Notes", "terseLabel": "Warrants issued in connection with convertible notes", "documentation": "Warrants issued in connection with convertible notes." } } }, "auth_ref": [] }, "ctcx_WarrantsIssuedInConnectionWithSeriesC1PreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://www.carmellrx.com/20231231", "localname": "WarrantsIssuedInConnectionWithSeriesC1PreferredStock", "crdr": "credit", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Warrants Issued In Connection With Series C1 Preferred Stock", "terseLabel": "Warrants issued in connection with Series C-1 preferred stock", "documentation": "Warrants issued in connection with Series\u00a0C1\u00a0preferred stock." } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average of shares outstanding , Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r316", "r323" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://www.carmellrx.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average of shares outstanding , Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r314", "r323" ] }, "us-gaap_WriteOffOfDeferredDebtIssuanceCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WriteOffOfDeferredDebtIssuanceCost", "crdr": "debit", "presentation": [ "http://www.carmellrx.com/role/DebtAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Deferred Debt Issuance Cost, Writeoff", "terseLabel": "Write off of debt issuance costs", "documentation": "Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt." } } }, "auth_ref": [ "r170" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "7", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-7" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "8", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-8" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-10" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-1B" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1D", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-1D" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "30", "Topic": "350", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "44", "SubTopic": "20", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-44" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(27)", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-6" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-7" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "S99", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480781/205-20-S99-3" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "25", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "330", "SubTopic": "10", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB TOPIC 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "450", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "450", "SubTopic": "20", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "25", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-2" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-2" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-4" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(CFRR 211.02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Subparagraph": "(12)(c)", "Section": "S99", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-3A" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Subparagraph": "(16)(c)", "Paragraph": "3A", "Section": "S99", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-3A" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Subparagraph": "14", "Paragraph": "3A", "Section": "S99", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-3A" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Subparagraph": "15", "Paragraph": "3A", "Section": "S99", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-3A" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "710", "SubTopic": "10", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483070/710-10-25-1" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(b),(f(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "05", "Paragraph": "4", "Subparagraph": "(a)-(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479515/805-10-05-4" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "55", "Paragraph": "37", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479303/805-10-55-37" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-14" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-20" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-6" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-18" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-11" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-12" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.10)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.15(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205-20/tableOfContent" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-11" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-1A" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-1B" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-1C" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-3" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-3A" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-3B" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-4" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3A" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4A" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4B" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5A" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5D" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "40", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205-40/tableOfContent" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r158": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r159": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r160": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r161": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r162": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r163": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r164": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r165": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-1" }, "r166": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r167": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r168": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.13)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r169": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r170": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r171": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r172": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r173": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r174": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r175": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r176": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r177": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "250", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//250/tableOfContent" }, "r178": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//275/tableOfContent" }, "r179": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r180": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r181": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r182": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r183": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//360/tableOfContent" }, "r184": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-9" }, "r185": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r186": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r187": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3A" }, "r188": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r189": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r190": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r191": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-10" }, "r192": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-5" }, "r193": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r194": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r195": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r196": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r197": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r198": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r199": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r200": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "12", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r201": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r202": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//805/tableOfContent" }, "r203": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1" }, "r204": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-38" }, "r205": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r206": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r207": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r208": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r209": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r210": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r211": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r212": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r213": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r214": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r215": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r216": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r217": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r218": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11B", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B" }, "r219": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-15" }, "r220": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-6" }, "r221": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "840", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//840/tableOfContent" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "210", "Topic": "946", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-20" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "270", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(1)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "SubTopic": "20", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "326", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-3" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "326", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-3" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-4" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(2))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//606/tableOfContent" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-10" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-12" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-3" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-1" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-1" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-2" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//330/tableOfContent" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-2" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//350-30/tableOfContent" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147477123/405-50-65-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//715-20/tableOfContent" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.E.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482551/740-270-45-3" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-4" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-5" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-2" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-5" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "832", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "832", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//855/tableOfContent" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "330", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "715", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482236/912-715-50-1" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r764": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r765": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r766": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r767": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r768": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r769": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r770": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r771": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r772": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r773": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r774": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r775": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r776": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r777": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r778": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r779": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r780": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r781": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r782": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r783": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r784": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r785": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r786": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r787": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-3" }, "r788": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r789": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r790": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r791": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r792": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r793": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r794": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r795": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r796": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r797": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r798": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2" }, "r799": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27" }, "r800": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r801": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r802": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r803": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r804": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r805": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r806": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r807": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r808": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-21" }, "r809": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r810": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r811": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r812": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r813": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r814": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r815": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r816": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r817": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r818": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r819": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r820": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r821": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r822": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r823": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r824": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r825": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r826": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r827": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r828": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r829": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r830": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r831": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r832": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r833": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r834": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r835": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r836": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r837": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r838": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r839": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r840": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r841": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r842": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r843": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r844": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r845": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r846": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r847": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r848": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r849": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3" }, "r850": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r851": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r852": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r853": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r854": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r855": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r856": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r857": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r858": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r859": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r860": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r861": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r862": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r863": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r864": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r865": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r866": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r867": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r868": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r869": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r870": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r871": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r872": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r873": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r874": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r875": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r876": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r877": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r878": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r879": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r880": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r881": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r882": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r883": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r884": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5A", "Subparagraph": "(SX 210.12-13A(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5A" }, "r885": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5A", "Subparagraph": "(SX 210.12-13A(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5A" }, "r886": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r887": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r888": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r889": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r890": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r891": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r892": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r893": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r894": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1" }, "r895": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r896": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r897": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r898": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r899": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r900": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2" }, "r901": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r902": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r903": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r904": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r905": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r906": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r907": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r908": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16" }, "r909": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21" }, "r910": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r911": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r912": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r913": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r914": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r915": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47" }, "r916": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r917": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8" }, "r918": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24" }, "r919": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r920": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r921": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r922": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r923": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r924": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r925": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r926": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r927": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r928": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r929": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r930": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r931": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r932": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r933": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r934": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r935": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K" }, "r936": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r937": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r938": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r939": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r940": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r941": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r942": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r943": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r944": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r945": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r946": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r947": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r948": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r949": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r950": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r951": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r952": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r953": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r954": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r955": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r956": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r957": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r958": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r959": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(3)", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r960": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r961": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r962": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r963": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Topic": "705", "Publisher": "FASB", "URI": "https://asc.fasb.org//705/tableOfContent" }, "r964": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r965": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(1)", "Publisher": "SEC" }, "r966": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(2)", "Publisher": "SEC" }, "r967": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(3)", "Publisher": "SEC" }, "r968": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r969": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r970": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r971": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r972": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r973": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r974": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r975": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r976": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r977": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r978": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r979": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r980": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r981": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r982": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r983": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r984": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r985": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r986": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r987": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r988": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r989": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r990": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55" }, "r991": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18" }, "r992": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r993": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r994": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r995": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r996": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r997": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480341/340-10-S99-1" }, "r998": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r999": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1000": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1001": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1002": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1003": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1004": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1005": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1006": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1007": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A" }, "r1008": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2" }, "r1009": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r1010": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482047/420-10-45-3" }, "r1011": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r1012": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1" }, "r1013": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r1014": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r1015": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r1016": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r1017": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r1018": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r1019": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r1020": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r1021": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r1022": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r1023": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1024": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1025": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1026": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1027": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1028": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1029": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1030": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1031": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1032": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1033": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1034": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1035": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1036": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1037": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1038": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1039": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1040": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1041": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1042": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1043": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1044": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1045": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1046": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1047": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1048": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1049": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1050": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r1051": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r1052": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r1053": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6" }, "r1054": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r1055": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r1056": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r1057": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r1058": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r1059": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r1060": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r1061": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r1062": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r1063": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r1064": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r1065": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r1066": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r1067": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r1068": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r1069": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r1070": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r1071": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r1072": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r1073": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r1074": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r1075": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r1076": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r1077": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r1078": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r1079": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r1080": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r1081": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r1082": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r1083": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" } } }